The Outlook

In 1960, twenty-two-year-old Tom Monaghan and his brother James borrowed $900 to buy a small pizza shop called DomiNick’s in Ypsilanti, Michigan, with Tom intending to use the income to fund his architecture studies. He never went back to architecture. He bought out his brother’s share, trading him a Volkswagen Beetle for his half of the business, dropped sandwiches from the menu, focused entirely on delivery to college campuses, and invented an insulated pizza box that could be stacked without crushing the pizzas inside. The model he built, make the same product consistently, deliver it fast, price it within reach of anyone, turned out to be not just a business but a replicable system. By the mid-1980s, nearly three new Domino’s franchises were opening every day. Sixty-five years later, that system operates in over 90 countries across 22,142 locations, and Domino’s has delivered 32 consecutive years of global retail sales growth in constant currency.

The business Domino’s operates today is almost entirely a franchise. Approximately 99% of stores are owned by independent franchisees who pay a royalty on every dollar of sales, contribute to a national advertising fund, and purchase their food ingredients through Domino’s own supply chain infrastructure. The company itself owns 262 stores in the United States. While the overall count has remained broadly stable over the decade, the strategic direction is toward franchise, the refranchising of the Maryland market in May 2025 being the most recent example, with company-owned stores serving primarily as operational laboratories and training grounds rather than profit centres. What Domino’s keeps is the brand, the system, and the royalty stream. What franchisees keep is the operating risk.

That structure creates an economic engine of unusual quality. Royalties arrive as a percentage of system-wide retail sales regardless of whether individual stores are profitable. When a new store opens anywhere in the world, the royalty income base expands at no incremental capital cost to the company. When same-store sales grow, royalty income grows proportionally.

The tension in the Domino’s story today is not about the franchise or the brand. It is about what the right price is to own them, and whether the growth levers available over the next decade can sustain the rate of per-share cash flow compounding that the last decade delivered. The United States is a mature market. International expansion continues but the low-hanging fruit of early market entry is largely harvested. The capital structure, approximately $4.8 billion in total debt against negative book equity, requires management and periodic refinancing. These are not disqualifying concerns. They are the context within which the investment case must be made honestly.

Key Terms

System-Wide Sales / Global Retail Sales

Global retail sales refers to total worldwide retail sales at all Domino’s stores, both company-owned and franchised. This is not revenue to Domino’s, it is the retail volume flowing through the entire system. Franchise royalties are calculated as a percentage of this figure. In 2025, global retail sales reached approximately $20.1 billion against consolidated company revenues of approximately $4.9 billion.

Same-Store Sales

Same-store sales growth measures the change in sales for stores open in both the current and prior comparable period. It is the clearest indicator of whether the brand is gaining or losing traction at the store level, independent of new unit openings. International figures are reported on a constant currency basis.

Asset-Backed Securitisation (ABS)

Domino’s finances its debt through an ABS structure in which subsidiaries securitise the royalty and supply chain cash flows and issue fixed-rate notes against those cash flows. The structure provides borrowing costs lower than conventional corporate debt but introduces covenants tied to cash flow coverage ratios and creates scheduled refinancing events at each note maturity.

At a Glance

Company: Domino's Pizza, Inc.

Ticker: $DPZ · NASDAQ

Sector: Consumer Discretionary

Industry: Restaurants / QSR

Market Cap: $11 billion (at $330)

First Coverage: May 2026

FY2025 Revenue: $4.94 billion

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. The author does not hold a position in DPZ. Read the full disclaimer here

1. The Business

Domino’s Pizza was founded in 1960 in Ypsilanti, Michigan and has grown into the largest pizza company in the world by store count and global retail sales. The company went public in 2004 and has operated as a publicly traded entity since. As of December 28, 2025, the system operated 22,142 stores across more than 90 countries, of which approximately 99% are franchised.

Consolidated revenue of approximately $4.94 billion in 2025 is divided across five reporting lines within three operating segments. Understanding the composition matters more than the total, because the economic quality of each stream is fundamentally different.

The supply chain segment is the largest at approximately 60.5% of consolidated revenue, generating about $2.99 billion in 2025 through the manufacture and distribution of dough and food ingredients to franchisees in the United States and Canada. This segment exists to support the franchise network, not to generate standalone returns, its margin reflects a distribution business, not a franchise business.

The U.S. stores segment contributed approximately $1.61 billion, comprising royalties and fees from franchisees, advertising contributions, and revenue from the 262 company-owned stores. Within this segment, U.S. franchise royalties and fees of $677.1 million in 2025 are the highest-quality revenue the company generates, collected as a percentage of franchisee sales with essentially no direct cost. The advertising contribution of $559.5 million is collected from franchisees and spent entirely on brand promotion with no margin contribution. It passes through the income statement as both revenue and expense, inflating the top line without adding any economic value to the company. The international franchise segment contributed $338.7 million in royalties from master franchisees outside the United States.

A U.S. franchisee pays Domino’s a royalty of approximately 5.5% of store retail sales, plus contributions to the national advertising fund. The company bears no capital responsibility for franchised stores. Franchisees finance their own build-outs and carry their own operating risk.

When same-store sales rise, royalty income rises proportionally. When a new store opens, royalty income increases with no additional capital outlay by the company. Global retail sales grew from approximately $9.9 billion in 2015 to approximately $20.1 billion in 2025, slightly more than doubling the royalty income base over the decade with no proportional increase in capital deployed by the company

Internationally, master franchisees pay Domino’s a royalty and take on responsibility for developing the brand within a defined geography. The largest, Domino’s Pizza Enterprises (DMP: ASX), operates across 12 markets including Australia, New Zealand, Japan, France, Germany, and several other European and Asian markets. As of year-end 2025, DMP operated approximately 3,524 stores, representing about 16% of the global Domino’s store count.

2. The Moat

Domino’s competitive advantage is built on three reinforcing pillars: a value equation that consumers trust and return to, a network density that makes the system structurally faster than competitors, and franchisee economics that sustain the investment required to keep both of those pillars intact. Each pillar can be tested against the financial record, a moat that cannot be demonstrated in the numbers is not a moat.

The Value Equation

Nobody orders Domino’s because they believe it is the finest pizza available. They order it because it delivers on every dimension simultaneously, reliably good, consistently fast, predictably priced, and available almost anywhere. That combination at scale is what creates the habit. A local pizzeria might produce a superior product. It cannot match the reliability of delivery time across thousands of locations, the pricing consistency, or the brand familiarity that decades of investment have built.

The financial evidence for this pillar is in the same-store sales record. Domino’s has grown U.S. same-store sales in the substantial majority of years over the past decade, including through the pandemic, through inflationary pressure, and through the rise of third-party delivery platforms that expose the brand to direct price comparison. The one meaningful period of same-store sales decline, 2022 through early 2023, was driven by identifiable external pressures: commodity driven menu price increases that disproportionately affected lower-income consumers, and a delivery driver shortage that degraded service times below the standard the brand is built on. When those pressures resolved, same-store sales returned immediately to positive territory, 3.0% in 2025. A brand with a structurally weakened value proposition does not recover that cleanly. The speed of the recovery is the evidence.

The brand itself reinforces the value equation. Recall was built over decades of advertising investment funded through franchise contributions of approximately 6% of sales, a pooled fund that no individual competitor can match in scale or consistency. That recall was tested severely in the late 2000s when the product was widely criticised. The company’s response in 2010, a public admission that the product was inadequate, followed by a documented recipe overhaul, produced one of the more notable brand recoveries in QSR (Quick Service Restaurant) history and demonstrated that the consumer relationship is based on trust that can be repaired when it is damaged honestly. That institutional willingness to confront reality rather than manage perceptions is a cultural characteristic that has defined how the company has operated since, and it is part of why the brand has held its position through multiple competitive cycles.

Network Density

Delivery speed is a function of store density. A market with high Domino’s store concentration serves customers faster than any competitor with fewer, more dispersed locations. This creates a self-reinforcing dynamic: denser networks produce better delivery times, better delivery times attract more orders, more orders justify more stores, more stores increase density further. In mature markets such as the United States, the density Domino’s has built is not replicable from scratch without a decade of sustained capital investment and operational losses during the build-out period.

The financial expression of this pillar is in the royalty yield on global retail sales. Domino’s extracts royalty income on approximately $20.1 billion of system-wide retail sales through 22,142 stores. A new entrant seeking to challenge this position would need to build a comparable store network to generate comparable delivery density, at franchisee investment levels of roughly $150,000 to $400,000 per store, the capital requirement for a 10,000-store network alone exceeds $1.5 billion at the low end, before accounting for the years of brand-building required to reach Domino’s order frequency. Network density is a moat that compounds with time and becomes more defensible precisely because it is expensive and slow to replicate.

Franchisee Economics

A franchise system is only as strong as the economics it delivers to its operators. If franchisees are not profitable, they stop investing, stop opening new stores, and eventually stop maintaining existing ones. The quality of the Domino’s franchise proposition is best evidenced by two facts: net store growth has been consistently positive for over two decades, and nearly all U.S. franchisees developed from within the system, beginning as delivery drivers or in-store operators before earning store ownership through the Franchise Management School programme.

That internal development pipeline is analytically significant. Franchisees who understand the Domino’s system from the inside are more likely to operate it correctly, maintain quality standards, and continue investing in their locations. It is also a natural selection mechanism; operators who struggle at the store level do not make it to ownership. The result is a franchisee base with above-average operational competence and genuine institutional alignment with the brand, because their entire career trajectory runs through it.

The supply chain infrastructure strengthens franchisee unit economics in a way that is often underappreciated. Domino’s manufactures and distributes the dough and key ingredients at scale, providing franchisees with food at prices that individual operators could not access independently. This built-in cost advantage makes the Domino’s franchise more economically attractive than alternatives where the franchisee bears full procurement risk, which in turn supports the continuous new unit openings that expand the royalty base.

Moat Assessment

The moat is stable. All three pillars are mutually reinforcing and have been tested by a difficult external environment. The competitive landscape has genuinely changed, third-party aggregators have made delivery available from any restaurant, which reduces the structural advantage of delivery availability itself and exposes the value equation to direct comparison. But the evidence from the financial record is that the value equation has held up in that environment. The 2025 same-store sales recovery, the decade-high operating margin, and the record FCF per share all point to a franchise that is generating stronger cash returns now than at any point in its history, despite operating in a more competitive delivery environment than existed a decade ago. That combination, more competition, better financial results, is the strongest possible evidence of a structural moat rather than a circumstantial one.

3. Financial Performance

Revenue grew from $2.2 billion in 2015 to $4.9 billion in 2025, a 10-year CAGR of 8.3%. That headline number requires immediate disaggregation because the revenue mix is not uniform and the economic quality of each stream is fundamentally different. Supply chain accounts for approximately 60% of consolidated revenue but operates at an 11.5% gross margin. Franchise royalties, the economically important stream, account for approximately 20% of revenue excluding the advertising pass-through, but generate the vast majority of operating profit. Company-owned stores account for the remainder, broadly flat over the decade.

The contrast between the two non-supply-chain streams tells the story of the decade precisely. Company-owned store revenue was $397 million in 2015 and $375 million in 2025, essentially flat. Combined franchise royalties, U.S. and international, grew from $436.4 million in 2015 to $1,015.8 million in 2025, a 10-year CAGR of 8.8%, marginally above the blended revenue CAGR of 8.3%. Every dollar of meaningful revenue growth in the business over the decade came from the franchise model.

The 1.3% revenue decline in 2023 requires precise treatment. Supply chain revenue fell as commodity prices normalised from their 2022 peaks, the food basket price Domino’s charged franchisees declined proportionally, mechanically reducing the top line. But the underlying franchise business strengthened that year: operating margins expanded from 16.5% to 18.3%, net income grew from $452 million to $519 million, and operating cash flow recovered from $475 million to $591 million. Revenue fell while profitability improved sharply across every metric that matters. That divergence is the clearest possible signal that the consolidated revenue line was distorting the picture, 2023 was a better year for the business than 2022 by every measure of economic quality.

Operating margins have been stable in the 17–19% range for most of the decade, which is analytically significant in itself. A business that sustains margins in a narrow band across a decade that included a global pandemic, a commodity shock, a historic labour dislocation, and aggressive competitive entry from aggregator platforms is demonstrating genuine pricing power and cost discipline. The stability is the signal, not just the level.

The 2022 compression to 16.5% is the decade’s outlier. Three forces converged simultaneously. The food basket cost rose 13–15% driven by the Russia-Ukraine war, wheat, dairy, and fuel all spiked together. A post-pandemic labour dislocation created a driver shortage severe enough to produce an 11.7% decline in delivery sales at its worst point, eliminating a high-margin revenue stream precisely when costs were rising. And the company’s defensive response, aggressive promotional discounting through Boost Week and inflation relief deals, protected transaction volumes but compressed unit margins further. The confirmation that 2022 was exogenous rather than structural comes from the recovery: operating margins reached 18.3% in 2023, 18.7% in 2024, and 19.3% in 2025. If the compression had reflected a structural deterioration in competitive position or unit economics, the recovery would not have been this clean or this fast.

Diluted EPS grew from $3.47 in 2015 to $17.57 in 2025, a 10-year CAGR of 17.6%. That rate is 9.3 percentage points above the revenue CAGR of 8.3% and requires decomposition. Operating income grew from $405 million to $950 million, a CAGR of approximately 8.9%, consistent with the revenue growth rate and modest operating leverage. The gap between 8.9% operating income growth and 17.6% EPS growth is explained by the sustained reduction in diluted share count from 55.5 million to 34.2 million, a 38% decline, alongside tax rate changes over the period. The share count reduction is the dominant driver of the per-share amplification.

SBC-adjusted FCF per share grew from $3.80 in 2015 to $18.31 in 2025, a 10-year CAGR of 17.0%, nearly identical to the EPS CAGR of 17.6%. The alignment between EPS and FCF per share growth over a full decade is an important quality signal. It means earnings are not being manufactured through accounting choices that diverge from cash reality. The business earns what it reports.

The 2022 drop in FCF per share to $9.96, a 29% decline from the $14.10 peak in 2021, was more severe than the EPS decline of 7.5% in the same year. The divergence is explained by the capex cycle: capital expenditure rose from $87 million in 2022 to $105 million in 2023 as the company invested in supply chain and technology infrastructure during a period of operational stress. Higher capex compressed FCF independently of the earnings compression. The recovery in FCF per share was correspondingly faster once both earnings normalised and capex returned to its longer-run trend, FCF per share reached $13.40 in 2024 and $18.31 in 2025.

The 2025 OCF reading of $792 million, a 27% year-on-year increase, produced the highest FCF per share of the decade. That jump deserves scrutiny. A single-year OCF increase of this magnitude in a business growing revenue at 5% is unusual and typically reflects favourable working capital timing rather than a step-change in underlying cash generation. The accounts payable and accrued liabilities movements in 2025 were a meaningful contributor. I treat the 2025 OCF as directionally correct but modestly overstating the sustainable run-rate; normalised FCF per share is probably closer to $17 on a through-cycle basis.

Total debt has ranged from $2.2 billion to $4.8 billion across the decade, and the absolute level is less informative than the trend in debt relative to cash generation. The debt / OCF ratio started at 7.7x in 2015, peaked at 10.5x in 2022, and declined to 6x in 2025. Both historical peaks require context. The 2022 spike to 10.5x was driven by OCF compression during the margin crisis, the same event that drove EPS and FCF lower, not by new debt issuance. Both were recoverable and both recovered, confirming that the leverage metrics are a mirror of operating performance rather than an independent variable.

The interest / OCF ratio tells a cleaner story across the decade: from 34% in 2015 to 24.7% in 2025, an improvement driven entirely by OCF growth since interest expense has been remarkably stable in the $190 million range annually since 2021. That stability reflects the fixed-rate ABS structure, existing notes do not reprice as market rates move. The risk is forward-looking: the 2017 Ten-Year Notes ($940 million) and 2018 9.25-Year Notes ($379 million) carry anticipated repayment dates in July 2027, and refinancing at current rates will increase the annual interest expense. The September 2025 refinancing, $1 billion in notes at 4.93% and 5.22%, is the most recent reference point for what the 2027 event will likely cost. A $30–50 million annual increase in interest expense is probable, which will compress the interest / OCF improvement trend modestly but is not expected to reverse it given the current OCF trajectory.

4. Capital Allocation

Domino’s carries negative total stockholders’ equity of approximately negative $3.9 billion, the direct result of a series of leveraged recapitalisations in which the company borrowed against its securitised royalty cash flows and returned the proceeds to shareholders through special dividends and buybacks. The consequence is that book-based return metrics produce meaningless results for this business.

Since 2015, Domino’s has retired approximately 21.3 million shares, a 38% reduction in the diluted count, from 55.5 million to 34.2 million. The company repurchased approximately 785,000 shares in 2025 for approximately $358 million. In April 2026, the Board authorised an additional $1 billion repurchase programme, bringing total outstanding authorisation to approximately $1.29 billion.

The buyback programme is the single largest contributor to the gap between 8.3% revenue growth and 17.6% EPS growth over the decade. Operating income grew from $405 million to $950 million, a CAGR of approximately 8.9%. The gap between that and the per-share earnings growth rate is almost entirely explained by the share count reduction, a 38% decline from 55.5 million to 34.2 million shares, funded through a combination of operating cash flow and leveraged recapitalisations.

The forward contribution of the buyback programme is discussed in the Valuation section. What the historical decomposition establishes here is the distinction between the two sources of per-share growth: the operational engine, which grew at approximately 8.9% annually, and the capital return engine, which amplified that into 17.6% EPS growth per share. Both engines have been running for twenty years. Understanding which contributed what is essential to forming a credible view of what the next decade delivers, and why the forward estimate differs from the historical CAGR.

Dividends of $6.96 per share in 2025 represent approximately 38% of SBC-adjusted FCF, a conservative payout ratio relative to cash generation. Dividends have grown every year of the decade, from $1.24 per share in 2015, a CAGR of approximately 18.9% over the period. Interest expense has been stable at approximately $190-196 million annually since 2021, reflecting the fixed-rate ABS structure. The 2025 refinancing added approximately $1 billion in new notes at 4.93% and 5.22%, extending maturities while adding modest incremental interest cost. The 2017 Ten-Year Notes ($940 million) and 2018 9.25-Year Notes ($379 million) carry anticipated repayment dates in July 2027, the next scheduled capital structure event of consequence.

Capital expenditure has run between $59 million and $121 million annually over the decade, averaging approximately 2.5% of revenue. The franchise architecture keeps this number structurally low; the physical infrastructure of the system is built and maintained by franchisees, not by the company. Domino’s own capex is concentrated in supply chain facilities, and technology investment.

5. Competition

Pizza Hut

Pizza Hut, owned by Yum! Brands, is Domino’s closest global competitor by store count at approximately 19,900 locations. The brand has historically been stronger in dine-in and carryout than delivery, and its delivery infrastructure has lagged in most markets. The financial evidence for Domino’s competitive superiority is in the same-store sales comparison: Domino’s has consistently outperformed Pizza Hut on U.S. comparable store sales over the last several years. That gap reflects not just marketing but the underlying operational advantages, supply chain infrastructure, franchisee quality, and delivery system efficiency, that Domino’s has built and Pizza Hut has not matched.

Papa John’s

Papa John’s operates approximately 6,000 stores globally, roughly a quarter of Domino’s footprint. The cost structure differential is telling: Papa John’s operating margin of approximately 5% compares to Domino’s 19.3%, and the gap is not primarily explained by scale. Papa John’s carries higher food and labour costs as a percentage of sales, operates with less supply chain leverage, and has a franchisee base that has been less profitable on average than Domino’s, which limits new unit investment and therefore limits the store count growth that drives the royalty income base. It is not a credible threat to Domino’s system economics.

Third-Party Delivery Platforms

DoorDash, Uber Eats, and Grubhub have permanently changed consumer behaviour; ordering delivery now means choosing from every available restaurant simultaneously. This is genuinely a structural change, not a cyclical one, and it reduces the advantage of delivery availability that was one of the original pillars of the Domino’s brand. The financial evidence that this has not yet materially damaged Domino’s is in the 2025 results, 3.0% U.S. same-store sales growth and 19.3% operating margins in a fully aggregator-competitive environment. But the risk is directional and worth monitoring; Domino’s selectively joined Uber Eats in the United States in 2023–2024, which captured incremental volume but introduced a strategic ambiguity about the long-term mix between direct and platform orders. The commercial rationale is sound. The strategic consequence is discussed in Risks.

6. Management

Russell J. Weiner - Chief Executive Officer

Russell Weiner joined Domino’s in 2008 as Chief Marketing Officer, following a decade at PepsiCo including a Vice President of Marketing role for Colas at Pepsi-Cola North America. His career at Domino’s progressed through President of Domino’s USA (2014–2018), Chief Operating Officer and President of the Americas (2018–2020), COO and President, Domino’s U.S. (2020–2022), and Chief Executive Officer from May 2022. His 14-year tenure before the top job spans almost every element of the brand’s transformation, the recipe overhaul, the technology investment, the shift to a digital-first ordering model, and the acceleration of international growth. The institutional knowledge embedded in that tenure is a genuine asset; Weiner does not need to learn the business or the brand. He built significant parts of it.

Weiner’s direct ownership stands at approximately 110,764 shares including exercisable options as of fiscal year-end 2025. At the current price, this represents a meaningful personal stake relative to his salary, though modest relative to the company’s market capitalisation. Total insider ownership across all directors and executive officers represents approximately 0.89% of shares outstanding. There is no founder stake and no controlling shareholder. Vanguard holds approximately 11.5% of shares, Berkshire Hathaway approximately 10.0%, BlackRock approximately 6.7%, and T. Rowe Price approximately 6.2%. Berkshire’s position is notable as a signal of quality recognition from a long-horizon institutional investor that is selective about franchise businesses.

Approximately 91% of Weiner’s target total direct compensation is variable: 18% annual cash incentive and 72% long-term equity. The equity mix is 55% performance-based restricted stock units, 25% stock options, and 20% time-vesting RSUs. PSU vesting is tied to three-year Consolidated Adjusted EBITDA growth and global retail sales growth, with a relative TSR modifier versus the S&P 1500 Restaurants Sub-Index. The heavy equity weighting creates genuine alignment, Weiner’s wealth is predominantly tied to the stock price over multi-year periods. The incentive metrics are EBITDA-based and do not penalise capital expenditure or stock-based compensation, which means management is not directly incentivised to minimise these costs. At current capex levels of approximately 2.4% of revenue, this is a modest structural concern rather than an immediate issue.

7. Growth Levers & Addressable Market

International Unit Expansion

International net store growth of 604 units in 2025, against a base of approximately 14,352 stores at year-end 2024, represents a growth rate of approximately 4.2%. This is the most direct and highest-conviction growth lever available because the economics are straightforward; each new franchised store generates an incremental royalty stream at negligible marginal cost to the company, and the store count grows on the franchisee’s capital, not Domino’s. The royalty income contribution from each new international store is small individually but compounds materially across hundreds of openings per year.

To quantify the contribution; if international same-store sales are flat and 600 new stores open annually, each averaging approximately $670,000 in annual retail sales at a 3% royalty rate, the incremental royalty income to Domino’s Inc. from new stores alone is approximately $12 million per year. That is a modest annual addition in isolation, but it compounds, each year’s cohort of new stores matures to higher sales volumes in subsequent years, and 600 openings annually over a decade builds a royalty base that is structurally larger than what exists today. The value of international unit growth is real but it is a long-duration compounder, not a near-term earnings driver

U.S. Same-Store Sales and Unit Expansion

The U.S. business delivered same-store sales growth of 3.0% in 2025 following a difficult 2022–2023 period. At a 5.5% royalty rate on approximately $9.9 billion in U.S. retail sales, a 1 percentage point increase in same-store sales generates approximately $100 million in incremental retail sales and approximately $5.5 million in incremental royalty income. The lever is real but not large on an absolute basis, its importance is as a compounding contributor to the royalty income base rather than a step-change generator. With approximately 7,186 domestic stores and management identifying potential for continued net unit growth in the low hundreds annually, each new domestic franchise store adds royalty income at no incremental capital cost to the company.

International Same-Store Sales Recovery

International same-store sales growth of 1.9% in 2025 was an improvement but remains below the historical average. The largest international master franchisee, Domino’s Pizza Enterprises (DMP: ASX), has been under pressure in certain markets including Japan and France, where competitive intensity and consumer affordability constraints have weighed on unit economics. A recovery in international same-store sales toward the historical 2–4% range would provide meaningful royalty income uplift across the 14,956-store international base. At a 3% royalty rate on approximately $10 billion in international retail sales, a 1 percentage point improvement in same-store sales generates approximately $100 million in incremental retail sales and approximately $3 million in incremental royalty income, again, a compounding contributor rather than a step-change.

8. Valuation

The future return on Domino's stock is a function of two engines; the future growth in free cash flow per share plus any valuation re-rating. Both are explained below:

Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, share count reduction from buybacks, and the structural margin tailwind from refranchising. For Domino’s, I estimate FCF per share growth of approximately 8% annually over the next decade. That estimate is built from two components that have been quantified through the analysis in this report rather than assumed.

The operational component is approximately 5% annually. International unit growth of approximately 600 stores per year generates roughly $12 million in incremental annual royalty income at an average store retail sales of $670,000 and a 3% master franchisee royalty rate. U.S. same-store sales growth of approximately 3% on a $9.95 billion retail base at a 5.5% royalty rate adds approximately $16 million in incremental royalty income annually. The refranchising of remaining company-owned stores adds a modest margin improvement as lower-margin operational revenue converts to higher-margin royalty income. Combined, these levers produce approximately 5% organic FCF growth, a modest but honest rate that reflects the maturity of the U.S. market and the master franchisee layer that sits between Domino’s Inc. and individual store operators in most international markets.

The capital return component adds approximately 3 percentage points. Domino’s has retired shares continuously since 2005, twenty years of uninterrupted execution through multiple interest rate cycles, a pandemic, a commodity shock, and a labour crisis. The programme has not been interrupted once. The financial position today supports its continuation: the interest / OCF ratio has improved from 38% in 2016 to 25% in 2025, and the debt / OCF ratio has declined from its 2022 peak of 11.3x to 6.3x in 2025. Whether the outstanding share count is 55 million or 34 million is irrelevant to the sustainability of the programme, retiring 2–3% of whatever count is outstanding annually produces the same per-share amplification effect, and the cash generation to fund $300–400 million in annual buybacks is not in question at current OCF levels.

The combined 8% estimate is not conservative and it is not optimistic. It is the rate the business can sustain when the growth levers are quantified honestly and the buyback contribution is given its proper analytical weight alongside the operational growth rate.

Engine 2: Valuation Re-Rating

At today’s price of approximately $330, the investor is paying for everything this business will earn over roughly the next 19 years, in today’s money. Everything it earns beyond that point comes to you for free. The fewer the embedded years, the more of the future you receive without paying for it.

Domino’s sits in the Attractive zone. The expected return is the 8% fundamental growth rate plus a partial upward revaluation as the market prices in a longer earnings horizon over time. There is a decent margin of safety at this price for this type of business.

The Attractive zone does not mean the price cannot go lower in the near term, it means that at this price, the investor is not depending on a heroic growth assumption or a valuation re-rating to generate a reasonable return. The 8% fundamental growth delivers a reasonable return on its own. The partial re-rating is additional.

For a detailed explanation of how this valuation framework works and the thinking behind it, please check A Comprehensive Guide to Business Valuation

9. Risks

Commodity Costs, Particularly Cheese

The supply chain segment sells a food basket to franchisees at prices that move with commodity markets. Cheese is the single largest variable input, Domino’s explicitly identifies it as the primary commodity exposure in its market risk disclosures, and it carries the most direct and immediate impact on supply chain margins. A sustained increase in cheese prices creates pricing pressure that the company must either absorb or pass through to franchisees.

If the cost increase is passed to franchisees, unit economics weaken. Weaker unit economics reduce franchisee investment appetite, slow new store openings, and can accelerate closures, all of which directly reduce the royalty income base that drives the company’s value. If the cost increase is absorbed by the company, operating income declines directly. The 2022 experience, food basket costs up 13–15% driven by the Russia-Ukraine commodity shock, showed how quickly this mechanism works; operating margins fell from 17.9% to 16.5% in a single year, EPS declined, and FCF per share fell by 29%. That was a one-year commodity event. A multi-year structural increase in cheese or wheat prices, from climate disruption, supply concentration risk, or sustained feed cost inflation, would create a more persistent margin headwind than the 2022 episode and would be harder to recover from. The ABS covenant structure requires sustained OCF generation at levels sufficient to service the debt; a severe and prolonged commodity shock that compresses OCF meaningfully would narrow the financial flexibility available at the 2027 refinancing.

2027 Refinancing and Leverage

The 2017 Ten-Year Notes ($940 million) and 2018 9.25-Year Notes ($379 million) carry anticipated repayment dates in July 2027, creating a near-term refinancing event in a rate environment materially higher than when those notes were originally placed at rates of approximately 3.8–4.5%. The September 2025 refinancing, $1 billion in new notes at 4.93% and 5.22%, establishes the most current reference point for what the 2027 event will likely cost. Replacing $1.3 billion in notes at an average incremental rate of 50–100 basis points above their original coupons would increase annual interest expense by approximately $7–13 million. That is manageable at current OCF levels. The more significant risk is the combination; higher refinancing rates occurring simultaneously with a commodity-driven OCF compression, or a same-store sales deterioration. In isolation, the 2027 refinancing is a known and manageable event. In combination with a cyclical operating downturn, it would compress the debt / OCF ratio and potentially trigger closer scrutiny of the ABS covenants, which require a minimum coverage ratio of 1.75x total debt service to securitised net cash flow.

Aggregator Channel Erosion of the Direct Relationship

Domino’s selectively joined the Uber Eats platform in the United States in 2023–2024 to capture volume from consumers who order exclusively through aggregators. The commercial rationale is to grow total order volume by reaching a segment of consumers who would not otherwise order directly. But the strategic consequence is a structural shift in how consumers discover and order from the brand.

Domino’s built its competitive position around the direct ordering relationship, first-party customer data, commission-free unit economics, and the habit of going to Domino’s directly rather than browsing a platform. Each of these advantages erodes when a meaningful share of orders flows through an aggregator. First-party data advantages diminish as aggregators capture the ordering behaviour. Unit economics compress as commission fees of 15–30% apply to platform orders. And the habit of direct ordering weakens as consumers normalise the aggregator interface as their primary food discovery mechanism. The current financial evidence does not yet show these effects: 2025 operating margins are at a decade high. But the aggregator channel is growing, and the financial damage from habit erosion typically lags the strategic concession by several years. If aggregator-sourced orders grow beyond a threshold where they materially affect unit economics or same-store sales contribution, the margin trajectory would inflect downward in ways that would not be visible in the near-term data.

Shift in Consumer Taste

Domino’s is a single-category operator. The entire business is built around the consumer’s appetite for pizza, and specifically for delivered pizza. A sustained shift in dietary preferences, toward healthier options, different cuisines, or cooking at home, would reduce the frequency of the Domino’s order occasion regardless of how well the franchise executes. This risk is the longest-dated and hardest to quantify of the four, but it is structurally real and carries no operational hedge.

The QSR industry has watched several once-dominant categories lose relevance over decades as consumer preferences evolved, the decline of traditional fast food burgers in the early 2000s, the pressure on carbonated beverages from water and energy drinks, the gradual erosion of certain breakfast formats. Pizza has proven more durable than most QSR categories, partly because the format adapts well to both delivery and carryout, and partly because the price point remains competitive against alternatives. But Domino’s has no meaningful product diversification to offset a structural decline in pizza consumption frequency. Its brand, its supply chain, its franchisee network, and its entire operational infrastructure are built for one product category. If that category declines, there is no pivot available. The risk probability is low on any near-term horizon, but the consequence, a gradual and permanent reduction in global retail sales volumes, would directly reduce the royalty income base in a way that no management action could fully offset.

Master Franchisee Restructuring

Domino’s Pizza Enterprises (DMP: ASX) is the company’s largest master franchisee, operating approximately 16% of the global store count across 12 markets and contributing approximately 20% of Domino’s international franchise royalty income. The concentration in a single franchisee relationship of this scale creates a risk that is not visible in the headline disclosure, Domino’s Inc. reports DMP royalties as approximately 1.4% of consolidated revenues, which frames the relationship as immaterial when it is in fact the single most important bilateral relationship in the international business.

DMP is in active restructuring across two of its largest markets. The root cause in Japan was a capital allocation failure, not a rejection of the product. DMP opened a net of 403 stores in Japan between 2020 and 2023 during a period of pandemic-elevated delivery demand. When post-pandemic consumer behaviour normalised, a large portion of those stores could not generate sufficient sales to sustain the advertising investment required to make the Domino’s model work, lower sales reduced advertising funds, lower advertising reduced new customer acquisition, and declining customer counts further compressed store economics in a self-reinforcing cycle. DMP closed 233 stores in Japan in FY2025, following earlier rounds of closures in Japan, France, and Denmark. Total store closures across the group in FY2025 reached 312, incurring AUD $162.3 million in significant costs that drove the group to a statutory net loss of AUD $3.7 million despite an underlying EBIT of AUD $198.1 million. France closed 32 additional stores, is facing franchisee legal action, and appointed its third CEO in recent years. Japan is currently operating under an interim CEO while a permanent replacement with deep local expertise is recruited.

The financial risk to Domino’s Inc. operates through two channels. The first is direct and permanent: every store that closes eliminates a royalty stream that does not return. At average store retail sales of approximately $670,000 annually and a 3% royalty rate, the 312 stores closed in FY2025 reduce annual royalty income to Domino’s Inc. by approximately $6.3 million. That is not catastrophic in isolation, but the closures are permanent and the pace, 312 in a single year across a 3,500-store network, represents a 9% contraction of the network in twelve months. The second channel is indirect: DMP’s financial capacity to reinvest, fund marketing, support franchisees, and resume growth is constrained by the restructuring costs and by the earnings trajectory. Free cash flow fell to AUD $47.4 million in FY2025, down AUD $56.7 million year-on-year. A financially constrained DMP is a DMP that opens fewer new stores, which directly reduces the royalty income growth that underpins the international expansion thesis.

The distinction between a mismanagement failure and a demand failure matters for how permanent this risk is. Japan is a genuine pizza market with decades of Domino’s presence. Germany is achieving record weekly sales. Benelux recorded national sales records in FY2025. Australia delivered its highest franchisee profitability in three years. The evidence from DMP’s own portfolio shows that the Domino’s brand works when the store network is correctly sized and the unit economics are healthy. The failure in Japan and France was in the decision to expand aggressively into locations that could not support profitable operations at steady-state demand. That is correctable, but the correction takes years, reduces the royalty base in the interim, and creates leadership instability at the market level in both Japan and France simultaneously. For a franchisee that accounts for 20% of international royalty income, the timeline of that recovery is a material variable in the Domino’s Inc. investment thesis.

10. The Verdict

Domino’s earns Approved status on the strength of a franchise system that has demonstrated genuine competitive durability across a full decade and through a period of serious adversity. The case for the quality of this business rests on three things; the financial record, the recovery from 2022, and the structural economics of the royalty model.

The financial record is unambiguous. FCF per share compounded at 17.0% annually from 2015 to 2025. EPS grew at 17.6%. Global retail sales more than doubled. The blended operating margin held in a narrow 17–19% range through commodity shocks, a pandemic, a labour crisis, and the rise of aggregator platforms. A business that sustains those results across a decade of significant external disruption is not doing so by accident. It is doing so because the underlying competitive advantages, the value equation, the network density, the franchisee economics, are structural and self-reinforcing.

The 2022 recovery is the most analytically important single data point in this report. The year was genuinely bad; operating margins fell to 16.5%, EPS declined from $13.54 to $12.53, and FCF per share fell 29% from its 2021 peak. Three independent external shocks hit simultaneously, a commodity cost surge, a labour market dislocation that crippled delivery capacity, and an inflation-driven demand reduction among the price-sensitive consumer segment that Domino’s relies on most. Under that combination of pressures, a franchise with a structurally weakening competitive position would have struggled to recover. Domino’s recovered in a single year. By 2023, operating margins had already returned to 18.3%. By 2025, they had reached 19.3%, the highest of the decade. The speed and completeness of the recovery is the proof of structural quality, not just the 2025 results in isolation.

The royalty model’s economics deserve specific acknowledgment in the Verdict because they are what makes Approved the right designation despite the leverage and the competitive changes around aggregators. International franchise segment income of $288.5 million on $338.7 million in revenue, an 85.2% segment margin, is the financial expression of what it means to own a brand that the world pays royalties to use. That margin does not come from operational efficiency or cost management. It comes from the structural position of being the brand that 14,956 international stores pay to operate under. Adding 600 stores per year to that network, each paying a royalty on every dollar of sales, is a compounding mechanism that is independent of commodity prices, labour markets, or aggregator strategies.

The risks are real and have been stated plainly. Cheese prices can spike in ways that damage franchisee economics and compress the company’s margins. The 2027 refinancing will cost more than the notes it replaces. The aggregator partnership introduces a strategic ambiguity that did not exist five years ago, and its long-term consequence for the direct ordering relationship is genuinely uncertain. A structural decline in pizza consumption frequency would reduce the royalty base in ways no management team could offset. None of these risks individually, or even collectively in a realistic scenario, changes the Approved designation. The franchise quality is above the threshold, and the risks are risks to the return, not to the fundamental business model.

The business quality is not in question and the current price offers a decent margin of safety. At $330, this is a high-quality franchise available at a price that does not require a heroic growth assumption or a perfect execution outcome to generate a reasonable return. The 8% FCF per share growth estimate is built from quantified components: approximately 5% from the organic royalty income growth across U.S. and international markets, plus approximately 3 percentage points from a buyback programme that has run without interruption for twenty years. An investor who owns Domino’s at this price is buying the fundamental growth rate plus a partial re-rating, which is precisely what the Attractive zone is designed to capture.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. The author does not hold a position in DPZ. Read the full disclaimer here

Investors spend considerable time analysing businesses, studying competitive positions, reading annual reports, tracking management decisions, and then hand the most consequential part of the process to a set of tools that are, at best, incomplete and, at worst, quietly misleading. Ratios like Price-to-earnings, Price-to-sales, or Discounted cash flow models anchored to a terminal value. These are the instruments of professional finance, taught in every business school, used in every investment bank, and repeated in every equity research report published every day. Their ubiquity is mistaken for reliability. It is not the same thing.

This article is about why conventional valuation methods carry significant limitations that are rarely acknowledged, what those limitations mean for the investor trying to make honest decisions, and what a more rigorous approach looks like.

The Problem with Conventional Multiples

Price-to-Sales

The price-to-sales ratio divides market capitalisation by annual revenue. It became particularly fashionable during periods of high-growth technology investing, where many businesses had no earnings to speak of and analysts needed some anchor for valuation.

The fundamental problem with price-to-sales is that it ignores everything that happens between the top line and the bottom line. Revenue is what comes in the door. What matters to the investor is what remains after paying employees, suppliers, landlords, tax authorities, and the capital expenditure required to keep the business running. A business generating $10 billion in revenue and converting 2% of it into free cash flow is a fundamentally different investment from one converting 25% of the same revenue, but a price-to-sales ratio treats them identically. The metric is indifferent to cost structure, capital intensity, and the business’s actual ability to generate cash for its owners. Using it as a primary valuation tool is the equivalent of buying a restaurant based on how many tables it has without asking whether it makes any money.

Price-to-Earnings

The price-to-earnings ratio divides the current stock price by the earnings per share over the past twelve months. It is the most widely used valuation metric in investing. It is also one of the most easily misunderstood.

A P/E ratio tells you what the market is currently paying per dollar of historical earnings. What it does not tell you is whether that price is right. When analysts compare a stock’s current P/E to its historical average, they are implicitly assuming that the historical average was a reasonable price, which assumes the market was pricing it correctly in the past, which is circular reasoning. The market is not a reliable reference point for its own rationality.

The P/E ratio also uses accounting earnings, which are subject to non-cash adjustments, depreciation schedules, and one-time items that can make the same underlying business look cheap or expensive depending entirely on accounting choices. Two businesses with identical cash generation can carry very different P/E ratios based purely on how their accountants treat certain expenses. This is a structural flaw in the metric.

Price-to-Free-Cash-Flow

Price-to-free-cash-flow is a more meaningful metric than P/E or P/S because free cash flow, operating cash flow less capital expenditure, is closer to what the business actually generates for its owners. But it carries its own distortions.

Free cash flow fluctuates significantly with capital expenditure cycles. A business that is investing heavily in new capacity, building new stores, expanding manufacturing, upgrading infrastructure, will show depressed free cash flow during the investment period even if the underlying earnings power is growing strongly. Conversely, a business that has deferred necessary investment will show elevated free cash flow in the short term while quietly eroding its competitive position. Point-in-time price-to-FCF ratios capture neither dynamic accurately. When free cash flow is distorted by these cycles, earnings per share can serve as a more stable proxy, or the analyst must normalise free cash flow to reflect the mid-cycle level rather than the current year’s figure, adjusting for both capital expenditure timing and inventory movements that can temporarily inflate or depress the reported number.

Critically, free cash flow per share must always be adjusted for stock-based compensation. SBC is a real economic cost to shareholders, it either dilutes existing ownership or requires buyback activity to offset, but it does not appear as a cash outflow in the free cash flow statement. A business that reports strong free cash flow while issuing significant equity compensation to employees is overstating its true cash generation. The adjustment is not optional; it is the difference between what the business earns and what the owners actually receive.

Conventional multiples, taken together, are useful as a rough sanity check, a way of quickly orienting to whether a business is in the general vicinity of reasonable or clearly extreme. They should never be the decision anchor. They describe the present and the past. Investment returns are determined by the future.

Fair Value is a Fiction

Beyond the specific flaws of individual multiples lies a more fundamental problem: the concept of fair value itself.

When an analyst says a business has a fair value of $X per share, they are implicitly claiming to know the sum of all future cash flows the business will generate, discounted back to today. That is a claim about everything the business will earn for the rest of its existence, decades of future performance, compressed into a single number. The precision is false. No one knows what a business will earn in fifteen years accurately. No model, however sophisticated, can reliably project the competitive dynamics, technological changes, regulatory shifts, and management decisions that will determine cash flows decades from now.

The standard tool for producing this false precision is the discounted cash flow model. A DCF model constructs a series of projected cash flows over an explicit forecast period, typically five to ten years, and then adds a terminal value representing all cash flows beyond that period in perpetuity. The terminal value typically represents 60% to 80% of the total calculated value of the business. The number that drives most of the answer is the one with the least analytical foundation, a single assumption about a growth rate that will persist forever, applied to a business operating in a world that will look nothing like today’s.

Practitioners know this. The terminal value assumption is where the model’s conclusion is engineered. An analyst who wants to justify a higher price assumption raises the terminal growth rate by half a percentage point. The model produces a higher fair value. The analysis looks rigorous because it is expressed in a spreadsheet with many rows. The subjectivity is hidden inside a single cell.

The WACC, the weighted average cost of capital used as the discount rate, carries its own problems. It is derived partly from beta, a measure of how much a stock’s price moves relative to the market. Beta is a property of the stock price, not the business. Using price volatility as an input to value the business means the discount rate is partly determined by the market’s own mood swings. On a day when the market is fearful and the stock falls 20%, the beta rises, the WACC rises, and the model produces a lower fair value, not because anything changed in the business, but because the market was nervous. This is tautology expressed in the language of finance.

The honest position is this: the value of a business is the sum of all its future discounted cash flows. That number is unknowable with precision. Any model that claims to calculate it exactly is being misleading. What can be done honestly is to estimate a range, acknowledge the assumptions explicitly, require a meaningful margin of safety between the price paid and even the conservative end of that range, and focus analytical energy on businesses whose future is sufficiently clear to make the estimation meaningful at all.

Clarity is a Pre-requisite

This last point deserves emphasis, because it connects the valuation methodology directly to the quality of the business being analysed.

A valuation is a representation of what the investor believes the business will produce in the future. The reliability of that representation depends entirely on how predictable the business’s cash flows are. A business with volatile, cyclical, or structurally uncertain earnings produces projections with enormous error bars. Even the most sophisticated framework applied to an unpredictable business produces an unreliable output, not because the framework is flawed, but because the input is noise.

This is why selectivity in business quality and rigour in valuation are not separate disciplines. They are the same discipline. Focusing analytical energy on businesses with durable competitive advantages, stable gross margins, predictable revenue streams, and a long track record of generating consistent free cash flow is not conservatism, it is the precondition for valuation to be meaningful at all. A business whose earnings fluctuate by 40% from year to year cannot be projected with confidence, which means the estimated embedded years carry so much uncertainty that the margin of safety required to invest responsibly becomes impractically large.

The framework described in the next section is only reliable when applied to businesses with sufficient clarity about their future to make the projection credible. Applied to highly cyclical, leveraged, or structurally uncertain businesses, it produces numbers that feel precise but are not. The investor must know the difference.

A More Honest Framework

Rather than asking what a business is worth, a question that implies a precision no one possesses, a more useful question is: at today’s price, how many years of future cash flows am I paying for?

The framework constructs a year-by-year series of discounted free cash flow per share projections and asks precisely this. The output is not a fair value. It is a number of embedded years, the stretch of the future that today’s price has already purchased. Everything the business earns beyond that point comes to the investor for free. The fewer the embedded years, the more of the future the investor receives without paying for it. The more embedded years, the longer the investor waits before the pre-paid portion of the future is exhausted and genuine excess returns begin to accumulate.

To make this concrete: imagine analysing a business like McDonald’s. The investor projects the next 20 years of free cash flow per share, accounting for the company’s growth opportunities, addressable market, pricing power, and share buyback behaviour, and discounts that entire stream back to today. If the current stock price reflects only the present value of the first 8 of those 20 projected years, the investor is paying for 8 years of future earnings and receiving the remaining 12 years of the projection, plus everything beyond year 20, entirely for free.

The question then becomes one of conviction about the business. McDonald’s has operated for over 70 years, serves tens of millions of customers daily across more than 100 countries, and has demonstrated through multiple economic cycles that its cash generation is durable and growing. If an investor believes with reasonable confidence that McDonald’s will continue operating and generating cash for decades beyond year 8, which its track record strongly supports, then a price embedding only 8 years of future earnings is not merely cheap. It is a bargain that can absorb meaningful errors in the underlying projections and still produce an exceptional outcome. The investor does not need to be precisely right about the growth rate in year 14 or year 19. The margin between what they paid for and what the business will likely deliver is wide enough to accommodate imprecision.

This is precisely why the number of embedded years matters more than a calculated fair value. It does not tell the investor what the business is worth, no one knows that. It tells them how much of the future they are pre-paying for, and how much they are receiving for free. The wider that gap, the more room exists for the investor to be wrong and still win.

What matters is not whether the embedded years are 14 or 16, both are in the same vicinity and call for the same investor behaviour. What matters is the difference between 12 embedded years and 35.

The Importance of the Entry Price

The practical implication of all of this is that the price paid at entry is one of the most consequential investment decisions an investor makes, more consequential, in many cases, than which business they choose.

Consider two examples from recent market history.

Apple ($AAPL). At the end of 2016, Apple’s stock price embedded approximately 10 years of future cash flows, at a moment when the market was uncertain about iPhone saturation and the company’s ability to sustain its growth. Warren Buffett initiated Berkshire Hathaway’s first Apple position in the first quarter of 2016 and continued building it aggressively. Over the following nine years, Apple’s free cash flow per share grew at a compound annual rate of approximately 11.7%. The stock price grew at approximately 27.7% annually over the same period. The share count fell by around 32% over the period through consistent buybacks, which contributed to per-share growth, but the gap between the 11.7% fundamental growth and the 27.7% price growth cannot be explained by buybacks alone. The dominant force was valuation expansion: the market re-rated Apple from 10 embedded years to over 40 embedded years as confidence in the franchise grew, and that re-rating added approximately 16 percentage points of annual return on top of what the business itself delivered. An investor who owned Apple through this period did not merely capture the fundamental growth of the business. They captured the fundamental growth plus an enormous revaluation bonus that was only available because the entry price was so compelling. Buffett has since significantly reduced Berkshire’s Apple position as the valuation entered and remained in the most stretched territory.

Alphabet ($GOOG). In early 2022, Google’s stock traded at approximately $148, embedding around 22 years of future cash flows. An investor who bought at that price and holds today at approximately $384 has generated a compound annual return of 27%. An investor who waited, and bought instead in late 2023 at $87, when the embedded years had compressed to approximately 12 and the market was deeply pessimistic about digital advertising and the competitive threat from AI-powered search, and holds today has generated a compound annual return of approximately 64%. The business is identical. The competitive position did not change materially between those two entry points. The difference in return is almost entirely a function of valuation at entry.

These are not cherry-picked anomalies. They are illustrations of a principle that operates in every market, in every cycle, for every business: the price paid at entry determines a significant portion of the return received, independent of how the underlying business performs. A great business bought at an excessive valuation can produce mediocre returns. The same great business bought at a compelling valuation can produce exceptional ones.

What This Means in Practice

Valuation is an estimation exercise that produces a range of plausible outcomes, shaped by assumptions about the future that will inevitably be imperfect. The honest investor acknowledges this and builds their process around it, requiring a margin of safety that provides room to be wrong, focusing on businesses whose futures are sufficiently clear to make the estimation meaningful, and treating the entry price as one of the few genuinely controllable variables in an otherwise uncertain process.

Conventional multiples have their place as a quick orientation tool. They are not a substitute for thinking carefully about what the current price implies about the future, whether that implication is reasonable given the evidence, and how much of the future the investor is pre-paying for before the free portion begins.

The goal is not precision. The goal is honesty about uncertainty, discipline in requiring adequate compensation for the risks taken, and the patience to wait for prices that make the investment genuinely compelling rather than merely defensible.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The Outlook

Beauty is one of the few retail categories where the physical experience has not merely survived digital disruption, it has remained the primary reason consumers shop at all. You cannot match a foundation shade on a screen with confidence. You cannot know whether a fragrance suits you until you smell it on your own skin. You cannot replicate the trust of a stylist’s recommendation through a product carousel. Discovery in beauty is tactile, social, and advisory, and for thirty five years Ulta Beauty has been constructing the infrastructure to own that moment, and then to extend it, through digital and loyalty channels, into everything that comes after.

The founding insight, when Richard George and Terry Hanson opened the first store in Bolingbrook, Illinois in 1990, was that the beauty retail market had fragmented itself by price tier in ways that served the trade rather than the consumer. Prestige products lived behind department store counters, mass products in drug store aisles, professional products in authorised salons. A consumer who wanted all three made three separate trips. Ulta collapsed those occasions into a single destination: a large format store in a suburban strip centre, carrying prestige, mass, and professional products side by side, with a full service salon at the back. That structure, breadth across price tiers, embedded services, and a loyalty programme that converts every purchase into a data point, is what has been scaling for three and a half decades.

The loyalty programme, Ultamate Rewards, is the operational heart of the model. With more than 46 million active members and approximately 95% of all net sales flowing through the programme, Ulta has built something rare: a consumer franchise where the relationship between brand and customer is mediated almost entirely through a proprietary data layer the company controls. A member who discovers a moisturiser at an in store consultation, confirms it works, and then reorders it through the Ulta app is not just a repeat customer, she is a data point that improves the next recommendation, the next promotion, and the next brand partner negotiation. The guest who shops both in store and digitally spends, historically, more than three times as much as the store only guest. That pattern, in store discovery leading to digital replenishment, is the highest value expression of the model, and Ulta has built its entire commercial infrastructure around deepening it.

The financial record produced by this model is, for most of the decade between fiscal 2015 and fiscal 2025, impressive. Revenue compounded from $3.9 billion to $12.4 billion. Return on invested capital (ROIC) averaged above 27% through much of the period. Free cash flow per share grew from approximately $1 in fiscal 2015 to approximately $22.90 in fiscal 2025, driven by both genuine earnings growth and a consistent programme of share repurchases that reduced the diluted share count from 64.3 million to 45.0 million over the same period. These are the numbers of a business that earned genuine returns on incremental capital and allocated that capital with discipline.

But a financial record is a description of where a business has been, not a guarantee of where it is going. And what the most recent three fiscal years describe, fiscal 2022 through fiscal 2025, is a business whose absolute earnings and cash flow have stopped growing. Net income in fiscal 2022 was $1,242 million; in fiscal 2025 it was $1,154 million. Operating cash flow in fiscal 2022 was $1,482 million; in fiscal 2025 it was $1,503 million, marginally higher over three years, before adjusting for the cost of the capital that generated it. Meanwhile, selling, general and administrative expenses as a percentage of revenue have risen from 23.5% in fiscal 2022 to 26.6% in fiscal 2025, a consistent and multi year trend that this report examines closely.

The question this report attempts to answer honestly is whether these developments represent a transitional period in a business that will resume compounding, or an inflection in the underlying economics of a model that is approaching the limits of its domestic growth runway.

At approximately $558 per share and a market capitalisation of roughly $24.3 billion, the current price embeds approximately 46 years of future cash flows, a level that demands a confident view of the growth trajectory that the current evidence does not fully support. The analysis that follows is an attempt to be precise about what the business has demonstrated, what it has not, and what would need to change to make this a compelling investment.

At a Glance

Company: Ulta Beauty, Inc.

Ticker: $ULTA · NASDAQ

Sector: Consumer Discretionary

Industry: Specialty Retail — Beauty

Market Cap: $24.3 billion (at $558)

First Coverage: April 2026

FY2025 Revenue: $12.4 billion

1. The Business

Ulta Beauty was founded in Bolingbrook, Illinois in 1990 on the premise that the fragmentation of beauty retail by price tier was a structural inefficiency serving the trade more than the consumer. The founding format, a large format freestanding store in suburban strip centres, carrying prestige, mass, and professional products side by side, with a full service salon at the back, was unconventional at the time and has proven durable over three and a half decades. The company went public on NASDAQ in October 2007 and used the capital to fund national expansion. By fiscal 2016 it operated 974 stores; by fiscal 2025, 1,505 stores across all 50 states, alongside 86 Space NK stores in the United Kingdom and Ireland acquired in July 2025.

Ulta is a specialty beauty retailer, not a brand owner. It acts as the discovery and distribution platform between beauty brands and consumers, carrying approximately 30,000 products from approximately 600 established and emerging brands across every major price tier and category. The typical US store is approximately 10,000 square feet, with roughly 950 square feet dedicated to a full service salon offering haircuts, colour, blowouts, brow services, and skincare treatments. A smaller store prototype of 5,000 to 7,500 square feet is used for secondary markets. E-commerce and the mobile app, where approximately 60% of online sales originate, serve as replenishment and loyalty engagement channels, with omnichannel members spending historically more than three times as much as store-only members.

Beyond its branded assortment, Ulta offers its own private label brand, Ulta Beauty Collection, as well as a portfolio of third party brands sold exclusively at Ulta, either on a limited time basis or as longer term exclusives. Examples of exclusive brand partnerships include Cécred and Peach & Lily. In fiscal 2025, Ulta Beauty Collection and long term exclusive products represented approximately 4% of net sales; including short term exclusive products, the combined figure was approximately 11% of net sales. These exclusive relationships serve a dual purpose, they differentiate the assortment from competitors and generate higher merchandise margins than branded product sales at standard terms.

In fiscal 2025, cosmetics accounted for 38% of net sales, skincare and wellness 24%, haircare 19%, fragrance 13%, services 4%, and other 2%. The cosmetics share has declined modestly as skincare and fragrance have grown, reflecting broader category trends. Services, at 4% of revenue, carry strategic weight disproportionate to their financial contribution: a guest who schedules colour appointments returns on a predictable cadence, and the stylist relationship is among the most durable loyalty anchors in the store.

Ulta centrally manages product replenishment through a merchandise planning group that operates an open to buy system updated weekly with point of sale data, receipts, and inventory levels. As of fiscal year end 2025, the company operates four regional distribution centres, two market fulfilment centres serving both stores and e-commerce, and one fast fulfilment centre dedicated to e-commerce orders. More than 1,000 US stores participate in a ship from store programme. The market fulfilment centres, smaller, focused on the most productive SKUs, are designed to improve responsiveness in high density markets. This distribution infrastructure is the operational backbone of the omnichannel model and a genuine barrier to replication for any new entrant seeking to compete at comparable scale.

The Ultamate Rewards loyalty programme is the commercial engine of the business. With more than 46 million active members as of fiscal year end 2025, and approximately 95% of net sales flowing through it, the programme has achieved a penetration rate that is exceptional in specialty retail. Annual member retention exceeds 70%. The $582.4 million deferred revenue balance represents unredeemed points and gift cards, a forward commitment to return that is growing faster than the membership base itself. In fiscal 2025, 73% of loyalty members transacted exclusively in stores, reflecting the enduring primacy of the physical shopping occasion for Ulta’s core guest.

In July 2025, Ulta acquired Space NK, a luxury beauty retailer with 86 stores in the UK and Ireland, for approximately $399 million, funded with cash and short term credit. Space NK carries a premium, niche forward assortment in a smaller store format than Ulta’s US stores and is well regarded within the UK prestige beauty market. Beyond Space NK, Ulta operates a joint venture in Mexico with Grupo Axo (9 stores at fiscal year end 2025) and a franchise arrangement in the Middle East with Alshaya Group (2 stores). The international platform is financially immaterial relative to the US business, Space NK was acquired only partway through fiscal 2025, and will require sustained execution to justify the capital deployed.

2. The Moat

Ulta’s competitive advantage is a self reinforcing commercial ecosystem built on loyalty data, multi tier product breadth, in store experience, and physical density. The mechanism has been operating for three and a half decades without being successfully replicated at scale.

The mechanism works as follows. More loyalty members generate more purchase data, which enables more precise personalisation, which increases visit frequency and spend per visit. Higher spend per member justifies investment in brand exclusives and deeper category assortment, which attracts more brands seeking access to the member base. More brands and a stronger assortment attracts new members. A larger member base gives Ulta stronger leverage in brand partner negotiations, on terms, on exclusives, and on being selected as the launch partner for new product introductions. Each element reinforces the others, and because 95% of transactions flow through the loyalty programme, the data layer captures nearly the entire economic output of the business and converts it into competitive intelligence.

Pillar One

With 46 million active members and 95% of sales processed through Ultamate Rewards, Ulta operates one of the most comprehensive first party consumer databases in US specialty retail. The practical value of this data is in personalisation that an anonymous transaction retailer cannot approach, targeted replenishment reminders, predictive discovery prompts, shade matching recommendations informed by purchase history, and in the leverage it provides in brand partner relationships. A brand partner placing a new product at Ulta is not just accessing shelf space; it is accessing a targeted, purchase verified audience of 46 million beauty consumers. The deferred revenue balance of $582.4 million at fiscal year end 2025, growing 16.3% year on year, is the most direct financial expression of the programme’s deepening engagement: members are earning points at a faster rate than they are spending them, indicating commitment rather than attrition.

Pillar Two

No competitor carries prestige, mass, and salon professional products at scale under one roof. Sephora is prestige focused and carries no mass products or in store salon services at comparable scale. Mass retailers carry mass products but no credible prestige assortment and no services. Department store beauty counters offer prestige but operate as brand specific concessions rather than a multi brand discovery environment. Closing this gap requires simultaneously maintaining trust with prestige brands, who are historically reluctant to be shelved alongside mass products, and building the operational infrastructure to deliver a genuine salon service. Both are multi year relationship and investment commitments. Ulta’s exclusive and private label products deepen this moat further: approximately 11% of net sales flowing through exclusive or proprietary brands creates assortment that simply cannot be found elsewhere.

Pillar Three

The salon services business is embedded in almost every one of the 1,505 US stores. Its strategic importance is precisely its non replicability: no e-commerce platform, social commerce channel, or shop in shop concept can offer a colour appointment, a skincare consultation, or the relationship between a guest and a stylist she has seen three times. A guest who books salon appointments is not weighing Ulta against Amazon or Sephora, she is returning to a person and an experience. Company research confirms what the transaction data suggests: its guests prefer to transact in physical stores, where they can discover and interact with products and other beauty enthusiasts. The 73% of loyalty members who transacted exclusively in stores in fiscal 2025 are, in meaningful part, the guests for whom the physical experience is itself the value.

Pillar Four

With 1,505 stores across all 50 states, predominantly in high traffic suburban strip centres, supported by four regional distribution centres, two market fulfilment centres, one fast fulfilment centre, and more than 1,000 ship from store locations, Ulta operates a physical and logistics network that functions as both a retail asset and a fulfilment infrastructure. Building this network from scratch would require not just capital but years of lease negotiation, supplier relationship development, and market by market customer acquisition. The combination of physical density and distribution capability is the operational foundation of same day delivery, in store pickup, and ship from store, services that require the network to already exist before they can be offered.

Assessment

The core moat is intact. The loyalty programme is deepening, the exclusive brand relationships are growing, the salon service infrastructure remains non replicable, and the data advantage compounds annually. The moat is not, however, without pressure. Social commerce is compressing Ulta’s role at the top of the discovery funnel for younger consumers. Sephora’s expansion at Kohl’s has improved prestige accessibility in a mass retail format at over 1100 locations. These are real competitive dynamics, though they are pressures on the perimeter of the model rather than challenges to its structural core. My assessment is that the moat is stable, and that the more pressing questions for this business are about the cost structure and the growth runway, not the durability of the competitive position itself.

3. Financial Performance

Revenue

Ulta’s revenue between fiscal 2015 and fiscal 2025 divides into three periods. From fiscal 2015 through fiscal 2019, the business grew from $3.9 billion to $7.4 billion, a compound annual growth rate of approximately 17%, driven by new store openings at pace and comparable sales growth consistently in the mid to high single digits. Fiscal 2020 was the COVID interruption: stores closed for approximately eight weeks, comparable sales fell 17.9%, and revenue declined 16.8% to $6.2 billion. From fiscal 2021 through fiscal 2023, revenue recovered sharply, growing 40.3%, then 18.3%, then 9.8%, as pent-up demand, stimulus spending, and the structural step change in gross margins combined to produce exceptional three year period in the company’s history. Fiscal 2024’s growth of 0.8% reflected a normalisation of that demand cycle, and fiscal 2025’s 9.7% growth, driven partly by the Space NK acquisition from July 2025 and a genuine 5.4% comparable sales recovery, represents the current run rate. What the revenue trajectory does not show clearly, but the earnings and cash flow lines do, is that the revenue growth of fiscal 2025 did not translate into earnings growth.

Gross Margin

Gross margins from fiscal 2015 through fiscal 2019 were stable in the 35% to 36% range. Fiscal 2020’s 31.7% reflects the deleverage of fixed store costs on dramatically lower revenue during the COVID closure period, the one clear anomaly in an otherwise consistent record. From fiscal 2021 onward, gross margins moved into a structurally higher band of 39% to 40%, reflecting a greater mix of prestige and skincare products carrying higher merchandise margins, reduced shrink, and supply chain efficiencies. This shift has been sustained for five consecutive years and represents a genuine structural improvement in the gross economics of the product mix. Gross margins have not been the source of the profitability pressure that has emerged since fiscal 2022; they have been a source of stability.

Operating Margin and SG&A

Operating margins tell the more complicated story. From fiscal 2015 through fiscal 2019, operating margins ran in the 12% to 14% range. During the post COVID demand surge of fiscal 2021 through fiscal 2023, operating margins expanded sharply, reaching 16.2% at peak in fiscal 2022, as revenue grew faster than the cost base could expand. Since fiscal 2022, operating margins have declined in each successive year: 15.1% in fiscal 2023, 14.0% in fiscal 2024, and 12.5% in fiscal 2025. The driver throughout has been SG&A.

SG&A as a percentage of revenue was 23.5% in fiscal 2022. It rose to 24.1% in fiscal 2023, to 24.9% in fiscal 2024, and to 26.6% in fiscal 2025, a consistent, multi year upward trend that predates fiscal 2025’s specific items and cannot be attributed to any single year’s activity. In absolute terms, SG&A grew $487.8 million, or 17.4%, in fiscal 2025, against revenue growth of 9.7%. The company attributed this increase to higher incentive compensation reflecting above plan performance, higher store payroll and benefits, higher corporate overhead from strategic investments, and higher store expenses.

Each of these components merits examination. Technology spending, amortisation of the Project SOAR enterprise resource planning implementation, cloud infrastructure costs, and AI personalisation systems, flows through SG&A over multiple years once the capital investment is made; it does not revert when the project is complete. Store payroll has repriced upward in a persistently tight labour market, and wage levels do not reverse when conditions ease. The Space NK acquisition, completed in July 2025, consolidated 86 stores’ worth of operating overhead into the SG&A line for the last two quarters of fiscal 2025, and that overhead is now a permanent part of the run rate. Marketing intensity has increased as the competitive environment requires greater promotional investment to maintain market share. Taken together, these are not temporary distortions around a stable underlying cost structure. They represent a cost base that has structurally repriced to a higher level, and the multi year trend in the SG&A-to-revenue ratio is the clearest evidence of that. Management has acknowledged the trajectory, CEO Kecia Steelman and the new CFO have introduced zero based budgeting and personal review of all new investment initiatives specifically to bring costs back into better alignment with revenue growth.

Net Income and Operating Cash Flow

The most important three numbers in this financial record are the ones that sit flat across the most recent three years. Net income was $1,242 million in fiscal 2022, $1,291 million in fiscal 2023, $1,201 million in fiscal 2024, and $1,154 million in fiscal 2025, lower at fiscal year end 2025 than it was three years earlier. Operating cash flow was $1,482 million in fiscal 2022, $1,476 million in fiscal 2023, $1,339 million in fiscal 2024, and $1,503 million in fiscal 2025, essentially flat over three years of revenue growth from $10.2 billion to $12.4 billion. The per share earnings growth that the EPS line shows over this period, from $24.01 to $25.64, is almost entirely the result of buybacks reducing the denominator rather than the numerator growing. The absolute earnings power of the business has not expanded since fiscal 2022.

Free Cash Flow

SBC adjusted free cash flow peaked at approximately $1.13 billion in fiscal 2022 and has since declined: $993 million in fiscal 2023, $921 million in fiscal 2024, and $1.03 billion in fiscal 2025. The fiscal 2025 figure recovered from fiscal 2024’s trough primarily through working capital timing rather than a structural improvement in earnings. FCF per share has grown modestly over this period, from approximately $22.61 in fiscal 2022 to approximately $23.74 in fiscal 2025, again driven almost entirely by the declining share count rather than FCF growth in absolute terms.

4. Capital Allocation

Ulta pays no dividend. Its capital return programme consists of share repurchases, supplemented in fiscal 2025 by the Space NK acquisition, the largest single inorganic capital commitment in the company’s recent history. This simplicity makes the allocation track record relatively easy to evaluate.

Over fiscal 2022 through fiscal 2025, Ulta repurchased approximately $3.8 billion of its own shares: $900 million in fiscal 2022, $1.01 billion in fiscal 2023, $1.02 billion in fiscal 2024, and $915 million in fiscal 2025. These repurchases reduced the diluted share count from approximately 51.7 million at the start of fiscal 2022 to approximately 45.0 million at fiscal year end 2025, a 13% reduction. As the absolute earnings base has been flat, buybacks have been the primary driver of per share metric growth over this period. Whether that represents value creation depends on whether the shares are being repurchased below their underlying worth. At 47 years of embedded cash flows, the current valuation does not make a compelling case that they are. As of fiscal year end 2025, approximately $1.8 billion remained available under the October 2024 $3.0 billion repurchase authorisation, and management has guided for approximately $1 billion in repurchases in fiscal 2026.

Capital expenditure has run at $150 million to $435 million annually across the decade, reflecting the varying intensity of store construction, remodelling, technology investment, and supply chain infrastructure. At approximately 3% to 4% of revenue, capex intensity is low relative to operating earnings, and the economics of new store construction, a net investment of approximately $2.4 million per location, with payback typically in under two years, make the expansion programme a high return use of capital. In fiscal 2025, Ulta opened 63 net new US stores and remodelled 42 existing locations.

The Space NK acquisition, at approximately $399 million net of acquired cash, placed $226 million of goodwill and $204 million of intangible assets on the balance sheet. These assets earn a return only if Space NK grows its contribution to Ulta’s brand partner relationships and, eventually, to revenue. The financial contribution from 86 stores in the UK and Ireland is currently immaterial, and the acquisition was completed partway through fiscal 2025, so its full year overhead impact will be visible for the first time in fiscal 2026. The capital was deployed at a moment when the domestic business was generating flat absolute earnings, which adds weight to the question of whether this was the highest return use of approximately $400 million.

Share

5. Competition

The US beauty retail market represented approximately $110 to $126 billion in annual sales in fiscal 2025. Ulta holds approximately 10% of that total, with no single competitor holding a comparably defined share of the multi format, multi tier beauty destination category.

Sephora (LVMH)

Sephora is Ulta’s most direct prestige competitor and has made the most strategically significant competitive move of the past five years in embedding shop in shops at Kohl’s, a programme that has grown to more than 1100 locations and brings prestige beauty into a mass retail format at scale. The Kohl’s partnership does not offer salon services, does not carry mass products, and does not operate a loyalty programme with Ultamate Rewards’ data depth, but it improves prestige beauty accessibility for a mainstream consumer who previously might have visited Ulta for the same occasion. The competitive overlap is direct and growing.

The Ulta Beauty at Target Partnership

From 2021 through its planned conclusion in August 2026, Ulta operated a shop in shop concept inside more than 600 Target locations. On August 14, 2025, both companies announced a mutual decision not to renew the agreement. The reasons that have been reported are instructive: analysts noted that Ulta Beauty at Target locations were frequently co-located in the same strip centres as standalone Ulta stores, cannibalising the company’s own traffic. Operational reports described understaffing and a lack of specialist beauty training at Target locations, producing a guest experience materially inferior to a standalone Ulta store. The exit also reflects the declining attractiveness of the Target retail environment itself, Target’s brand reputation and store traffic have weakened materially in recent years, and Ulta’s association with a deteriorating host retailer was an incremental liability rather than an asset. For Ulta, the decision to exit refocuses growth investment on the owned store fleet and international expansion, the businesses over which it has direct operational control and which benefit fully from the loyalty programme.

Social Commerce and the Discovery Shift

The most structurally significant long term competitive challenge to Ulta’s model is the migration of beauty discovery from physical retail toward social platforms. TikTok Shop, Instagram Checkout, and the influencer to cart ecosystem are compressing the role of the physical retailer at the top of the customer journey, particularly for younger consumers who build their beauty vocabulary through content rather than store browsing. Ulta has responded with its own TikTok Shop launch, the UB Collective influencer programme, and the UB Creates content platform. But the structural reality cuts in two directions simultaneously: if social commerce drives discovery, then Ulta’s in store discovery occasion, the foundation of its loyalty data engine, faces long term pressure. And if beauty consumers begin purchasing directly through social platforms rather than through Ulta’s own channels, the advantage of Ulta’s data and the threat from online only competitors both intensify. These two outcomes are not compatible with the thesis that physical experience is structurally non replicable, and that tension is worth holding honestly.

Amazon and Replenishment

Amazon’s competitive impact on Ulta is concentrated in replenishment, the reorder of a known product at a known price, and is limited in discovery, advisory, and service occasions. The loyalty programme is Ulta’s primary defence in the replenishment channel: a member who earns and redeems points on repeat purchases at Ulta has a financial incentive to return through Ulta’s channels rather than routing orders to Amazon. The data Ulta collects on replenishment purchases also feeds the personalisation that makes the discovery relationship stronger. The defence is real, but it is not absolute, and it depends on the loyalty programme maintaining its economic value to the consumer over time.

6. Management

Ulta has had three CEOs since June 2021. Mary Dillon, who oversaw the majority of the company’s growth from 2013 to 2021, stepped down in June 2021 and was replaced by then President Dave Kimbell. Kimbell unexpectedly retired in January 2025 and was replaced by Kecia Steelman, who had served as President and COO since September 2023 and as Chief Operating Officer since June 2021. In mid 2025, CFO Paula Oyibo resigned after just over one year in the role; her replacement, Christopher DelOrefice, joined from Becton Dickinson in December 2025. At the time of this report, the CEO has been in the role for approximately 15 months and the CFO for approximately five months. The frequency of leadership change at the top of the organisation, during a period when the competitive environment is intensifying and the cost structure is requiring active intervention, is a genuine risk factor, even if corporate strategy and capital allocation policies have not materially changed through the transitions.

Steelman’s background is operational: she joined Ulta in 2015 as Chief Store Operations Officer and has spent a decade inside the business building the store operations, supply chain, and guest experience systems that underlie the competitive position. That operational foundation is relevant for a business whose moat is delivered at store level, through the salon appointment, the specialist recommendation, the loyalty programme interaction. The Ulta Beauty Unleashed strategic plan, Drive Core Business Growth, Scale New Accretive Businesses, Align Foundation for Success, is the framework under which fiscal 2025’s 5.4% comparable sales recovery was delivered. Management has guided fiscal 2026 EPS at $28.05 to $28.55, implying growth of 9.4% to 11.4% from fiscal 2025’s $25.64, with operating income growing 6% to 9% on revenue growth of 6% to 7%.

Executive compensation is predominantly variable. Base salary represents a minority of total package; the balance is split between short term incentive awards tied to annual financial targets including revenue, operating income, and FCF, and long term equity awards split between time vesting restricted stock and performance based restricted stock tied to EPS and return metrics over a three year period. The performance equity pays on a 0% to 150% scale against targets. The above plan fiscal 2025 financial performance drove materially higher incentive compensation, a direct contributor to the SG&A increase, which is the design of the programme working as intended. Whether that design produces the right long term outcomes depends on whether the targets being set are genuinely stretching relative to the business’s underlying potential.

7. Growth Levers & Addressable Market

1. Domestic Store Expansion

Management’s stated view is that long term US freestanding store potential exceeds 1,800 locations, implying approximately 300 additional stores from the current 1,505. At fiscal 2025’s pace of 63 net new openings annually, that runway represents roughly five years of store driven revenue contribution. At an average unit volume of approximately $8 million per store, 300 additional stores represent roughly $2.4 billion of incremental revenue, meaningful over the period, but finite. Once the store count approaches the stated ceiling, the organic growth engine for the domestic business narrows to comparable sales growth alone. If comps stabilise in the 2% to 3% range, consistent with management’s fiscal 2026 guidance of 2.5% to 3.5%, the revenue growth algorithm becomes structurally more modest, and the ability to leverage a largely fixed cost base diminishes accordingly.

2. Comparable Sales and Operating Leverage

Fiscal 2025’s 5.4% comparable sales growth, driven by simultaneous improvement in both transaction count and average ticket, is the most encouraging near term signal in the business. Ulta’s store cost structure contains significant fixed and semi fixed elements, meaning that comparable sales growth above a threshold level translates into operating margin expansion. Management’s fiscal 2026 guidance of 2.5% to 3.5% comparable sales growth is below fiscal 2025’s actual result. Whether that reflects deliberate conservatism or genuine uncertainty about the durability of the recovery is unclear. What is clear is that the operating leverage available from comps is most powerful precisely at the point when structural cost pressures are also at their highest, and the net effect on operating margins will be the most important financial development to monitor in fiscal 2026.

3. International Expansion

The international platform, Space NK in the UK and Ireland, the Grupo Axo joint venture in Mexico, and the Alshaya Group franchise in the Middle East, is the strategic optionality that Ulta did not possess three years ago. Space NK provides an established brand, a curated prestige assortment, and a route to deepen brand partner relationships in European markets. The Mexico and Middle East operations are early stage and represent Ulta’s first testing of its format and brand in emerging international markets. The strategic rationale, that global brand partners increasingly value international distribution capability in their retail relationships, is coherent. The financial contribution is currently immaterial, and the execution risk of managing multiple international markets simultaneously, while the domestic business is under cost pressure, is real. International expansion is an option that requires several years of evidence before it can be underwritten as a meaningful earnings contributor.

4. Retail Media and Data Monetisation

UB Media, Ulta’s retail media network, earns advertising revenue from brand partners paying for targeted placement within the Ulta digital ecosystem. With 46 million loyalty members and purchase level data covering the vast majority of transactions, Ulta’s audience targeting precision in the beauty category is superior to what horizontal platforms can offer. The economics of retail media are attractive: revenue is earned on an audience the business already owns, with advertising inventory created by existing digital traffic rather than incremental capital. The model has been demonstrated at scale by Amazon, Walmart, and Target. For Ulta, UB Media remains early stage and is not currently a material revenue contributor, but it is a genuine candidate to generate high margin incremental revenue over a five year horizon without requiring significant capital investment.

5. Omnichannel Deepening

The omnichannel guest, shopping both in stores and digitally, represents the highest value member profile in the loyalty programme. In fiscal 2025, active app users grew 15% year on year, with approximately 60% of online sales originating through the app. Each enhancement to the digital platform, personalised recommendations, reorder shortcuts, shade matching capabilities, is an investment in converting store only members into omnichannel members and deepening the replenishment relationship. The data supports the investment: the spending differential between omnichannel and store only guests is the clearest financial proof that the digital channel is additive rather than substitutive.

8. Valuation

Every price paid for a business contains an implicit question: how many years of future cash flows are already baked into what you are paying today? Rather than assigning a terminal value, which requires many assumptions about growth in perpetuity that no analyst can honestly support, Bearhold’s framework constructs a year by year series of discounted free cash flows and asks: at today’s stock price, how many years of future earnings are embedded? Everything the business earns beyond that point comes to you for free. The fewer the embedded years, the more of the future you receive without paying for it.

At today’s price, you are paying for everything Ulta will earn over roughly the next 47 years, in today’s money. Everything it earns beyond that comes to you for free, but that free portion begins nearly half a century from now.

Growth Engine 1: Fundamentals

The first engine is the business itself. FCF per share grows over time through revenue expansion, operating leverage, and share count reduction from buybacks. That growth, compounded annually, is what the fundamental engine delivers regardless of any valuation re-rating. Based on the recent earnings trajectory, net income flat for three years, SG&A repricing structurally higher, the domestic expansion runway approaching its ceiling, I expect FCF per share growth at or below 6% annually.

Growth Engine 2: Valuation Re-Rating

The second engine is valuation. When the embedded years are low, the market is under pricing the business relative to what it will eventually pay as confidence grows, and that re-rating produces a return on top of the fundamental growth. At 47 embedded years, the opposite is true. The market is already pricing in a growth trajectory more optimistic than what the evidence supports. A negative re-rating is possible here, which could affect the future returns from engine 1 negatively.

9. Risks

1. Structural SG&A Repricing

This is the most important risk in the current period, and the one with the least favourable resolution path. SG&A as a percentage of revenue has risen from 23.5% in fiscal 2022 to 26.6% in fiscal 2025, a consistent, four year upward trend. The components driving it, technology amortisation from multi year ERP and cloud investments, store payroll repriced in a persistently tight labour market, consolidated overhead from the Space NK acquisition, do not revert automatically when conditions change. They represent a permanent repricing of the cost base. Management has introduced zero based budgeting and personal executive review of new investment initiatives as corrective measures, which signals that the trend has been recognised as a problem requiring active intervention rather than a cyclical effect that will self correct. Until the SG&A-to-revenue ratio stabilises and reverses across multiple consecutive years, the structural interpretation is the more honest one.

2. Flat Absolute Earnings

Net income has not grown in absolute terms since fiscal 2022. Operating cash flow is essentially flat over the same period. The per share earnings growth that the EPS line presents is a function of buybacks, not business growth. A business that is returning capital to shareholders faster than it is growing its earnings base may be creating per share value in the short run, but it is also reducing the asset base available to generate future earnings.

3. Management Instability

Three CEOs since 2021, a CFO who resigned after 14 months, and a replacement CFO five months into his tenure at the time of this report constitute a pattern of leadership instability that coincides with the period in which the cost structure has been most in need of discipline and the competitive environment has been most demanding. Corporate strategy and capital allocation have not materially changed through the transitions, but strategic continuity at the policy level is not the same as operational and cultural continuity at the execution level. The cost discipline initiatives, zero based budgeting, executive review of investments, will take time to demonstrate results, and the leadership team executing them is relatively new.

4. Social Commerce and Discovery Channel Erosion

The migration of beauty discovery toward social platforms is a slow but real structural pressure on Ulta’s model. A business whose fundamental advantage is in-store discovery is exposed to any sustained shift in where consumers form beauty preferences and initiate purchase journeys. Ulta’s response, TikTok Shop launch, influencer programmes, digital personalisation investment, is appropriate, but it is also a concession that the discovery channel is evolving. If a meaningful portion of the next generation of beauty consumers builds their product relationships through social channels and purchases through brand direct or social commerce channels, the loyalty programme’s acquisition funnel weakens at its source.

5. International Execution Risk

The Space NK acquisition, at approximately $399 million, and the early stage Mexico and Middle East operations represent Ulta’s first significant international capital commitments. International retail is operationally demanding, regulatory requirements, consumer preferences, supplier terms, real estate markets, and talent pools all differ materially from the US. Ulta has no track record of managing international retail operations at scale. The goodwill and intangible assets from Space NK ($430 million combined) earn a return only if the acquisition delivers its strategic rationale, and the execution risk during the first several years of managing a UK business while the domestic cost structure is under pressure is real.

The Verdict

Ulta Beauty built something real over three and a half decades. The loyalty programme with 46 million active members, 95% transaction penetration, and $582 million in deferred revenue growing at 16% annually. The multi tier store format, the in-store salon services, the exclusive brand relationships, and the physical distribution network are collectively a competitive position that has outlasted 35 years of disruption attempts and has not been successfully replicated at scale by any competitor. That track record earns genuine respect and earns the business a place on the Watchlist, a recognition that the quality is real, even if the current circumstances do not support a conviction investment.

The reasons it does not earn the Approved designation at this time are specific and data driven. Net income has not grown in absolute terms since fiscal 2022. Operating cash flow has been essentially flat over three years of revenue growth from $10.2 billion to $12.4 billion. SG&A as a percentage of revenue has risen in each of the past four years and is now structurally higher than the pre surge period, reflecting a cost base that has permanently repriced through technology investment cycles, labour market repricing, and the Space NK acquisition overhead. The domestic growth runway is finite, approximately 300 additional stores, and beyond it the business is dependent on comparable sales growth at a rate that management’s own guidance suggests will be modest. International expansion is early stage and unproven at scale. The leadership team has not been stable.

What Would Change My Mind

A significant improvement in the valuation, combined with demonstrated stability in the management team across at least two full annual reporting cycles, and evidence that international markets are becoming a meaningful and measurable earnings contributor, are the three conditions that would warrant upgrading Ulta from Watchlist to Approved and considering initiation. I would also want to see the SG&A-to-revenue ratio declining across at least two consecutive fiscal years before accepting that the structural repricing has been addressed. Until those conditions are met, the business sits on the Watchlist, acknowledged as a genuine franchise with a durable loyalty moat, but not one where the current evidence supports a conviction position.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The Outlook

Approximately one in every five Americans will enter a hospital this year. When they do, there is roughly a one in six chance they will walk through the doors of an HCA Healthcare facility. HCA operates 189 hospitals across 19 US states and England, with 50,459 licensed beds and approximately 320,000 employees. It generated $75.6 billion in revenue in 2025 and a return on invested capital, the percentage return earned on every dollar deployed into the enterprise, of 18.9%. For a capital intensive, heavily regulated industry, those numbers are exceptional. No for profit hospital company in the United States comes close.

The business was founded in Nashville in 1968 by Dr. Thomas Frist Jr. and entrepreneur Jack Massey on the conviction that professional management and shared infrastructure could transform a fragmented, inefficient hospital industry. That conviction has been validated by five decades of compounding. The Frist family, now in its third generation, with Thomas Frist III serving as Chairman of the Board, still owns approximately 32% of the company, a continuity of ownership and institutional purpose that has shaped the long term orientation of management throughout.

HCA’s competitive position is built on scale, market density, and institutional depth that no competitor has replicated. Its return on invested capital has averaged 16.7% over the past decade, a 7 to 9 percentage point premium over its nearest publicly traded for profit peers. Gross margins have expanded from 37.6% in 2015 to 41.5% in 2025. The cash generation of the business has grown consistently enough that, despite a decade of aggressive share repurchases funded partly through debt, the leverage ratio has improved from 6.4 times debt to operating cash flow in 2015 to 3.85 times in 2025.

REFERENCE

Key Terms

Several terms in this report are specific to the healthcare industry. The following definitions are intended to make the analysis accessible without interrupting it each time a term appears.

Admission

An admission is when a patient is formally checked into a hospital for at least one overnight stay. It is the primary unit of volume measurement in the hospital business, the equivalent of passengers for an airline. A related metric, equivalent admissions, adjusts this figure to also capture outpatient procedures, giving a more complete picture of total patient volume across both inpatient and outpatient settings.

Reimbursement

Hospitals do not set their prices freely. Most revenue is collected through reimbursement, the amount that insurers and government programmes agree to pay for a given service. Reimbursement rates vary widely by payer: government programmes typically pay at rates set below the cost of care, while private managed care plans negotiate higher rates. The mix of who is paying is one of the most important determinants of hospital profitability.

Medicare

Medicare is the US federal government’s health insurance programme for Americans aged 65 and over, and for certain disabled individuals. It is administered directly by the federal government and sets its own reimbursement rates by regulation.

Managed Medicare

Managed Medicare, also known as Medicare Advantage, refers to private health insurance plans that receive a fixed payment from the federal government to provide Medicare benefits to enrolled patients. Rather than the government paying hospitals directly, a private insurer manages the coverage and negotiates rates with hospitals on the government’s behalf. Managed Medicare typically pays hospitals somewhat better than traditional Medicare, which is why its growing share of the Medicare population is generally viewed as a modest positive for hospital operators. HCA derived approximately 18% of its 2025 revenues from Managed Medicare.

Medicaid

Medicaid is a joint federal state programme covering lower income individuals. Reimbursement rates are set by each state within federal guidelines and are typically the lowest of any payer category, often below the cost of providing care. Together, Medicare and Medicaid account for approximately 45% of HCA’s revenues.

Managed Care

Managed care refers to private health insurance companies, such as UnitedHealth, Cigna, and Aetna, that negotiate directly with hospitals on the rates they pay for procedures. These negotiated rates are typically the highest of any payer category, making managed care patients the most commercially valuable to hospital operators. HCA derives approximately 49% of its revenues from managed care and private insurers.

Supplemental Payments

Many states make additional payments to hospitals above their base Medicaid rates, to partially bridge the gap between what Medicaid pays and what care actually costs. These are called state directed payments or supplemental payments. For HCA, these represented approximately $6.2 billion of 2025 revenues. They are now under active pressure from federal legislation, and their expected gradual decline is the most important near term financial risk in this report.

At a Glance

Company: HCA Healthcare, Inc.

Ticker: $HCA · NYSE

Sector: Health Care

Industry: Hospital Operations & Health Services

Market Cap: $98.4 billion (at $438)

First Coverage: April 2026

FY2025 Revenue: $75.6 billion

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

1. The Business

Hospital Corporation of America was founded in Nashville in 1968 by Dr. Thomas Frist Jr., a physician and former US Air Force flight surgeon, alongside entrepreneur Jack Massey. The founding premise was that the US hospital industry was unnecessarily fragmented, hundreds of independently managed facilities each reinventing the wheel on purchasing, staffing, and administration. Professional management and shared resources, applied at scale, could lower costs and improve outcomes. That premise has been validated across five decades of operation.

The company has passed through multiple ownership structures, a leveraged buyout (an acquisition financed primarily with debt rather than equity) in 1989, a return to public markets in 1992, a second and larger leveraged buyout in 2006 at $33 billion, and a re listing in 2011. Through each transition, the operating business was uninterrupted. HCA Healthcare, Inc. as it exists today was incorporated in Delaware in 2010 and listed on the New York Stock Exchange in 2011. The Frist family’s continued 32% ownership stake is a thread of institutional continuity running through every structure the business has had.

What HCA Does

HCA operates hospitals and related health care facilities. Patients arrive through emergency rooms, physician referrals, or scheduled procedures, receive care, and are discharged. HCA bills the relevant payer, Medicare, Medicaid, a private insurer, or the patient directly, for the services rendered. The margin between the cost of delivering care and the reimbursement received is the economic engine of the business.

As of March 31, 2026, HCA operated 189 hospitals: general acute care facilities, behavioural health hospitals treating mental health and substance use conditions, and rehabilitation hospitals. It also operated approximately 2,600 ambulatory sites of care, including freestanding ambulatory surgery centres, freestanding emergency rooms, urgent care centres, and physician clinics. These outpatient facilities are an increasingly important part of the network as medicine shifts toward procedures that do not require overnight hospital stays.

Geographic Structure

HCA organises its US operations into three geographic groups. The National Group covers hospitals across states including California, Tennessee, Virginia, and Nevada. The Atlantic Group covers hospitals concentrated in Florida, Georgia, and South Carolina. The American Group covers hospitals primarily in Texas, Colorado, and Louisiana. Eight hospitals in England are managed within the Corporate segment.

Florida and Texas together generated 51% of HCA’s total revenues in 2025. They are also the two fastest growing major US states by net domestic migration, Florida gained approximately 370,000 net new residents in 2024 and Texas approximately 230,000. Each new resident is a potential future patient. Florida’s above average share of residents over 65, the heaviest users of hospital services, creates structural demand that compounds quietly year after year regardless of the economic cycle.

Revenue Mix

Managed care and private insurers represent approximately 49% of HCA’s revenues, the commercially negotiated, higher paying category that drives most of the profitability. Medicare accounts for approximately 15% of revenues, with Managed Medicare adding a further 18%. Medicaid contributes approximately 8%, with Managed Medicaid adding 5%. Uninsured and other sources account for the remainder.

Embedded within the Medicaid figure is approximately $6.2 billion in supplemental payments from state governments, additional reimbursement above base Medicaid rates intended to bridge the gap between what Medicaid pays and what care actually costs. New federal legislation enacted in 2025 restricts these payments going forward. Their expected gradual decline is the most important near term financial risk in this analysis, and it is addressed in the Capital Allocation and Risks sections.

2. The Moat

HCA’s competitive advantage is scale driven operational superiority, the ability to deploy shared infrastructure, purchasing power, clinical data, and capital access across a hospital network that no competitor has matched in size or geographic density. This advantage was built over five decades, facility by facility, and it compounds with each passing year.

Consider what it means to be a private health insurer trying to offer a competitive plan for employers and families in metropolitan Houston. To offer meaningful network coverage across cardiology, oncology, emergency care, and surgical services, you need access to HCA’s Texas hospitals. Excluding them is not commercially viable, your members would be directed away from facilities they already rely on. So you negotiate. And in those negotiations, HCA’s network density is leverage. This dynamic repeats in every major market where HCA has built density. More density means stronger insurer relationships. Stronger relationships generate better reimbursement rates. Better rates fund further investment in facilities and physician recruitment. Better facilities attract more physicians, which drives more patient referrals. The cycle reinforces itself continuously.

1. Purchasing Scale

At $75.6 billion in annual revenue across 189 hospitals, HCA is the largest buyer of medical supplies, equipment, and pharmaceuticals in the for profit hospital sector. This purchasing scale translates into supplier terms that smaller operators cannot access at equivalent pricing. The gross margin expansion from 37.6% in 2015 to 41.5% in 2025, a 390 basis point improvement over a decade, reflects this purchasing leverage compounding over time.

2. Clinical Data Infrastructure

HCA has accumulated clinical outcome data from tens of millions of patient encounters across its entire network over decades. This allows the company to benchmark performance across all facilities, identify operational inefficiencies, and standardise best practices system wide, a capability that no regional competitor can replicate without comparable scale. The ongoing investment in a new enterprise wide electronic health record platform and an AI assisted nursing platform will materially strengthen this analytical foundation over the next several years.

3. Capital Access and Infrastructure Compounding

HCA’s scale gives it access to debt and equity capital markets on terms that smaller hospital operators cannot match. This access funds a continuous programme of facility construction, bed additions, physician practice acquisitions, and technology upgrades. For 2026, HCA has guided capital expenditure of approximately $5.1 to $5.4 billion, a figure that reflects not just maintenance of the existing network but deliberate expansion into high growth markets. Every dollar spent on this programme compounds the competitive advantage that took five decades to build.

Financial Evidence

The most compelling financial evidence of the moat is the sustained ROIC gap relative to peers. HCA’s return on invested capital averaged approximately 16.7% over the decade from 2015 to 2025. Tenet Healthcare averaged approximately 7% ROIC over the same period. Universal Health Services averaged approximately 9%. A 7 to 9 percentage point ROIC premium, sustained for ten consecutive years in a capital intensive regulated industry, is the financial expression of a structural competitive advantage. The moat is stable to strengthening.

3. Financial Performance

The ten year financial record of HCA Healthcare reflects consistent operational excellence alongside a financial structure that demands careful reading. The table below presents key metrics across all available years from 2015 through 2025.

Revenue grew from $39.7 billion in 2015 to $75.6 billion in 2025, a compound annual growth rate of approximately 6.6%. The growth was driven by volume increases in admissions and equivalent admissions, price improvement from commercial contract renewals, geographic expansion, and the supplemental Medicaid payment programmes. In 2025, same facility revenues grew 6.6%, driven by 2.4% equivalent admissions growth and 4.1% revenue per equivalent admission growth.

The $6.2 billion in Medicaid supplemental payments embedded in 2025 revenues requires specific attention. New federal legislation enacted in 2025, referred to throughout this report as the FBA, or Federal Budget Act, restricts these mechanisms going forward. The Q1 2026 results, discussed in the update subsection below, indicate the near term impact is tracking materially better than initially feared.

Gross margin expanded from 37.6% in 2015 to 41.5% in 2025, a 390 basis point improvement over ten years. The direction of travel has been consistent throughout and reflects the compounding effect of better commercial contract pricing relative to the cost of delivering care. A business losing competitive ground does not expand gross margins at this pace.

Operating margin was 15.8% in 2025, above the decade average of approximately 14.8%. The peak in the available record was 16.5% in 2021, reflecting the combination of pandemic era volume and government support before the full labour cost inflation materialised. By 2022, the nursing shortage crisis had hit at full force, hospitals across the industry were forced to rely heavily on temporary travelling nurses hired on short term contracts at exceptional premium rates, inflating the industry wide labour cost ratio by an estimated 200 to 250 basis points and compressing operating margin to 15.0%. As that crisis resolved through 2023 and 2024, costs receded and margins recovered toward the current 15.8%. The current level is structurally sound, though it is worth noting that the labour cost ratio has not returned to the pre pandemic baseline of approximately 38% of revenues, the current level of approximately 43 to 44% represents a structural upward shift of several percentage points from the pre 2020 norm, which is relevant context for modelling the margin ceiling.

Diluted earnings per share grew from $4.99 in 2015 to $28.33 in 2025, a compound annual growth rate of approximately 19%. HCA’s revenues grew at 6.6% annually over the same period. The gap between 6.6% revenue growth and 19% EPS growth is almost entirely explained by the share buyback programme. HCA reduced its diluted share count from approximately 427 million in 2015 to approximately 240 million in 2025, a 44% reduction over the decade. The mechanics of how this reduction was funded are addressed in the Capital Allocation section.

Free cash flow, operating cash flow less capital expenditure, grew from approximately $2.4 billion in 2015 to $7.7 billion in 2025, a compound annual growth rate of approximately 12.4%. The trajectory has been consistently upward with one interruption in 2022 when elevated capital investment temporarily reduced FCF. The recovery was sharp: $4.7 billion in 2023, $5.6 billion in 2024, and $7.7 billion in 2025. I deduct stock based compensation of $401 million in 2025 as a real economic cost to shareholders. After this adjustment, normalised FCF is approximately $7.3 billion, or approximately $30.50 per share at the average 2025 diluted share count of 239.5 million.

ROIC of 18.9% in 2025 is the highest reading in the decade long record and comfortably above any reasonable estimate of the cost of capital. Averaged across the full decade, ROIC was approximately 16.7%. This consistency, through a global pandemic, an industry labour crisis, and sustained regulatory uncertainty, is the most reliable indicator that HCA’s competitive advantages are structural rather than circumstantial.

Q1 2026 Update

HCA reported its first quarter 2026 results on April 24, 2026. The full year financial analysis above is anchored to FY2025 annual figures, quarterly results are too noisy to anchor financial ratios on and are included here solely to confirm or challenge the annual thesis.

Volume was softer than the 2025 trend, with same facility admissions up 0.9% and equivalent admissions up 1.3%. Management attributed this directly to two temporary factors: respiratory related admissions declined 42% year over year following an unusually strong respiratory season in Q1 2025, and a winter storm in January disrupted operations in certain markets. Volumes improved progressively through the quarter. Full year 2026 guidance was reaffirmed without revision, projecting revenues of $76.5 to $80.0 billion and diluted EPS of $29.10 to $31.50.

The most important update concerns the supplemental payment headwind. The Q1 2026 results revealed that certain state supplemental programmes, Georgia’s grandfathering approval, the reinstatement of the ATLAS programme in Texas, and the ongoing benefit from the Tennessee programme, generated approximately $200 million more in adjusted EBITDA benefit than management had initially guided. Management revised their full year SDP net benefit decline to a range of $50 to $250 million versus prior year. The near term SDP risk is proving less severe than the cautious tone of initial management guidance suggested.

4. Capital Allocation

Capital allocation is the section that most clearly illustrates both the strength and the structural complexity of HCA’s financial model.

Between 2015 and 2025, HCA deployed capital in three primary ways. Capital expenditure accounted for approximately $41.2 billion, spent on new facilities, additional licensed beds, technology upgrades, and physician practice acquisitions. Share repurchases accounted for approximately $45.3 billion. Dividends accounted for approximately $4.5 billion. Together, these three uses of capital over the decade exceeded the cumulative operating cash flow the business generated during the same period. HCA was a net borrower to fund its capital return programme. Total financial debt, including all short term and long term debt and lease obligations, which represent fixed future cash commitments that behave economically like debt, grew from approximately $30.5 billion in 2015 to approximately $48.7 billion in 2025.

In 2025 alone, HCA repurchased approximately $10.1 billion of its own shares, the single largest annual buyback in the company’s history, while issuing approximately $3.3 billion in net new debt to help fund it. The diluted share count fell from approximately 262 million at the start of 2025 to approximately 240 million by year end, a reduction of approximately 9% in a single year.

The 19% annual EPS compound annual growth rate is real in the sense that shareholders who held HCA shares did see per share earnings compound at that rate. But the source of that growth deserves precise disaggregation. The underlying business, growing revenues at approximately 6.6% annually with operating leverage, generates perhaps 9 to 11% annual growth in total net income. The remaining 8 percentage points of EPS growth came from the mechanical effect of a shrinking share count. That share count reduction has been funded substantially through continuous new debt issuance.

The leverage picture at any single point in time is less informative than the trajectory over the full decade. The debt to OCF ratio started at 6.4 times in 2015 and ended at 3.85 times in 2025. That improvement happened despite the buyback programme running aggressively throughout the full period. OCF grew faster than debt in the majority of years. The interest to OCF ratio declined from 35.2% in 2015 to 17.8% in 2025. The business is carrying more absolute debt than a decade ago, but carrying it significantly more comfortably relative to what it generates. However, the structural dependency on government reimbursement, approximately 45% of revenues, means the OCF that underpins this improving ratio is itself subject to political and legislative risk. That dependency, not the leverage ratio in isolation, is the primary basis for the rejection.

The growth capex programme is the most strategically important use of capital in the HCA story. The $5.1 to $5.4 billion planned for 2026 represents the continued construction of the physical infrastructure moat, new facilities, additional licensed beds in high growth markets, expanded freestanding emergency rooms, and the enterprise wide technology overhaul. This is genuine competitive investment, not maintenance spending.

Share

5. Competition

The for profit hospital industry in the United States has a clear competitive structure: one dominant national platform, two significantly smaller publicly traded operators, and a large network of not for profit and government owned systems operating under different financial constraints. HCA is the dominant platform by every relevant financial metric.

Universal Health Services

Universal Health Services (UHS) operates approximately 400 acute care and behavioural health facilities across the United States, the United Kingdom, and Puerto Rico, generating $17.4 billion in revenue in 2025. UHS maintains a conservative balance sheet relative to the sector and has delivered consistent EPS growth through operational improvement and a disciplined buyback programme. ROIC of approximately 11.5% in 2025 reflects a legitimate, well run operator that has nonetheless consistently trailed HCA by 7 to 9 percentage points over the decade. The gap is structural: UHS does not have HCA’s market density in high growth markets or HCA’s system wide purchasing and data advantages.

Tenet Healthcare

Tenet Healthcare operates approximately 60 hospitals alongside a large ambulatory care business, generating $21.3 billion in revenue in 2025. Tenet has spent the better part of a decade restructuring its balance sheet and divesting underperforming hospital assets. ROIC improved to 11.7% in 2025 following a decade average of approximately 7%, the weakest sustained performance among the major for profit operators. The 2024 results were significantly distorted by approximately $5 billion in gains from facility sales. Stripping those out, Tenet remains a business in operational recovery mode rather than a genuine competitive threat to HCA’s market position.

Not for Profit Systems

The most substantive competitive pressure HCA faces does not come from its for profit peers. Large not for profit integrated health systems, organisations like Ascension, CommonSpirit Health, and Advocate Health, operate in many of the same markets under materially different financial conditions. Not for profit hospital systems do not pay federal or state income taxes, can issue tax exempt bonds at lower rates, and receive philanthropic donations and government grants. These advantages are particularly significant in physician recruitment, the leading competitive indicator I monitor most closely.

6. Management

Samuel N. Hazen - CEO

Samuel Hazen has served as Chief Executive Officer since January 2019. He joined HCA in 1984 and spent his entire 41 year career within the organisation, progressing from hospital level financial roles through regional and group leadership before becoming President and Chief Operating Officer in 2016. His predecessor was also an internal promotion. HCA has never appointed an external CEO in its modern operating history, a reflection of both the institutional depth of the management bench and the genuine complexity of the role. Managing 189 hospitals, 320,000 employees, and hundreds of reimbursement negotiations across 19 states requires operational and regulatory knowledge that cannot be acquired quickly from outside the institution.

Hazen’s tenure since 2019 covers an unusually difficult operating period: COVID 19, the labour crisis of 2021 and 2022, the post pandemic normalisation, and the current regulatory headwinds around supplemental payments. The financial record through those years, ROIC consistently above 15%, gross margins expanding, no meaningful market share loss, reflects operational execution that is difficult to dismiss.

Ownership and Alignment

Samuel Hazen beneficially owned 2,164,071 shares of HCA common stock as of February 23, 2026. At approximately $438 per share, this represents approximately $948 million in personal wealth tied directly to the company’s long term performance. That alignment is genuine and material.

The broader ownership picture is shaped by the Frist family. Their holding vehicles, Frisco Holding II and Hercules Holding II, collectively represent the Frist Group, which owned approximately 32% of shares outstanding as of February 23, 2026, per the 2026 proxy statement. Thomas F. Frist III, grandson of co founder Dr. Thomas Frist Jr., serves as Chairman of the Board. The family retains the contractual right to nominate two directors for as long as they hold at least 3% of outstanding shares. All directors and executive officers as a group, 16 persons, beneficially own approximately 3,354,148 shares, or approximately 1.5% of outstanding shares. Including the Frist Group, total affiliated ownership is approximately 33 to 34% of the company.

Compensation

Hazen’s total direct compensation for 2025 was approximately $26.5 million. Base salary was $1.58 million, approximately 6% of total. Stock appreciation rights and restricted stock awards comprised approximately 64% of total compensation, creating multi year alignment with the share price. Annual performance cash through HCA’s Performance Excellence Programme comprised the remaining 30% and paid out at approximately 196% of target for 2025. For 2026, Hazen’s base salary was increased by 2.5% to $1,620,555. The compensation structure is appropriate: a CEO whose pay is predominantly variable and linked to long term share price performance has incentives pointing in the right direction.

7. Growth Levers & Addressable Market

• Organic Volume in Sunbelt Markets

HCA’s geographic concentration in Florida and Texas is its most durable growth engine. These states are experiencing structural net population inflows that have persisted through multiple economic cycles. Each new resident is a potential future patient. Each ageing resident, Florida’s above average proportion of over 65s is a sustained structural tailwind, creates more intensive recurring demand for hospital services. The 2025 same facility admissions growth of 2.3% is consistent with this demographic compounding.

• Revenue Per Admission Through Commercial Pricing

HCA’s most controllable near term growth lever is the rate at which it grows revenue per equivalent admission through managed care contract renewals. In markets where HCA holds network density, private insurers cannot construct a competitive health plan without including HCA facilities. This gives HCA structural pricing power at contract renewal that has consistently translated into revenue per admission growth of 3 to 4% annually. Even with the FBA reducing government reimbursement, the commercial pricing lever remains intact and partially offsets.

• Outpatient and Ambulatory Expansion

The long term structural shift in healthcare from inpatient to outpatient settings is both a challenge and an opportunity for HCA. It is a challenge because outpatient procedures generate lower revenue per case than inpatient equivalents. It is an opportunity because HCA is investing aggressively in ambulatory surgery centres, freestanding emergency rooms, and urgent care facilities that capture patient volume at lower cost while maintaining the physician and patient relationships that drive future inpatient referrals.

• Technology and Data Investment

HCA is deploying a new enterprise wide electronic health record platform across all hospitals and implementing an AI assisted nursing platform. The financial returns from this investment cycle will become visible in the 2027 to 2030 period. The competitive advantage it creates begins to compound from the moment of deployment: no regional operator can justify investment at this scale, widening the analytical and operational gap between HCA and its peers.

8. Risks

1. Political and Legislative Dependency

Approximately 45% of HCA’s revenues flow from government programmes, Medicare, Medicaid, and their managed equivalents, whose reimbursement rates are set by political and regulatory decisions rather than market negotiation. This is the central risk and the one that no management team, regardless of capability, can fully control or predict.

The concern is not only the current FBA supplemental payment restriction, which is quantifiable and tracking better than feared. The deeper concern is the structural nature of the dependency itself. A future administration pursuing aggressive Medicaid base rate cuts, reducing per admission payments rather than supplemental payments, would create a sustained, multi year margin compression with limited commercial offset. Unlike the supplemental payment mechanism, which affects a discrete and identifiable revenue layer, base rate cuts affect every government payer admission. The historical record shows that Washington has periodically used Medicare and Medicaid reimbursement as a lever for fiscal adjustment, the sequestration cuts of 2013, the managed Medicaid rate pressures of 2016 to 2019, and the FBA provisions of 2025 are all examples of this pattern. The frequency and unpredictability of these interventions, rather than any single event, is what makes the dependency uncomfortable as a long term holding.

The scenario I monitor most closely is a slow, multi year compression, where base reimbursement rates are held flat or increased below the rate of cost inflation for an extended period. This does not produce a visible crisis but gradually erodes margins in a way that is difficult to offset commercially and hard to identify clearly until the trend is well established. HCA’s commercial pricing leverage is real, but it has limits: managed care plans cannot pass unlimited cost increases to employers and individuals, and the ceiling on commercial rate extraction is lower than it might appear.

2. Exchange to Uninsured Payer Mix Shift

The expiration of enhanced premium tax credits at year end 2025, federal subsidies that had made exchange based private health insurance affordable for lower income Americans, has caused a portion of that population to lose coverage and become uninsured. HCA estimates that same facility exchange equivalent admissions declined approximately 15% in Q1 2026 versus the prior year, while uninsured equivalent admissions increased approximately 16%. An uninsured patient generates significantly less reliable revenue than a commercially insured patient, and may generate no revenue at all. This shift will persist through 2026 and beyond depending on federal policy, another dimension of the same structural dependency on government programme design that drives Risk 1.

3. FBA Supplemental Payment Restrictions

HCA received approximately $6.2 billion in Medicaid supplemental payments in 2025, representing approximately 8% of total revenues. The FBA restricts these mechanisms going forward: arrangements not grandfathered before July 4, 2025 face immediate limitations, and grandfathered arrangements will be reduced by 10 percentage points annually from January 1, 2028 until they reach legislatively defined caps. Management guided for a full year 2026 net benefit decline of $50 to $250 million, materially better than the cautious tone of initial guidance suggested, driven by Georgia’s grandfathering approval, the reinstatement of the ATLAS programme in Texas, and the ongoing Tennessee programme benefit.

The risk is real but the near term trajectory is better than feared. The longer term 2028 phase down remains intact and will create a more sustained headwind from that point. The scale of that headwind will depend on how many additional state programmes receive grandfathering approvals between now and January 2028, a variable that is genuinely uncertain and worth monitoring closely as the schedule approaches. What is clear is that the partial commercial pricing offset available to HCA, through its network density leverage with private insurers, means the net OCF impact will be smaller than the gross revenue decline in any scenario.

4. Leverage Interacting With Regulatory Risk

HCA carries approximately $48.7 billion in total financial debt against $12.6 billion in annual operating cash flow. The leverage is improving, the debt to OCF ratio declined from 6.4 times in 2015 to 3.85 times in 2025, and the interest burden relative to OCF has fallen from 35.2% to 17.8% over the same period. But the combination of this debt level with the structural government reimbursement dependency creates an interaction risk that neither element would produce independently. If OCF comes under sustained pressure from legislative action while the debt balance remains elevated, the financial margin for error narrows in a way that a business without this regulatory dependency would not face. A sustained reversal of the debt to OCF improvement trend, or a meaningful rise in the interest burden relative to operating cash flow, would intensify this concern materially.

5. Labour Market

The United States faces a projected shortage of 100,000 to 200,000 nurses by 2030, driven by an ageing nursing workforce and insufficient training pipeline capacity. The 2021 to 2022 period demonstrated how quickly the cost structure can deteriorate under supply constraints, HCA’s labour cost ratio rose by an estimated 200 to 250 basis points above pre-pandemic levels at the peak. The subsequent normalisation has been genuine, but the labour cost ratio has not returned to the pre pandemic baseline and likely will not. Any future supply disruption would compound upward from the current elevated starting point.

6. Legal and Compliance Exposure

HCA operates in a heavily regulated environment and faces several active legal matters. The most significant ongoing investigation relates to the Anti Kickback Statute and the False Claims Act, federal laws governing physician referral arrangements and billing accuracy. The Department of Justice is investigating whether HCA provided illegal incentives to physicians in exchange for patient referrals, and whether the company engaged in upcoding, meaning billing for more expensive services than were actually provided. HCA is cooperating with the investigation. The potential financial consequences are unknown. Additionally, in late 2025, a federal court granted final approval for HCA to settle a class action lawsuit arising from a 2023 data breach that affected approximately 11 million patients. The Mission Health litigation, the North Carolina Attorney General’s lawsuit against HCA over emergency and cancer care services at Mission Hospital, remains a significant ongoing legal risk. HCA also faces continuing scrutiny over billing practices related to trauma centre fees.

9. The Verdict

Exceptional Business. Structural Dependency We Cannot Ignore.

HCA Healthcare is Rejected in the Bearhold Universe. The designation has nothing to do with the quality of the competitive position, which is genuine and documented throughout this report. ROIC averaging 16.7% over a decade. Gross margins expanding from 37.6% to 41.5% over ten years. A leverage trend improving from 6.4 times debt to OCF to 3.85 times despite running one of the most aggressive capital return programmes of any major US company. A management team that has navigated a global pandemic, an industry wide labour crisis, and sustained regulatory headwinds without losing meaningful market share. The business earns every bit of the admiration directed at it.

The rejection is driven by the structural dependency on government reimbursement decisions that approximately 45% of HCA’s revenues are subject to. This is not a temporary risk that resolves with a single legislative outcome. It is a permanent feature of the hospital business model that creates a category of uncertainty, the decisions of politicians and regulators in Washington, that no management team can fully anticipate, control, or offset. The FBA supplemental payment restriction is one concrete manifestation of this dependency. The exchange to uninsured payer mix shift, driven by the expiration of federal premium tax credits, is another. The history of Medicare and Medicaid reimbursement is a series of periodic legislative adjustments, sequestration cuts, rate freezes, managed care expansion, supplemental payment restrictions, that have recurred across administrations of both parties for four decades.

The scenario I am most cautious about is a slow, grinding multi year compression where base reimbursement rates are held flat or increased below the rate of cost inflation. This is the version of the political risk that is hardest to identify in real time, hardest to offset commercially, and most damaging to a business carrying $48.7 billion in financial debt. HCA’s commercial pricing leverage is real, but it has limits, managed care plans cannot indefinitely absorb cost increases that government programmes push toward the commercial sector.

The leverage position, while improving, interacts with the regulatory dependency in a way that neither element would produce independently. A business with minimal debt can absorb a sustained government reimbursement headwind. A business with $48.7 billion in debt and $2.2 billion in annual interest costs has less room to manoeuvre when OCF comes under pressure from sources outside management’s control.

There is genuine respect in this analysis for what HCA has built. The competitive infrastructure, the management track record, and the demographic tailwinds in Florida and Texas make this a business worth monitoring. The Bearhold framework requires that the investment can be held with conviction through periods of regulatory turbulence. HCA cannot be held with that conviction given the structural nature and historical frequency of government reimbursement interventions. The designation stands until the dependency is structurally reduced or the regulatory environment becomes demonstrably more stable and predictable.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

THE OUTLOOK

There are approximately 6.1 million in-ground swimming pools in the United States. Each one needs chemicals, replacement parts, and regular maintenance throughout its lifetime, regardless of what interest rates are doing, regardless of whether anyone is building new pools, regardless of the broader economy. The market for maintaining these pools does not disappear in a downturn. It grows, steadily, as the installed base expands year after year.

Pool Corporation (POOL) sits at the wholesale distribution layer between the manufacturers who make pool products and the 125,000 contractors, service companies, and retailers who sell those products to end consumers. It is the largest business of its kind in the world, with 456 sales centres, approximately 40% of the US wholesale distribution market, and a flywheel of scale that has been compounding for over four decades.

The business is currently earning below its normalised level. New pool construction fell to just below 60,000 units in 2025, roughly half of pandemic-era peak volumes. Elevated financing costs have suppressed homeowner discretionary spending on pools, renovations, and upgrades for three consecutive years. The result is a peak-to-trough earnings-per-share (EPS) compression from $18.70 in 2022 to $10.85 in 2025.

The maintenance revenue base, which represents approximately 64% of Pool’s sales and comes from the inelastic, recurring demand of existing pool owners, held steady throughout this period and grew modestly as the installed base expanded. The competitive position did not weaken. Gross margins held within a few basis points of their historical range. Return on invested capital (ROIC) declined from its peak but remained above 16%, above the cost of capital, in a trough year for the industry. No meaningful market share was lost to competitors.

Pool Corporation is Approved in the Bearhold Universe. The business has demonstrated over four decades that its scale advantages compound, its competitive position strengthens through cycles, and its maintenance revenue base is structurally permanent.

My valuation puts Pool at approximately 15 years of embedded discounted cash flows at current prices. I hold a position initiated before publication of this report. This report explains the business, the thesis, and where the risks sit.

Disclosure: The author holds a position in POOL. This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

At a Glance

Company: Pool Corporation

Ticker: $POOL · NASDAQ

Sector: Industrials

Industry: Wholesale Distribution

Market Cap: $8.3 billion (at $225)

Status: Approved

First Coverage: April 2026

Valuation Zone: Attractive (last updated in April 2026)

1. The Business

The Origin

Pool Corporation traces its roots to 1980, when Frank St. Romain, a former warehouse manager, and his partner Richard Smith founded South Central Pool Supply in New Orleans. The founding insight was simple and durable: insurance companies and pool professionals needed a professional, geographically distributed source for pool supplies and equipment. The fragmented local dealers serving that need were doing it poorly.

For its first decade, South Central Pool Supply grew modestly, building a reputation for service and expanding steadily across the Southeast and into Oklahoma, Texas, and Tennessee. Growth was constrained by access to capital, as then-president Manuel Perez de la Mesa later described it, the company funded expansion almost entirely from retained earnings. By 1993, annual revenues had reached approximately $67 million.

The inflection came in 1993, when private equity firm Code Hennessey & Simmons acquired the company in a leveraged buyout (LBO), incorporated it in Delaware as SCP Holding Corp, and set out to use South Central Pool Supply as a platform for aggressive national consolidation. The strategy was straightforward: the US pool distribution market was deeply fragmented, and a well-capitalised consolidator with the right model could roll it up. Wilson B. ‘Rusty’ Sexton became Chairman and Chief Executive Officer (CEO).

In 1995, the company renamed itself SCP Pool Corporation and went public on the NASDAQ stock exchange under the ticker POOL, raising capital that retired its debt and funded further expansion. The initial public offering (IPO) proceeds unleashed the acquisition campaign: within five years, SCP had acquired dozens of regional distributors and opened scores of new sales centres. Annual revenues grew from $102 million in 1994 to $670 million by 2000.

A pivotal expansion came in August 2000, when SCP acquired Superior Pool Products from Arch Chemicals, at the time a 19-location distributor operating primarily in California, Arizona, and Nevada with revenues exceeding $80 million. Rather than absorbing Superior into the SCP network, management made the strategic decision to operate two distinct domestic distribution networks side by side, each with its own product selection, sales personnel, and supplier relationships. The logic was deliberate competition between internal networks to drive service quality, an unusual approach that has proven effective.

Manuel Perez de la Mesa, who joined as Chief Operating Officer (COO), became President and CEO in 2001 and led the company for nearly two decades. Under his leadership, Pool expanded internationally, launched the Horizon Distributors irrigation business, and broadened the product offering far beyond pool chemicals into building materials, outdoor living, and commercial pool products. At the end of 2018, Peter D. Arvan succeeded him as CEO, bringing over 20 years of distribution industry experience. On May 16, 2006, SCP Pool Corporation became Pool Corporation, a single name for what had become the world’s dominant force in pool wholesale distribution.

What Pool Corporation Does

Pool Corporation does not build pools. It does not install them, service them, or repair them. It is the wholesale distribution layer, the intermediary that sits between manufacturers and the fragmented network of pool professionals who serve end consumers.

When a pool builder needs concrete, pumps, filters, tiles, and chemicals for a new installation, they order from Pool. When a service technician needs a replacement part for a malfunctioning heater, they call Pool. When a specialty retailer needs to restock their shelves with chemicals and accessories, they order from Pool. Pool takes possession of product from over 2,200 manufacturers, holds inventory across 456 geographically distributed sales centres, and delivers to contractors and retailers, often the same day. It earns a margin on every product it passes through the supply chain.

This hub-and-spoke model is the foundation of the business. Pool does not compete nationally in any meaningful sense, it competes market by market. Each sales centre is positioned within a population centre, close to contractor customers, with well-stocked inventory and local delivery capability. A pool professional in suburban Houston does not care about national market share; they care whether their local Pool centre can get them what they need, today, at a competitive price. Pool’s network is built to answer yes to that question in virtually every significant pool market in North America.

The Five Networks

Pool Corporation operates through five wholly-owned subsidiary distribution networks, each serving a distinct segment of the market. Understanding these networks matters because they are not divisions of the same business in a superficial sense, they have different brand identities, different product selections, and in some cases, different types of customers. Pool maintains them separately by design.

SCP Distributors (SCP) is the original network, descended from South Central Pool Supply. It is the largest of the five, operating 224 sales centres domestically and 48 internationally as of year end 2025. SCP handles the full range of swimming pool supplies, equipment, and related leisure products for the domestic market and serves as Pool’s primary international distribution platform.

Superior Pool Products (Superior) is the second domestic swimming pool network, acquired in 2000 and deliberately maintained as a separate operation. Superior operates 75 centres, primarily serving pool builders, service companies, and retailers with a different product mix and distinct supplier relationships from SCP. The rationale for two separate domestic pool networks is intentional competitive tension: SCP and Superior compete in many markets, which management believes drives better service quality than a single monopoly distributor would provide. This may seem counterintuitive, why compete with yourself? but the track record suggests it works.

Horizon Distributors (Horizon) is Pool’s irrigation and landscape maintenance subsidiary, operating 88 sales centres focused on irrigation system components, professional turf care equipment, hardscapes, and landscape maintenance supplies. Horizon serves landscape contractors and commercial operators rather than pool professionals. The business shares many characteristics with the pool distribution model, fragmented customers, recurring demand, local delivery, and benefits from Pool’s purchasing scale and supplier relationships.

National Pool Trends (NPT), formerly known as National Pool Tile until a rebrand in November 2025, is a specialised network focused on swimming pool tile, composite pool finishes, decking materials, and interior pool surfacing products. NPT operates 19 standalone sales centres, but its reach is substantially broader: 124 SCP and Superior locations also feature NPT consumer showrooms where contractors and homeowners can view and select tile, decking, and surfacing options. NPT’s products are more discretionary in nature than chemicals or replacement parts, making this segment more sensitive to the construction and renovation cycle.

Sun Wholesale Supply is the most recently added network, acquired as part of Pool’s December 2021 purchase of Porpoise Pool & Patio. Sun Wholesale’s primary role is servicing the Pinch A Penny franchise network, a chain of independently owned specialty retail pool stores, the largest pool franchise system in the United States. Sun Wholesale supplies these franchisees with pool chemicals, equipment, and accessories, and owns a chemical re-packaging plant in Florida that produces proprietary branded products sold through the Pinch A Penny system. The Pinch A Penny network grew to over 300 franchise locations by year-end 2025, adding 10 new stores during the year and expanding into two new states.

The Revenue Mix

In 2025, approximately 64% of Pool’s sales came from recurring maintenance and minor repair of existing pool installations. These are the chemicals, replacement parts, and minor consumables that pool owners must purchase to keep their pools functional and safe, the non-discretionary foundation of the business. Approximately 22% came from remodeling, renovation, and upgrades, and the remaining 14% from new pool construction. This structure matters because the 64% non-discretionary base does not compress in downturns. It grows every year with the installed base, providing the revenue floor that sustains the business through every economic cycle.

Scale and Geography

Pool’s 456 sales centres at year-end 2025 are disproportionately concentrated in the markets with the greatest pool density. California, Florida, Texas, and Arizona together account for approximately 53% of annual net sales. Pool operates 77 locations in California, 67 in Florida, 55 in Texas. These are also the states receiving the largest net domestic migration inflows. The demographic tailwind of population movement toward warmer climates creates pool installation demand and maintenance volume growth that flows directly to Pool’s most dense network regions.

Internationally, Pool operates in Europe, primarily through the UK, France, Spain, Germany, Belgium, Croatia, Italy, and Portugal, and in Australia. International operations represented approximately 5% of net sales in 2025, growing 5% in local currency terms. Europe is structurally earlier in its pool distribution evolution than the US, representing a long-runway optionality rather than a near-term growth driver.

2. The Moat

Pool’s competitive advantage is scale economies shared, one of the most durable forms of moat in distribution because it is self-reinforcing and strengthens with each passing year.

How the Flywheel Works

Pool’s scale allows it to purchase from 2,200 suppliers at better prices than any regional distributor can negotiate. It passes a portion of those better economics to contractor customers as better pricing, better product availability, and faster delivery. Contractors consolidate purchasing with Pool. Pool’s volumes grow. Purchasing leverage increases. Smaller competitors are squeezed on margins and cannot match Pool’s service levels. They lose customers or exit. Pool absorbs their volume. Repeat.

This flywheel has been running for over 40 years. Revenue per sales centre has grown at nearly 6% per year since 2014, outpacing the approximately 3% annual growth in centre count over the same period. Each location is becoming more productive, not just the network expanding. That is the flywheel operating.

Four Pillars

The first pillar is purchasing leverage from scale. Pool’s volumes across 2,200 suppliers give it negotiating power that no regional competitor can match. Its preferred vendor programme concentrates purchasing to extract better terms, rebates, early-buy discounts, priority allocation, which flow into gross margin stability even as the revenue mix shifts through cycles.

The second pillar is product breadth. Pool offers over 200,000 products across more than 700 product lines and 40 product categories. A contractor purchasing from a smaller regional distributor faces a fundamentally inferior selection. In a service business where time is money, the convenience of a single trusted source with comprehensive inventory is worth more than marginal savings on individual items. No competitor can replicate this breadth without decades of supplier relationship building and the capital to finance the inventory position.

The third pillar is local delivery infrastructure. Pool’s sales centres sit within population centres near customer concentrations. The ability to deliver same-day or next-day to contractors in their local market is operationally critical. A pool professional who needs a pump motor today cannot wait for an online order. This geographic density is a physical infrastructure moat, expensive to build, slow to replicate, and self-reinforcing as Pool adds 8 to 12 new centres per year.

The fourth pillar is POOL360 digital integration. POOL360 is Pool’s proprietary business-to-business (B2B) digital platform, which includes e-commerce ordering, water testing software (POOL360 WaterTest), and a field service management application (POOL360 PoolService) that allows pool professionals to manage their scheduling, routing, billing, and customer relationships from a single mobile application. A contractor who has embedded POOL360 into their daily workflow is not switching distributors to save 2% on one product category. POOL360 reached an all-time high of 15% of total sales in FY2025, up from 10% in 2023. The trend has been consistently upward for four consecutive years, which is the most important forward-looking signal in the moat analysis.

Financial Evidence

Gross margins averaged approximately 29% to 30% across every year of the past decade, including the trough years of 2023 through 2025. A business losing its competitive position would see gross margins compress as it discounts to retain volume. Pool’s gross margins have not compressed.

ROIC averaged above 20% over the decade, and in 2025, with earnings per share (EPS) having fallen from a peak of $18.70 in 2022 to $10.85, ROIC still sits at approximately 16%. For a wholesale distribution business with no proprietary physical products, sustaining returns above the cost of capital through a decline of that magnitude is a meaningful signal that the structural economics of the business are intact. The capital invested in the network is generating returns. No meaningful market share has been lost to competitors in this period.

The supplier concentration itself confirms market power. Pool’s top three suppliers, Pentair, Zodiac, and Hayward, collectively account for approximately 43% of Pool’s cost of goods sold (COGS). These are large, sophisticated manufacturers who sell through Pool because Pool is the most efficient route to the fragmented contractor market. They depend on Pool. That dependency is evidence of distribution leverage, not exposure.

3. Financial Performance

The financial record of Pool Corporation over the past ten years tells two stories simultaneously. The first is structural: a business with genuine competitive advantages compounding revenue, earnings, and free cash flow at exceptional rates over the long arc. The second is cyclical: a business whose earnings expanded dramatically during an extraordinary pandemic-era demand surge and have since normalised back toward their historical range. Reading the numbers correctly requires keeping both stories in view.

Revenue

Revenue grew from $2.36 billion in 2015 to a peak of $6.18 billion in 2022, a compound annual growth rate (CAGR) of approximately 15% over seven years. Since 2022, revenue has declined to $5.29 billion in 2025, entirely reflecting the reduction in new pool construction and renovation activity. The maintenance revenue base did not contract. The compression is entirely in the discretionary segment.

The Pandemic Surge and the Normalisation

Understanding the operating margin trajectory requires understanding what happened during 2020 through 2022. For the decade prior to the pandemic, Pool’s operating margin averaged approximately 10%, a stable, predictable range that reflected the economics of a distribution business with consistent gross margins and a fixed cost structure.

The COVID-19 pandemic created an extraordinary and temporary departure from that baseline. As families spent more time at home and sought to create or expand outdoor living spaces, demand for new pool construction surged dramatically. Combined with homeowners who were already invested in their properties, supported by rising home values, low mortgage rates, and a perception that their homes had become their primary entertainment and recreation venues, Pool’s revenue grew from $3.9 billion in 2020 to $6.2 billion in 2022. Operating leverage on a fixed cost base that could not scale as fast as revenue drove operating margins to 15.7% in 2021 and 16.6% in 2022, levels that had never been seen in the company’s history.

Since the second half of 2022, this surge has reversed. Elevated interest rates have suppressed new pool construction. Consumer discretionary spending has moderated from pandemic highs. Revenue has declined from its peak, and operating margins have returned to approximately 11% in 2025, essentially the pre-pandemic normal. This is not deterioration. The operating margin has returned to its historical range, not fallen below it. The 2021 and 2022 margins were the anomaly.

Earnings Per Share

Diluted EPS grew from $2.90 in 2015 to $18.70 at the 2022 peak, a 7-year CAGR of approximately 30%. From the peak, EPS has declined to $10.85 in 2025, reflecting the revenue normalisation described above. Neither number represents the mid-cycle earning power of the business. The $18.70 incorporated extraordinary pandemic demand; the $10.85 reflects a construction market at approximately half of normalised levels. The normalised earning power sits somewhere in between, and the Valuation section addresses this directly.

The share count has declined from approximately 44.3 million diluted shares in 2015 to 37.3 million in 2025, a reduction of approximately 16% through consistent buyback programmes. In 2025 alone, Pool repurchased $341 million of its own shares. That discipline compounds EPS growth on top of the underlying business performance.

Gross Margin

Gross margin has held in a narrow band of 28.6% to 31.3% across the full decade. The 2025 gross margin of 29.7% is essentially identical to 2024. Adjusting for the one-off $12.6 million import tax reversal that benefited 2024’s gross margin, the underlying 2025 gross margin actually improved 20 basis points year over year, reflecting Pool’s pricing discipline and supply chain management even in a softer demand environment.

Free Cash Flow and the OCF Story

Operating cash flow (OCF) was $888 million in 2023, $659 million in 2024, and $366 million in 2025. The decline from 2024 to 2025 appears dramatic but is substantially explained by working capital timing rather than a deterioration in the underlying business.

Three components of working capital combined to suppress OCF in 2025. First, inventory increased by $165 million during the year. Management explicitly attributed this to strategic purchasing ahead of anticipated vendor price increases, a deliberate decision to build stock before tariff-related and inflation-driven cost increases took effect. Second, accounts receivable increased by approximately $33 million, primarily driven by higher sales in December 2025, which fell outside the collection window for year-end cash. Third, accounts payable declined by approximately $44 million as Pool paid down supplier balances at a faster rate relative to the elevated payable levels of 2024, when the company had benefited from extended seasonal payment terms. These three working capital movements together subtracted approximately $150 million from operating cash flow. The fourth and largest factor was a $68.5 million federal income tax payment in 2025 that had been deferred from 2024, a one-time cash outflow with no impact on the underlying profitability of the business.

Adjusting for the deferred tax payment alone, 2025 OCF would have been approximately $434 million, or 107% of net income, consistent with Pool’s historical cash conversion rate. Free cash flow of $310 million therefore understates run-rate cash generation. The 2024 OCF of $659 million, with normal working capital dynamics, is the more reliable anchor for what the business can produce at stable conditions.

Inventory Days: A Decade-High That Deserves Scrutiny

Days inventory outstanding (DIO), the number of days Pool holds inventory before it is sold, has climbed steadily from approximately 96 days in 2020 to 135 days in 2025, the highest level in a decade. This is worth examining carefully because elevated inventory days affect multiple financial metrics simultaneously: they tie up working capital, reduce free cash flow, and, if the inventory cannot be sold at full margin, compress profitability.

The 2025 inventory build reflects a deliberate strategic decision by management. Pool purchased ahead of anticipated price increases, both from inflation running at approximately 2% to 3% in 2025 and from tariff impacts that management expected to flow through the supply chain. Pool explicitly disclosed this in the Q4 2025 earnings presentation, noting that inventory growth reflected inflation, strategic pre-buy purchasing, acquisitions, and new sales centre additions.

The bull case for this strategy is straightforward: if vendor prices rise as expected, Pool’s early-bought inventory sits on the balance sheet at below-market cost, and when sold, generates better margins than inventory purchased at higher post-increase prices. Pool has a long history of making similar strategic inventory decisions during inflationary periods, the company’s preferred vendor programme and early-buy arrangements with manufacturers are specifically designed for this kind of counter-cyclical purchasing.

The risk case is equally clear. If the price increases management anticipated do not materialise, if tariff impacts are reversed, if inflation moderates, or if demand remains soft and inventory sits longer than planned, then Pool is holding a larger stock of product than it needs, at cost prices that may be above what it can charge in a deflationary environment. The company acknowledges this explicitly in its risk factors: overestimating demand and purchasing too much of a particular product creates the risk that prices fall, leaving inventory that cannot be sold at optimal margins or, in a worst case, requires a write-down.

The chemical and maintenance portion of Pool’s inventory, approximately 14% of net sales comes from pool and hot tub chemicals, adds a specific wrinkle. Pool chemicals such as chlorine products, algaecides, and pH adjusters have finite shelf lives. While Pool manages this risk through its reserve for inventory obsolescence (currently $23.9 million), elevated holding periods increase exposure to degradation, regulatory change, and shifts in consumer preferences for specific chemical formulations. Equipment and building materials carry lower obsolescence risk but are more sensitive to technology cycles and construction activity levels.

To contextualise the scale: the 2023 DIO of approximately 139 days was the decade peak, coinciding with the period when Pool was drawing down the inventory it had aggressively built during the pandemic surge. The 2025 level of 135 days is approaching that level again from a different direction, a deliberate build rather than a demand-driven drawdown. The distinction matters, but the risk of being wrong is real and I carry it explicitly.

Balance Sheet and Equity Trajectory

Pool’s balance sheet has undergone a meaningful structural shift over the past several years that is worth examining carefully.

Total equity grew consistently from $256 million in 2015 through $1.31 billion in 2023, an expansion driven by profitable growth, modest leverage, and retained earnings accumulating on the balance sheet. From 2023 onward, equity has declined, from $1.31 billion to $1.27 billion in 2024 and $1.19 billion in 2025. This reversal is not a sign of financial distress, but it does reflect a clear and deliberate capital allocation choice.

The primary driver is the share buyback programme. Pool repurchased $306 million of shares in both 2023 and 2024, and $341 million in 2025, the largest annual repurchase in company history. These buybacks are funded partly from operating cash flow and partly from incremental borrowing, which is why total debt increased by $249 million in 2025. When a company borrows to buy back its own shares, equity shrinks, buyback proceeds reduce equity directly, while the debt that funded them sits on the liability side of the balance sheet.

Retained earnings tell the same story. Retained earnings peaked at approximately $700 million in 2023 and declined to $521 million in 2025, as the combination of buybacks and dividends paid out more than the net income being retained. Pool paid $185 million in dividends in 2025, marking the 21st consecutive annual dividend increase.

The debt-to-equity (D/E) ratio has risen from 1.00x at year-end 2024 to 1.30x at year-end 2025. This remains within management’s stated target leverage range of 1.5x to 2.0x on a debt/EBITDA basis (Pool’s preferred internal leverage metric). For context, the D/E ratio reached 2.98x in 2018 at a prior leverage peak, and the business remained healthy throughout. The current level is moderate and well within the boundaries of Pool’s financing capacity.

The question this raises for a long-term investor is whether aggressive buybacks at current prices represent good capital allocation. At $225 and approximately 15 years of embedded cash flows, buying back shares at attractive prices is a reasonable use of capital. Management has consistently demonstrated that they would rather deploy capital to buybacks than hold excess cash, and the per-share compounding effect of a declining share count is real regardless of entry price.

4. Competition

A Fragmented Market with One Dominant Player

The competitive structure of US pool wholesale distribution is unlike most industries. At national scale, Pool Corporation is effectively the only fully-formed competitor. The remaining approximately 60% of the US market is distributed among regional and local distributors who lack Pool’s purchasing leverage, product breadth, and logistics infrastructure. This is not a duopoly or a tight oligopoly, it is one dominant national platform and several hundred smaller regional players.

Pool holds approximately 40% of the US wholesale pool distribution market. Management’s 2025 annual report notes that the company believes its selection of pool products is the most comprehensive in the industry, with more than 700 product lines across approximately 40 product categories. That breadth, combined with geographic density that allows same-day delivery in virtually every major pool market, is a service proposition that smaller distributors simply cannot replicate at comparable cost.

The competitive gap has widened over time. While specific current data on competitor facility counts versus Pool’s is not available from the 2025 annual report, the long-term trajectory is clear from the financial record: Pool has been consistently gaining share through network expansion at a pace that smaller competitors cannot match, and the structural advantages of scale, purchasing leverage, product breadth, POOL360 digital integration, compound each year.

The Amazon Question

The e-commerce and direct distribution question is the one I hold with genuine uncertainty over a long horizon. Amazon already sells pool chemicals and basic equipment directly to consumers and some contractors. The question is whether direct-from-manufacturer or Amazon purchasing becomes cost-effective enough for contractor workflows to displace Pool as the primary source.

Pool’s defence has three components, and the evidence on each is currently favourable. Same-day local delivery is an advantage that Amazon cannot replicate without the same physical infrastructure investment Pool has made over four decades. Product breadth of 200,000 SKUs means a contractor relationship involves hundreds of different items across dozens of categories, the convenience premium of a single trusted source is real. And POOL360 integration at 15% of total sales and rising means Pool is building its own digital capability before the competitive challenge fully develops.

None of this permanently closes the question. It means the defence is well-constructed, the early evidence is encouraging, and the competitive outcome over the next decade looks meaningfully better than the disruption narrative implies. I monitor it rather than dismiss it.

The Leslie’s Contrast

Leslie’s (LESL), the publicly traded specialty pool supply retailer, is sometimes cited as a peer. It is not a direct competitor. Leslie’s is a consumer-facing retail operation, not a wholesale distributor, and its financial trajectory has been one of significant distress in recent years, with deep losses and balance sheet stress. The contrast with Pool’s wholesale distribution model is instructive: serving professional contractors with a more defensible service proposition, at higher volumes, with better economics, is structurally superior to consumer retail in this industry.

5. Management

Peter Arvan became President and CEO of Pool Corporation at the end of 2018, succeeding Manuel Perez de la Mesa, who had led the company for nearly two decades. Arvan brought over 20 years of distribution industry experience to the role, which matters more here than it would in most industries. Pool’s business model is operationally intensive, managing 456 sales centres, 2,200 supplier relationships, a 200,000-SKU inventory position, and a contractor customer base that values service consistency above all else. A CEO who understands distribution economics at the operational level is better equipped to manage this complexity than a generalist executive would be.

The tenure since 2019 coincides with a period of significant operational challenge: the pandemic demand surge, the subsequent normalisation, three years of construction suppression, and a deliberate technology platform build-out in POOL360. Through this cycle, the structural economics of the business have remained intact, gross margins held, ROIC stayed above the cost of capital at the trough, and market share was not lost. That is not a given outcome; it reflects operational execution.

Arvan holds approximately 86,400 shares, worth roughly $19 million at current prices. That represents approximately 0.23% of shares outstanding, a meaningful personal position for an individual, though not large enough to constitute a controlling interest or to align management and shareholder incentives in the way founder ownership does. It is the kind of holding that keeps a CEO focused on share price over a five-year horizon; it is not the kind that makes him a co-owner in spirit.

In December 2025, Arvan sold a portion of his holdings (approximately 11,000 shares) in a single transaction. I note this honestly rather than dismissing it. A single sale during a period when the stock was trading below its 52-week high, by a CEO who still holds $19 million in company shares, does not strike me as a meaningful negative signal. But it is a data point worth tracking. A pattern of consistent net selling would change my view; one transaction does not.

On the board, Manuel Perez de la Mesa, Arvan’s predecessor as CEO and the architect of Pool’s modern business model, remains a director and holds approximately 97,500 shares. His continued involvement at board level and his personal economic stake in the business is a meaningful signal: the person who built the flywheel believes in its continued value. Total insider ownership across all directors and officers stands at approximately 388,000 shares, or 1.04% of shares outstanding. This is not a founder-led business in terms of insider concentration, but neither is it a company where management has no economic skin in the outcome.

Compensation Structure

Arvan’s total compensation for FY2025 was approximately $5.3 million, below the median of the peer group Pool uses for benchmarking. Base salary is $900,000, roughly 17% of total compensation, meaning 83% of pay is variable and tied to performance outcomes. I consider this an appropriate structure. A CEO whose pay is predominantly fixed has limited downside exposure to poor decisions; a CEO whose pay is predominantly variable is aligned with shareholders in a meaningful way.

The long-term equity component, the largest slice of total pay, is split equally between time-based restricted stock (three-year cliff vesting) and performance-based restricted stock tied to diluted EPS targets. The performance awards pay out on a 0% to 150% scale depending on whether EPS targets are met, providing upside for outperformance and meaningful forfeiture risk if results disappoint. EPS as the performance metric is well-chosen for Pool: it captures the combined effect of earnings growth and the share buyback programme, both of which are within management’s control and directly relevant to shareholder value creation. The overall compensation structure is judged appropriate.

6. Growth Levers & Addressable Market

Four Structural Drivers

1. Construction Recovery

New pool installations fell from pandemic peaks of over 100,000 units annually to just below 60,000 units in 2025. The suppression is entirely financial: pools are primarily financed through home equity borrowing, and when mortgage rates rose sharply from 2022 onwards, homeowners deferred the decision. This is not a permanent structural decline in demand for pools, it is a rate-driven deferral.

The important nuance is that management’s 2026 guidance explicitly assumes new construction units consistent with 2025. Pool is not projecting a recovery; they are projecting another trough year. That conservatism is appropriate given current rate levels, but it also means the construction recovery is not priced into the business at current earnings levels. When rates normalise and construction recovers toward the historical average of 80,000 to 85,000 units annually, Pool captures that revenue incrementally, on top of a maintenance base that is growing regardless.

Each new pool is also not a one-time event for Pool. It joins the installed base permanently and begins generating recurring annual maintenance demand for 20 to 30 years. A recovery in construction from 60,000 to 80,000 units adds not just current-year construction revenue but a compounding permanent addition to the non-discretionary revenue base.

2. The Technology Upgrade Cycle

The installed base of US pools is ageing. Pools installed in the 1990s and early 2000s are now 25 to 35 years old and require equipment replacement. The technology gap between old and new equipment is substantial. Variable speed pumps use 75% to 80% less electricity than single-speed equivalents. LED pool lighting uses 70% less energy than incandescent. Automated pool controls, allowing smartphone management of pump schedules, heating, lighting, and chemical dosing, are now standard on new installations and desired retrofits on older ones.

California mandated variable speed pumps statewide from 2025. Pool operates 77 locations in California, making it the single largest state in Pool’s network. Other states historically follow California’s energy efficiency leadership with a multi-year lag. This mandate creates a legally-enforced replacement cycle across Pool’s largest market, with similar mandates likely spreading. The upgrade cycle is broad-based, multi-year, and structural, it does not depend on consumer confidence, interest rates, or new construction activity.

3. Sunbelt Demographics

Florida, Texas, California, and Arizona account for approximately 53% of Pool’s net sales. These are also the states receiving the largest net domestic migration inflows. Pool’s network concentration in these markets is not accidental, it is the result of decades of market-by-market expansion following population density. The ongoing migration toward warmer climates creates pool installation demand and maintenance volume growth that accrues directly to Pool’s most concentrated network regions without requiring any strategic repositioning.

4. Fragmented Market Consolidation

Pool adds 8 to 12 new sales centres annually. Each new centre is positioned to serve a local market more effectively than smaller competitors, absorbing volume through better service and pricing. In 2025, Pool added 8 new greenfield centres and acquired 3, for a net addition of 8 after 3 closures. At this pace, Pool’s structural lead over regional competitors widens year after year, and the flywheel described in the Moat section turns one more cycle.

Adjacent Opportunity

Pool’s expansion into irrigation, landscape maintenance, hardscapes, and outdoor living products through Horizon and NPT is early-stage. I treat it as optionality rather than a core driver. The Horizon 24/7 B2B platform and the NPT consumer showroom network are genuine value additions, but they do not yet move the needle on overall earnings in a material way. The potential is there; the execution record in these adjacencies is still developing.

7. valuation

What Today’s Price Assumes

My valuation framework expresses intrinsic value as years of embedded discounted cash flows. Rather than using a terminal value, which requires assumptions about perpetuity growth rates I find too speculative to be reliable. I model an explicit series of annual free cash flows per share, discount each one back to the present at an appropriate rate, and ask: how many years of future cash flows does today’s price already contain?

The framework has five zones. Exceptionally Attractive sits below 15 years. Attractive runs from 15 to 20 years. Hold covers 20 to 30 years. Expensive runs from 30 to 35 years. Exceptionally Expensive is anything above 35 years. I initiate new positions only in the Attractive or Exceptionally Attractive zones

The single most important decision in valuing Pool is choosing the right starting point for free cash flow (FCF) per share. Current FCF of approximately $8 to $9 per share is not the right number, it reflects a construction environment at roughly half of normalised levels, working capital timing distortions from the 2025 inventory build, and the deferred tax payment described in the financial section. Using current FCF as the base would be like pricing a hotel chain on occupancy rates during a recession.

The framework I apply here is the same used in prior Bearhold reports where current FCF understates normalised earning power: I use a normalised FCF per share estimate with an explicit explanation of why current figures are distorted. My base case is $15 per share, representing mid-cycle conditions, construction volumes recovering to approximately 80,000 to 85,000 units annually, normal renovation activity, maintenance base growth continuing at approximately 1% to 2% per year, and stock-based compensation (SBC) deducted from operating cash flow as a real economic cost to shareholders. The upper end of my range is approximately $17 per share, anchoring to 2024 OCF of $659 million as a more representative year for underlying cash generation capability.

I present the range rather than a single number because the honest answer is that normalised FCF has genuine uncertainty. If mid-cycle earning power settles at $13 rather than $15, because cost inflation proves stickier, or because the construction recovery is shallower than expected, the valuation picture is less attractive. I carry that uncertainty explicitly.

The Result

At approximately $225, my model puts Pool at around 15 years of embedded discounted cash flows, the lower boundary of the Attractive zone, approaching Exceptionally Attractive territory. I hold a position initiated before this report’s publication.

The 2026 guidance from Pool’s management, projecting EPS of $10.85 to $11.15 with no construction recovery assumed, confirms that the market is pricing the business at close to trough earnings. That is a different and more interesting situation than being priced at trough earnings with a trough valuation multiple. At 15 years in the Attractive zone, Pool’s current valuation is attractive, especially considering we are at a cyclical low point for earnings in such a high-quality business

Growth Engines

I evaluate the return potential of any business through two engines running simultaneously.

The first engine is FCF per share growth, the fundamental driver of intrinsic value over time. For Pool, this engine has multiple components: the construction recovery adds to the revenue base as rates normalise; operating leverage on a cost structure maintained through the downturn amplifies earnings as revenue recovers; and a consistent share buyback programme reduces the denominator. Pool repurchased $341 million of its own shares in 2025 at prices well below any reasonable mid-cycle intrinsic value estimate. That per-share compounding is real and operates independently of the business cycle.

The second engine is valuation re-rating. At 15 years at the lower boundary of Attractive, this engine is beginning to work in the investor’s favour. An investor adding at current prices captures the construction recovery through fundamental earnings growth and the subsequent re-rating from attractive territory simultaneously. That combination, fundamental compounding plus valuation correction, is what the framework is designed to identify.

8. Risks

Where the Thesis Can Be Wrong

1. Cyclical Earnings Compression

This is the most important risk, and the one most often understated. EPS declined from a peak of $18.70 in 2022 to $10.85 in 2025, a 42% compression over three years, driven by the normalisation of pandemic-era construction demand and elevated financing costs. This will happen again. In the next significant economic downturn, Pool’s discretionary revenue segment will compress. Construction will slow. Renovations will be deferred.

A long-term investor can look through cycles if the business is structurally intact, and the evidence strongly suggests it is. But the volatility is real and must be understood before entering a position. Pool is more cyclical than a pure-maintenance business would be, precisely because 36% of revenues are discretionary. The cyclicality is a feature, not a bug, of a business that participates fully in the upside of construction booms. But it means the entry price matters considerably, and owning Pool at the wrong price through a downturn is a genuinely uncomfortable experience.

2. Inventory Pile-Up

Inventory days of 135 in 2025 are approaching decade-high levels. Management’s rationale, purchasing ahead of anticipated price increases, is a standard and historically successful practice for Pool. But the downside scenario is real: if anticipated price increases do not materialise, or if demand remains soft, Pool is carrying more inventory than it needs at cost prices that may be above what the market will bear. This could result in either margin compression on the sale of elevated-cost inventory, or in a worst case, write-downs. Pool’s reserve for inventory obsolescence was $23.9 million at year-end 2025, not alarming in absolute terms, but worth monitoring against actual write-off trends in coming quarters.

3. E-Commerce Structural Challenge

Amazon and direct-from-manufacturer purchasing represent a long-term structural question for wholesale distribution economics. Pool’s defence, same-day local delivery, 200,000 SKU breadth, POOL360 digital integration, is well-constructed and already working. But the question is not closed over a 20-year horizon. I monitor POOL360 adoption rates, gross margin trends, and any signals of customer defection as the most important leading indicators of this risk.

4. Tariff Exposure

Pool sources products from manufacturers globally, including Chinese-manufactured pool equipment. The current tariff environment introduces cost uncertainty that Pool largely passes through to contractors, but the timing mismatch between cost increases and price realisation creates quarterly earnings volatility. Inflationary product cost increases included a 1% tariff impact in 2025. The tariff environment remains dynamic and will continue to create noise in quarterly results.

5. Housing Market Dependency

New pool construction correlates strongly with housing market activity, home equity availability, and consumer willingness to take on debt for home improvement. In a scenario where housing prices decline significantly, from a broader recession or from housing-specific stress, the construction recovery thesis is delayed or reversed. Consumers who have seen home equity erode are unlikely to finance pool installations. This is the scenario where my normalised FCF estimate of $15 proves too optimistic in the medium term.

6. Normalised Earnings Uncertainty

The honest acknowledgment is that $15 per share as normalised FCF is an estimate, not a number readable from the financial statements. If structural operating cost inflation proves stickier than expected, or if the construction recovery is shallower or slower than my model assumes, the normalised earning power may settle lower. That is a risk I hold explicitly rather than papering over with a point estimate.

What Would Change My Mind

Persistent gross margin compression below 28% for two or more consecutive years, not explained by a temporary mix shift, would signal something more structural than a cyclical trough. A sustained reversal in POOL360 adoption rates. A major supplier announcing direct distribution capability at scale. EPS on a normalised basis, after rates decline meaningfully, failing to recover toward $14 to $15. Any of these would warrant a fundamental reassessment of the thesis.

9. The Verdict

Pool Corporation is Approved in the Bearhold Universe. The business has demonstrated over four decades that its scale advantages compound, its competitive position strengthens through economic cycles, and its maintenance revenue base is structurally permanent. The financial track record, ROIC consistently above 16% through a 42% EPS compression from peak to trough, gross margins stable at 29% to 30% throughout, is empirical evidence of a genuine and durable moat. The cyclicality of the business does not disqualify it from the Approved designation; what matters is that the moat itself has not weakened during the downturn.

At approximately $225 and 15 years of embedded cash flows, Pool sits at the lower boundary of the Attractive zone. I hold a position initiated prior to this publication.

What makes the current moment analytically interesting is this: Pool’s management is guiding for 2026 EPS in line with 2025 and explicitly assumes no recovery in new pool construction. The market is therefore pricing the business at trough earnings, with no meaningful premium for a recovery that, at some point, is structurally inevitable. The construction suppression is rate-driven and financial in nature, not a permanent structural loss of demand for pools. When rates normalise and construction recovers, the earnings recovery is expected to be significant, and investors who entered in the Attractive zone will capture both the fundamental compounding and the re-rating from trough levels.

The risks are real, cyclical earnings volatility, the inventory build, the long-term e-commerce question. None of them, assessed honestly against the quality of what has been built over 40 years and the price at which it is currently available, changes my view that Pool Corporation belongs in the Bearhold Universe.

Disclosure: The author holds a position in POOL. This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

Sources

Pool Corporation FY2025 Annual Report on Form 10-K (filed February 2026).

Pool Corporation Q4 2025 Earnings Presentation (February 19, 2026).

Pool Corporation company history at poolcorp.com.

P.K. Data, Inc., US in-ground pool installation data.

The Outlook

There is a hormone produced in the human gut after you eat. It signals to your brain that you have had enough. It slows the stomach from emptying. It tells the pancreas to release insulin. For most of medical history, this hormone, glucagon-like peptide-1, or GLP-1, was just a footnote in endocrinology textbooks. Then a Danish pharmaceutical company spent thirty years studying it, synthesising molecules that mimic it, extending their half-life in the bloodstream from a few minutes to a full week, and iterating on the formulation until they could put it in a once-weekly injection. And then, remarkably, into a pill.

What Novo Nordisk has built is not just a drug franchise. It is a century-old institution that made the right scientific bet at the right moment in history, and found itself at the centre of what may be the most commercially significant pharmacological development of our generation. GLP-1 drugs are not a weight loss trend. They are a reclassification of obesity from a lifestyle problem to a treatable chronic disease, and Novo Nordisk is the company that did the reclassifying. My valuation framework puts the stock at 17 years of embedded discounted cash flows, firmly in the Attractive zone.

The business is on the Bearhold Watchlist, not yet Approved, and this report explains the distinction.

At a Glance

Company: Novo Nordisk A/S

Ticker: NVO · NYSE / NOVO B · Nasdaq Copenhagen

Sector: Healthcare

Industry: Pharmaceuticals

Market Cap: ~$168 billion

Dividend Yield: ~4.8% (price $37.5)

Current Stock Price: $37.50

First Coverage: April 2026

Bearhold Universe Status: Watchlist

Valuation Zone: Attractive (last updated April 2026)

This report reflects the author's personal views and does not constitute investment advice. Investing carries the risk of permanent capital loss. The author held a position in NVO during the research process and exited prior to publication. No position is held at the time of publishing. Read the full disclaimer here

1. The Business

From Insulin to the Drug That Changed Everything

The story of Novo Nordisk starts in 1923, the same year insulin was first commercially produced, just two years after its discovery in Canada. A group of Danish scientists recognised that this life-saving hormone would need to be manufactured reliably, at scale, for the millions of people with type 1 diabetes who would otherwise die without it. They built a small laboratory in Copenhagen and began producing insulin from pig and cow pancreas. That business became Novo Nordisk.

For most of the 20th century, the company’s identity was simple: it made insulin. Its early products were animal-derived insulins, extracted directly from livestock pancreas. These worked, but they were not identical to human insulin, which meant the body sometimes rejected them. In the 1980s, Novo Nordisk was among the first companies to produce human insulin through recombinant DNA technology, meaning scientists could engineer bacteria to produce an exact replica of the human molecule. This was a step-change in treatment quality and marked the company’s transition from a manufacturer to an innovator.

Through the 1990s and 2000s, the company developed long-acting insulins, versions that are released slowly into the bloodstream over 24 hours, eliminating the need for multiple daily injections. Tresiba (insulin degludec), one of Novo Nordisk’s flagship insulins, is a once-daily injection that lasts over 40 hours, offering far more flexibility than older formulations. These innovations matter because the management of type 2 diabetes, which affects roughly 500 million people globally, traditionally relied entirely on insulin injections. The more convenient and precise those injections became, the more patients could comply with treatment, and the better their outcomes.

The GLP-1 Discovery

In the 1980s, researchers discovered that the intestinal hormone GLP-1 had remarkable properties: it stimulated insulin release only when blood sugar was elevated, suppressed glucagon (the hormone that raises blood sugar), and slowed digestion. Unlike insulin, which works regardless of blood sugar levels and can cause dangerous hypoglycaemia (dangerously low blood sugar) if dosed incorrectly, GLP-1 had a built-in safety mechanism. It only worked when it was needed.

The problem was that natural GLP-1 is destroyed in the bloodstream within a few minutes. To be useful as a drug, scientists needed to create a version that lasted long enough to have a therapeutic effect. This is where Novo Nordisk’s decades of molecular engineering experience paid off. Their scientists modified the GLP-1 molecule to make it resistant to the enzyme that breaks it down, and bound it to a carrier protein to extend its life in the body. The result was semaglutide, a once-weekly injectable that mimics GLP-1 with dramatically extended duration.

The Same Drug, Different Names

This is one of the most frequently misunderstood aspects of Novo Nordisk’s business, so I want to explain it clearly.

Ozempic and Wegovy contain the exact same active ingredient: semaglutide. The difference is the dose. Ozempic, approved for type 2 diabetes, is available at doses of 0.5mg and 1mg per week. Wegovy, approved for obesity, is dosed at 2.4mg per week. Rybelsus is the oral version of semaglutide, available in daily pill form at doses of 7mg and 14mg, approved for diabetes. The Wegovy pill, approved by the FDA (US Food and Drug Administration) in January 2026, is an oral version for obesity at 25mg per day.

The reason these identical molecules have different names is both regulatory and commercial. Regulatory agencies approve drugs for specific indications at specific doses, a company cannot simply sell its diabetes drug off-label for obesity without a separate approval process. More importantly, it is commercial. Insurance companies in the US have historically refused to cover obesity as a disease, meaning they will reimburse Ozempic for a diabetic patient but not Wegovy for an obese patient who does not have diabetes, even though the molecule is the same. By separating the brands, Novo Nordisk can price and position each product for its specific reimbursement channel. Ozempic’s lower dose and diabetes indication gives it a clearer path to insurance coverage. Wegovy’s obesity approval opens a different, harder, but rapidly expanding reimbursement channel.

Why GLP-1 Is Replacing Traditional Insulin Therapy

The conventional treatment pathway for type 2 diabetes used to look like this: start with oral medication (metformin), add more oral medications as the disease progresses, and eventually transition to daily insulin injections as the pancreas loses its ability to produce enough insulin on its own. Patients often spent years on multiple medications and ended up injecting insulin multiple times daily, managing complex carbohydrate intake, and still experiencing high rates of cardiovascular disease, kidney disease, and nerve damage.

GLP-1 drugs changed this trajectory. Clinical trial after clinical trial showed that semaglutide not only controlled blood sugar as effectively as insulin but also reduced body weight, lowered blood pressure, reduced inflammation, and, critically, reduced cardiovascular mortality. The SELECT trial, completed in 2023, showed that Wegovy reduced major adverse cardiac events such as heart attack and stroke by 20% in people with obesity and established cardiovascular disease. The FLOW trial showed Ozempic reduced the progression of chronic kidney disease by 24%. These are outcomes that insulin, despite decades of use, has never convincingly demonstrated.

The result is that GLP-1 drugs are no longer just an add-on to diabetes therapy. They are increasingly the first-line treatment, with insulin reserved for patients who cannot tolerate GLP-1 drugs or whose disease has progressed beyond what GLP-1 can manage. This is why Novo Nordisk’s older insulin products, Victoza, Levemir, are declining. Victoza sales fell 43% in constant currency terms in FY2025. These are not accidents. They are the natural consequence of a superior drug replacing its predecessor.

How a Diabetes Drug Became the Defining Weight Loss Treatment

The weight loss effect of GLP-1 drugs was noticed early in clinical trials but treated initially as a side effect. Patients taking these drugs for diabetes were losing significant body weight, not through stimulant effects, but because the brain was receiving genuine satiety signals, reducing appetite naturally. Novo Nordisk’s scientists understood what this meant: there was a separate, enormous market here.

The STEP trials, completed in 2021, tested semaglutide 2.4mg specifically for obesity in people who did not have diabetes. Participants lost an average of 14.9% of their body weight. That may sound modest, but in the context of obesity pharmacology, where most approved drugs had achieved 3–5% weight loss at best, it was extraordinary. The FDA approved Wegovy in June 2021, and the obesity treatment market was never the same.

Today the business operates across three segments. Obesity care generated DKK 82.3 billion in FY2025, up from essentially zero in 2019, when it barely existed as a category, growing 31% at CER (constant exchange rates). Diabetes care generated DKK 207.1 billion, growing 4% at CER. Rare disease, treatments for growth hormone disorders and haemophilia, generated DKK 19.6 billion, growing 9% at CER. Total revenue reached DKK 309 billion in FY2025, up from DKK 157.5 billion five years earlier.

2. The Moat

What Makes This Business Hard to Compete with

Novo Nordisk’s competitive position rests on four reinforcing pillars, and understanding each one is important before looking at the financial results.

The first is molecular depth. Semaglutide has been in development since the early 2000s and has accumulated a clinical evidence base that no competitor can replicate quickly. Cardiovascular outcomes trials take five to seven years to complete and cost hundreds of millions of dollars. Novo Nordisk has completed the SELECT trial for obesity, the SUSTAIN-6 trial for diabetes, and the FLOW trial for kidney disease. These are not marketing claims, they are data sets generated from tens of thousands of patients over years. A new entrant today, even with a technically equivalent molecule, would need to spend a decade and billions of dollars to generate comparable evidence. That is structural protection.

The second is manufacturing expertise. GLP-1 drugs are biologics, they are not simple chemical compounds. They are produced through complex biological processes that require precision at every step, from fermentation to purification to formulation for injection or oral delivery. The development of a stable oral semaglutide formulation, which required solving the problem of getting a large peptide molecule through the stomach without being destroyed, is a technical achievement that took years of R&D investment. The current DKK 60 billion annual capital expenditure is explicitly aimed at expanding this infrastructure. It takes time and expertise that cannot be purchased overnight.

The third is commercial infrastructure. Novo Nordisk has one of the deepest specialist sales forces in pharmaceutical history, built over a century of selling to endocrinologists and diabetologists. These relationships are not purely transactional, prescribers who have spent fifteen years trusting Novo Nordisk’s insulin products were natural early adopters of Ozempic. That trust transfers, and it creates a distribution advantage that is invisible in the financial statements but profoundly real.

The fourth is patient stickiness. GLP-1 drugs require continued use to maintain their effect, body weight returns on discontinuation, and blood sugar control deteriorates. This means a patient who starts on Ozempic or Wegovy is, in practice, a recurring revenue stream. It is not a perfect annuity, discontinuation rates are real and I will discuss them in the Risks section, but the baseline adherence creates a revenue durability that few pharmaceutical franchises can match.

The empirical evidence of the moat is in the margins. The operating margin has ranged from 41.3% to 45.8% across every year from 2015 to 2025, averaging 43.1% over the decade. A business that is losing its competitive position does not sustain margins at that level across ten years of significant disruption, including pricing pressure from biosimilars on older products, a global pandemic, supply constraints, and a complete transformation of the revenue mix.

3. The Paradox at the Heart of the Business

One Company Treating the Same Disease it is Helping Prevent

I want to pause on something that I have not seen discussed clearly enough in most analyses of Novo Nordisk. It is a genuine strategic tension at the heart of the business model, and it deserves honest examination.

Novo Nordisk sells two categories of products. In the diabetes segment, it sells drugs that treat and manage diabetes, products that patients typically use for life, generating stable, recurring revenue. In the obesity segment, it sells drugs that cause significant weight loss, and we now have substantial evidence that sustained weight loss reverses or prevents type 2 diabetes in a meaningful share of patients.

I do not think this resolves neatly. Here is how I think about it.

In the near term, the two businesses are growing simultaneously and serve largely different patient populations. Most Ozempic patients are type 2 diabetics with established disease. Most Wegovy patients are obese without a diabetes diagnosis. The overlap exists but it is not yet the dominant dynamic.

In the medium term, say five to ten years, if GLP-1 drug adoption reaches a meaningful share of the obese population, and if adherence rates are sustained, we should expect a measurable reduction in the incidence of new type 2 diabetes cases. This is good for society and genuinely good for patients. For Novo Nordisk’s diabetes franchise, it means the pool of newly diagnosed type 2 diabetics will eventually shrink. At the same time, the surviving diabetes franchise will treat a patient population with more advanced and complex disease, the patients for whom lifestyle intervention and GLP-1 therapy alone were not enough.

In the long term, the company’s own strategic positioning tells you what management believes: obesity care is the growth engine of the next decade, and diabetes care is the stable cash-generating foundation. The restructuring announced in FY2025, redirecting DKK 8 billion in annualised savings toward obesity and diabetes innovation, confirms this. They are not treating this as a zero-sum game within the portfolio. They are betting that the obesity market is large enough to more than offset any erosion in the diabetes base.

I think this is probably correct, but I hold it with appropriate uncertainty. The honest risk is that if obesity drugs penetrate much faster and at much higher adherence rates than current models project, the diabetes franchise could decline faster than the obesity franchise grows. I do not think this is the base case, the sheer scale of the undiagnosed and untreated obesity population is simply enormous, but it is the kind of second-order risk that deserves a place in any serious analysis of this business.

This unresolved dynamic is one of the reasons the obesity franchise has not yet earned the Approved designation, the long-term interaction between these two segments is genuinely uncertain in ways that a decade of insulin history was not.

4. Financial Performance

A Decade in Numbers

The ten-year financial record of Novo Nordisk is, on almost every metric except one, exceptional.

Revenue grew from $15.7 billion in FY2015 to $48.5 billion in FY2025, a compound annual growth rate of approximately 11.9% over ten years. The growth was not linear. Through 2021, the diabetes franchise expanded steadily. Then the GLP-1 obesity inflection arrived: from 2022 onwards, the company added roughly seven to nine billion dollars of revenue per year. The 2025 figure is more than three times the 2015 base.

Diluted EPS grew from $0.99 in FY2015 to $3.61 in FY2025, a compound annual growth rate of 13.8%. This is the number I trust most as a proxy for earnings power, because it is clean, consistent, and not distorted by the current capex cycle. The share count declined from 5,155 million to 4,448 million over the decade, a consistent buyback programme that reduces the per-share denominator. Dividends per share grew from $0.37 in 2015 to $1.82 in 2025.

The gross margin averaged approximately 83.9% from 2015 through 2025, near the pharmaceutical ceiling, reflecting proprietary manufacturing and durable pricing power. In FY2025, gross margin fell to 81.0%. This is a real and material decline, driven primarily by the enormous surge in cost of goods sold as the company scaled manufacturing rapidly and absorbed restructuring costs related to facility consolidation.

The operating margin has ranged from 41.3% to 45.8% across every year of the decade, averaging 43.1%. FY2025 came in at 41.3%, adjusted for the DKK 8 billion restructuring charge (In September 2025, Novo Nordisk announced a “company-wide transformation” involving approximately 9,000 job cuts, this resulted in a one-off DKK 8.0 billion restructuring cost), underlying operating profit grew 13% at constant exchange rates, and the reported operating margin would have been meaningfully higher. The consistency of margins at this level across ten years of significant business model change is one of the most powerful signals of competitive quality I have seen in this type of analysis.

ROIC (return on invested capital) was 73.4% in FY2015 and declined to 26.8% in FY2025 as the capital base expanded with the manufacturing buildout. The directional decline is expected, the denominator grew faster than the numerator as capital was deployed into assets not yet generating returns. The absolute level of 26.8% is still exceptional for a business of this scale. Eli Lilly’s ROIC reached 33% in FY2025 after a decade of expansion from 10.9% in 2015. The two companies are converging at the high end of the global pharmaceutical industry.

The FCF Story, Why the Headline Number is Not the Full Story

Free cash flow (FCF: cash left after all operating expenses and capital investment) was remarkably stable from 2015 through 2023, growing from $4.7 billion to $10.2 billion. OCF (operating cash flow: cash generated from the business before investment) margins throughout this period ranged from 35% to 47%, and FCF margins ranged from 24% to 36%.

In FY2025, FCF collapsed to $4.5 billion, a margin of 9.4%, compared to a ten-year average of approximately 28%.

The cause is entirely capital expenditure. Capex (spending on factories and equipment) was $935 million in FY2015, representing 17% of OCF. By FY2025, it had reached $14.1 billion, 76% of OCF. The company spent DKK 60 billion on property, plant, and equipment in FY2025, principally to build manufacturing capacity for GLP-1 drugs.

The important distinction is that OCF margins remained within historical norms: 38.5% in FY2025. The business is not generating less cash from its operations, it is reinvesting aggressively in infrastructure. Because FCF per share is temporarily distorted, I use EPS as my primary earnings proxy throughout this report. The operating health of the business is intact.

The Balance Sheet Has Changed

Debt-to-equity was 0.02x in FY2015, essentially no debt. By FY2025, it had risen to 0.68x. The company now carries meaningful net debt, having taken on borrowings to fund both the manufacturing buildout and several acquisitions, including the Catalent manufacturing sites that Novo Holdings purchased in 2024 for $11.7 billion and subsequently deployed to Novo Nordisk’s production. This is manageable at current earnings levels, but it represents a structural shift from the near-pristine balance sheet that characterised this company through most of the last decade.

5. Regional Breakdown

The Numbers by Region (FY2025)

The detailed revenue data from the FY2025 annual report tells a story that the headline figures do not.

US Operations generated DKK 173.2 billion in total sales in FY2025, growing 3.4% as reported (8% at CER). Within that, Wegovy in the US generated DKK 51 billion, up from DKK 45.8 billion in 2024. Ozempic US sales were DKK 88.5 billion. These are extraordinary numbers for two products that barely existed five years ago.

International Operations generated DKK 135.9 billion, growing 10.5% as reported (14% at CER). The breakdown within International Operations reveals where the real opportunity sits:

EUCAN (Europe and Canada) generated DKK 66.1 billion, growing 14.9% as reported (16% at CER). Wegovy in EUCAN generated DKK 15.4 billion, up from DKK 7.7 billion in 2024, a doubling in a single year. This is what the early phase of a proper launch looks like. Europe is roughly two years behind the US in GLP-1 obesity adoption, constrained by more conservative payer systems and slower reimbursement approvals. The trajectory is clear.

Emerging Markets (mainly Latin America, Middle East, and Africa) generated DKK 30.4 billion, growing 3.1% as reported (8% at CER). Wegovy in Emerging Markets generated DKK 6.1 billion in FY2025, up from DKK 2.7 billion in 2024. This is one of the most interesting long-term opportunities and one of the most underdiscussed. Obesity prevalence in Latin America and the Middle East is extremely high, Brazil, Mexico, and Saudi Arabia are among the most obese nations on earth. The barrier is affordability and reimbursement coverage. As Novo Nordisk develops lower-cost formulations and access programmes, this market has a long runway.

APAC (Japan, Korea, Oceania, and Southeast Asia) generated DKK 20.7 billion, growing 18.8% as reported (25% at CER). Wegovy in APAC generated DKK 5.8 billion, up from DKK 1.9 billion in 2024, a tripling in a single year. Japan and South Korea have both launched Wegovy relatively recently, and the cultural and clinical context is different from the West. Japanese patients tend to be obese at lower BMI (body mass index) thresholds than Western patients, and the regulatory framework for obesity treatment has historically been restrictive. As awareness grows and reimbursement expands, APAC represents a meaningful expansion opportunity.

Region China generated DKK 18.7 billion, growing 0.8% as reported (5% at CER). This is the most complicated region, and I will address it directly in the Risks section. Wegovy in China generated DKK 796 million, still a very small number relative to the scale of the opportunity. China has a massive obesity and diabetes burden, but the semaglutide active ingredient patent expires there in 2026, which means low-cost domestic biosimilar competition is coming. The next two to three years in China will be a test of brand loyalty versus price.

The Global Penetration Opportunity

Here is the number I keep coming back to: the World Health Organization estimates approximately 890 million adults globally have obesity. Current GLP-1 treatment penetration is in the low single digits. The United States has an obesity prevalence of roughly 42% in adults, and fewer than 6% of eligible patients are currently on a branded GLP-1 drug. Even after the explosive growth of the last three years, the penetration story is genuinely in its early chapters.

6. Competition: Novo Nordisk vs. Eli Lilly

The Duopoly That Defines the GLP-1 Market

Novo Nordisk and Eli Lilly together represent the vast majority of commercial GLP-1 (glucagon-like peptide-1) prescriptions globally. No other company is remotely close to their combined scale in either diabetes or obesity. Understanding how these two businesses compare is essential.

Novo Nordisk pioneered this market. It was the first to achieve large-scale commercial success with semaglutide, the first to build a manufacturing infrastructure capable of supplying tens of millions of patients globally, and the first to bring an oral GLP-1 pill for obesity to market. That first-mover advantage is real and it matters, both commercially and in terms of the clinical evidence base accumulated across cardiovascular disease, kidney disease, and liver disease.

But Eli Lilly has overtaken Novo Nordisk in prescription market share, and that shift deserves honest acknowledgment. By the third quarter of 2025, Lilly held more than 57% of US monthly GLP-1 prescriptions across diabetes and obesity, with Novo Nordisk at approximately 43%, down from a position of clear leadership just two years earlier. The primary driver is tirzepatide, which activates two hormone receptors simultaneously, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), compared to semaglutide’s one. In Lilly’s SURMOUNT-1 trial, tirzepatide produced average weight loss of approximately 21–22% at the highest dose, compared to semaglutide’s 15% in the STEP trials. When a drug delivers meaningfully better efficacy and is available in adequate supply, prescribers and patients notice. Lilly’s 2026 revenue guidance projects approximately 27% growth. Novo Nordisk’s 2026 guidance is for negative adjusted sales growth at constant exchange rates. The divergence in near-term momentum is real and not easily dismissed.

Where It Gets More Complicated — The Pill Battle

The injectable competition is clear: Lilly leads on efficacy. But the oral market, which is where the next major wave of GLP-1 adoption is likely to come from, driven by patients who have consistently refused injections, is a more nuanced picture, and one that has shifted meaningfully in Novo Nordisk’s favour in just the past two weeks.

Novo Nordisk’s Wegovy pill was approved by the FDA in December 2025 and reached over 600,000 US prescriptions in its first few weeks. On April 1, 2026, 12 days before this report, the FDA approved Eli Lilly’s oral GLP-1, orforglipron, now branded as Foundayo. The pill competition is now live and direct.

The initial market framing was that Novo had first-mover advantage but Lilly had a convenience edge: Foundayo is a small-molecule drug that can be taken at any time with or without food, while the Wegovy pill is a peptide that requires a 30-minute fast each morning. For patients who already struggle with daily medication adherence, that restriction was seen as a meaningful disadvantage for Novo.

Then, on April 2, 2026, one day after Foundayo’s approval, Novo Nordisk presented the ORION study at the Obesity Medicine Association’s annual conference in San Diego. The study used a population-adjusted indirect comparison of data from the OASIS 4 trial (Wegovy pill) and the ATTAIN-1 trial (Foundayo), and the results were notable. Oral semaglutide showed 3.2 percentage points greater weight loss than orforglipron on a real-world adherence basis. On tolerability, patients on orforglipron had approximately four times higher odds of discontinuing due to any adverse event, and nearly 14 times higher odds of discontinuing specifically due to gastrointestinal side effects. A separate patient preference survey of 800 adults found that 84% favoured the oral semaglutide profile over orforglipron, and 65% of those respondents said the morning fasting requirement would not significantly disrupt their daily routine.

I want to be clear about what this data is and what it is not. The ORION study is an indirect comparison across two separate trials, not a head-to-head study with identical protocols. The researchers themselves flagged substantial uncertainty in the tolerability findings, the confidence interval on the gastrointestinal discontinuation figure runs from 2.0 to 96.0, which is wide enough to counsel humility. The study was also funded and presented by Novo Nordisk, which means it should be read with appropriate critical distance even if the methodology is standard. No direct head-to-head trial between these two pills exists, and neither company is likely to fund one voluntarily.

With those caveats stated, the direction of the finding is meaningful. In a chronic disease drug that patients take daily for the rest of their lives, tolerability and real-world adherence matter more than any single efficacy number. A drug that patients stay on compounds its benefit over years and generates recurring revenue. A drug that patients are significantly more likely to discontinue due to side effects loses both the clinical benefit and the commercial durability. The convenience narrative that Lilly was relying on to offset Novo’s first-mover advantage in the oral market has been meaningfully complicated by this data.

The Margin and Balance Sheet Picture

On financial quality, Novo Nordisk maintains the structural advantage. Its gross margin averaged approximately 83.9% from 2015 through 2024, falling to 81.0% in FY2025, compared to Eli Lilly’s expansion from 74.8% in 2015 to 83.0% in FY2025. Lilly has only just reached the margin level that Novo Nordisk has sustained for a decade. Operating margins tell the same story: Novo Nordisk’s range of 41.3% to 45.8% throughout the decade versus Lilly’s expansion from 18% in 2015 to 45.6% in FY2025. Both companies are now experiencing the same capex-driven FCF (free cash flow) compression, Lilly’s FCF margin was 9.2% in FY2025 versus Novo Nordisk’s 9.4%, as both build manufacturing infrastructure for the same market opportunity. On leverage, Novo Nordisk is more conservatively capitalised at 0.68x debt-to-equity versus Lilly’s 1.60x.

One metric I flag for both companies is inventory. Eli Lilly’s Days Inventory Outstanding, a measure of how long products sit in inventory before being sold, increased from 196 days in FY2021 to 352 days in FY2025, nearly a doubling in four years. This could reflect pre-launch positioning or manufacturing buffer-building, but it is a number worth watching in future quarterly reports for signs of demand forecasting error.

The Summary

The injectable market: Lilly leads on efficacy with tirzepatide and has taken prescription share from Novo Nordisk. That is a fact.

The oral market: Novo Nordisk leads on efficacy and, based on the most current available data, leads on tolerability as well, though the evidence is indirect and requires a head-to-head trial to confirm definitively.

The financial quality: Novo Nordisk has the stronger historical margin profile and more conservative balance sheet.

The pipeline: Novo Nordisk’s CagriSema, filed for FDA approval in December 2025 with a decision expected around October 2026, produced 22.7% weight loss in the REDEFINE 1 trial, essentially matching tirzepatide’s injectable efficacy. If approved, it closes the injectable efficacy gap before Lilly’s next-generation retatrutide (a triple receptor agonist) reaches market.

I would describe the current state as a genuine competition between two exceptional businesses, with Lilly holding the commercial momentum in injectables and Novo Nordisk mounting a more credible defence in the oral market than the market appears to currently price in. The coming 18 months, CagriSema approval, head-to-head oral data if it emerges, and the real-world prescription trends between Wegovy pill and Foundayo, will determine whether Novo Nordisk’s defensive position stabilises or continues to erode. At $37.50, I believe the current price more than compensates for that uncertainty.

7. Growth Levers & Addressable Market

The Pipeline: Novo Nordisk’s Response to the Lilly Challenge

CagriSema is the most important near-term pipeline catalyst. It is a fixed-dose combination of cagrilintide (a long-acting amylin analogue, amylin is another satiety hormone produced by the pancreas) and semaglutide 2.4mg. In the REDEFINE 1 Phase 3 trial, participants lost an average of 22.7% of body weight assuming full adherence to treatment, and 20.4% on a real-world basis regardless of adherence. Both figures substantially exceed Wegovy’s current results. Novo Nordisk filed the NDA (new drug application) with the FDA in December 2025, and a decision is expected approximately October 2026.

Zenagamtide (amycretin), a single molecule that activates both GLP-1 and amylin receptors, is entering Phase 3 trials in 2026 in both injectable and oral forms, with early-phase data showing weight loss in the 20% range. The semaglutide 7.2mg dose achieved 20.7% weight loss and has received a positive opinion from the EMA (European Medicines Agency), with an FDA submission also filed. Wegovy was approved for MASH in the US in FY2025, MASH affects approximately 6% of the global population and has very limited approved treatment options, making this a meaningful new revenue channel.

The oral Wegovy pill, approved by the FDA in December 2025, is worth emphasising specifically. Injection hesitancy is a real and documented barrier to GLP-1 adoption. A meaningful share of patients who would benefit from these drugs decline or discontinue them because of the injection requirement. An oral formulation that achieved 16.6% average weight loss in trials, better than any previously approved oral obesity drug, removes that barrier entirely. This is a market expansion story, not just a market share story.

8. Management

Lars Fruergaard Jørgensen, Mike Doustdar, and a CEO Transition at a Critical Moment

Lars Fruergaard Jørgensen served as CEO from 2017 through August 2025. His tenure included the most transformative period in Novo Nordisk’s modern history, the pivot to obesity care, the launch of Wegovy, the extraordinary growth from 2021 to 2023, and the beginning of the current manufacturing buildout. On May 16, 2025, the company announced he would be stepping down following a period of market challenges and declining share price. On July 29, 2025, Mike Doustdar, then head of International Operations, was named as successor, with the formal handover taking place on August 7, 2025.

I read the transition thoughtfully. Jørgensen built the strategic architecture of the current business. Doustdar is, in many ways, the commercial architect of its execution: as head of International Operations, he oversaw the global Wegovy launch and was responsible for the market access strategy that determined how quickly the drug reached patients outside the US. His appointment is not a reversal of strategy. It is a shift in emphasis, from the scientific and strategic decisions of the build-out phase to the commercial and operational execution required to turn that investment into revenue.

The capital allocation record under the previous leadership is solid. Share count declined by approximately 14% over the decade through consistent buybacks. R&D (research and development) spending reached DKK 52 billion in FY2025, 16.8% of revenue, reflecting a genuine commitment to the pipeline rather than cost-cutting to protect near-term margins. The DKK 8 billion restructuring announced in FY2025, reducing the global workforce by approximately 9,000 positions, signals that management is willing to make uncomfortable structural decisions. I read that positively.

The governance structure deserves a note. Novo Holdings, controlled by the Novo Nordisk Foundation, holds approximately 77% of the voting rights through a dual-class share structure. This insulates management from short-term market pressure. It is a structural positive for a business with a multi-decade strategic horizon, though minority shareholders have limited influence over capital allocation decisions.

9. The Compounding Pharmacy Story

The GLP-1 compounding story is important context for understanding the FY2025 performance, and its resolution is one of the reasons I believe the near-term earnings trajectory is better than the FY2026 guidance implies.

When demand for Wegovy and Ozempic surged in 2022 and Novo Nordisk’s manufacturing could not keep pace, the FDA placed semaglutide on its official drug shortage list. Under US law, compounding pharmacies can produce copies of drugs on the shortage list. What followed was a large parallel market: an estimated 3.7 million Americans accessing compounded semaglutide through telehealth platforms at $150–$400 per month versus the $1,349 list price of Wegovy.

The FDA declared the shortage resolved on February 21, 2025. The legal basis for most large-scale compounding of semaglutide no longer exists. Courts sided with Novo Nordisk and the FDA in the key preliminary injunction hearings. As of September 2025, Novo Nordisk had filed 140 lawsuits and issued over 1,000 cease-and-desist letters against compounders. The management team acknowledged that the persistence of compounded semaglutide was a meaningful drag on branded volumes in 2025. As compounding recedes, that volume either transitions to branded Wegovy or is lost, but the channel overhang is clearing.

The TrumpRx Pricing Deal, Volume for Price

In November 2025, Novo Nordisk reached an agreement with the Trump administration under which Wegovy and Ozempic prices will be reduced to $350 per month through the TrumpRx government portal, down from the $1,349 Wegovy list price. The deal also extends Medicare coverage of Wegovy for obesity for the first time. In exchange, Novo Nordisk received a three-year exemption from the pharmaceutical tariffs the administration announced, tariffs that would otherwise apply at 100% to patented drugs imported without a Most Favored Nation (MFN) pricing agreement. Given that Novo Nordisk manufactures substantially in Denmark and Europe, the tariff exemption through approximately 2028 is valuable insurance during the period when its US manufacturing buildout is still coming online.

Management expects a negative low-single-digit impact on global sales growth in 2026 from the pricing agreement. That is a real near-term headwind. The medium-term logic is that lower prices plus expanded Medicare access could ultimately drive higher volumes that more than offset the per-unit reduction. I believe that logic is sound, but it will take time to play out.

10. Valuation

What the Market is Pricing in, and What I Think it is Missing

My valuation framework for Bearhold Research expresses intrinsic value as a number of years of embedded discounted cash flows. Rather than using a terminal value, which requires assumptions about perpetuity growth rates that I find too speculative to be reliable, I model an explicit series of annual free cash flows, discount each one back to the present, and ask a simple question: how many years of future cash flows does today’s price already contain? The answer tells me whether I am paying a fair price, a cheap price, or an expensive one.

The framework has five zones. Exceptionally Attractive sits below 15 years. Attractive runs from 16 to 20 years. Hold covers 21 to 30 years. Expensive runs from 31 to 35 years. Exceptionally Expensive is anything above 36 years. I initiate new positions only in the Attractive or Exceptionally Attractive zones and add most aggressively when a business I understand well enters Exceptionally Attractive territory. I sell when a position reaches Expensive or Exceptionally Expensive and reallocate to Attractive names in the Bearhold Universe.

17 Years — Attractive Zone

At $37.50 per share, Novo Nordisk sits at around 17 years of embedded cash flows, firmly in the Attractive zone of the Bearhold framework.

The most important thing to understand about this number is what it does and does not assume. It does not assume a flawless recovery. It explicitly accounts for the near-term FCF (free cash flow) compression driven by the capex cycle, modelling the gradual normalisation as the manufacturing buildout matures rather than assuming an immediate return to historical cash generation levels. It applies a growth rate that is a meaningful haircut to the company’s historical FCF per share CAGR, acknowledging competitive pressure from Lilly in the injectable market, gross margin headwinds from the TrumpRx pricing deal, and patent expiries in China. And it uses a discount rate at the conservative end of the reasonable range for a business of this quality, reflecting the genuine operational uncertainty of this particular moment.

In other words, 17 years is not an optimistic number dressed up as a conservative one. It is what the arithmetic produces when you take the near-term headwinds seriously.

At 17 years, the thesis requires the capex cycle to normalise broadly on schedule, revenue to recover from the 2026 transition year, and FCF per share to compound at a rate that reflects the underlying quality of the franchise rather than the distortions of the current investment cycle. If those things happen, and I believe they will, for reasons I have set out throughout this report, then 17 years represents a genuine margin of safety in a business whose quality justifies a much higher price.

Growth Engines

I evaluate the return potential of any business through two engines running simultaneously.

The first engine is FCF per share growth, the fundamental driver of intrinsic value over time. For Novo Nordisk, the near-term FCF figure is distorted by the capex cycle, and as that distortion clears over the next two to three years, FCF per share growth should re-converge with the underlying earnings power of the franchise. The combination of revenue growth, operating leverage, and a consistent share buyback programme, which has reduced the diluted share count from 5,155 million in FY2015 to 4,448 million in FY2025, provides a quiet compounding mechanism that operates in the background of every other assumption in the model. Even modest share count reduction adds to per share growth without requiring any improvement in the absolute cash generation of the business.

The second engine is valuation re-rating. At 17 years in the Attractive zone, this engine is working in the investor’s favour. The real optionality lies in the scenario where execution delivers, CagriSema approved, capex cycle matures, gross margins recover, oral market share consolidates in Novo Nordisk’s favour, and the market re-rates the stock from Attractive back toward the upper end of Hold or beyond. In that scenario, the investor earns the fundamental compounding of FCF per share growth and a valuation multiple expansion simultaneously. That combination is what makes the Attractive zone entry compelling for a long-term investor

11. Risks

Every investment thesis has a version of events where it is wrong. I want to walk through the scenarios that would genuinely change my view on Novo Nordisk, not the boilerplate risks that appear in every pharmaceutical analysis, but the specific dynamics that keep me thinking carefully about this position.

The Gross Margin is the Number I Watch Most Closely

This is not the risk that gets the most attention, but it is the one I consider most important to the long-term thesis. Novo Nordisk’s gross margin fell from a decade average of approximately 83.9% to 81.0% in FY2025. The official explanation is a combination of rapid manufacturing scale-up costs, one-off restructuring charges, and the initial inefficiency of newly commissioned facilities. If that explanation is correct, gross margins normalise as the new capacity reaches full utilisation over the next two to three years, and the underlying earnings power of the business is largely intact.

But there is an alternative explanation that I cannot dismiss. The TrumpRx pricing deal reduced Wegovy and Ozempic prices to $350 per month on government channels. Competitive pressure in the oral market is pushing both Novo Nordisk and Lilly toward $149 starting prices for their pills. Biosimilar competition is coming in China and eventually in Western markets as patents expire. If these pricing pressures are structural rather than temporary, the long-term gross margin of this business may settle permanently lower than its historical range. A business that earns 79% gross margins rather than 84% is still exceptional, but the difference compounds significantly over a decade of growth at this scale. I do not think this is the most likely outcome, but it is a risk I watch carefully.

The Capex Cycle

Novo Nordisk is spending DKK 60 billion per year, approximately $9 billion, on capital expenditure, and has committed approximately USD 5.6 billion in additional US manufacturing investment through 2028. The total committed capital across the current buildout cycle runs into the tens of billions of dollars. This infrastructure is being built on the assumption that GLP-1 demand will continue to grow rapidly for years and that Novo Nordisk will capture a meaningful share of that growth.

The risk is not that demand for GLP-1 drugs disappoints in aggregate. I believe the structural demand case is overwhelming, as I discussed in the market view section. The risk is more specific: that Novo Nordisk’s share of that demand disappoints relative to the assumptions embedded in the capex decisions. If Lilly continues to gain injectable market share at Novo Nordisk’s expense, and if the oral market develops more slowly than projected, then the company will have built manufacturing capacity for volumes it cannot fill. Capital expenditure is largely irreversible. Factories cannot be unbuilt. The financial consequence would be years of elevated depreciation charges on underutilised assets, compressing returns on invested capital precisely when the business needs to demonstrate that the investment cycle is paying off.

I think this risk is manageable but it is not theoretical. Management made their capacity decisions when Novo Nordisk’s growth trajectory looked dramatically more positive than it does today. The FY2025 full-year sales growth of 10.3% at constant exchange rates versus the FY2026 guidance of negative adjusted sales growth represents a sharp deceleration. How much of that deceleration is transitional, compounding headwinds, pricing adjustments, China patent expiry, and how much of it represents a more durable slowdown in the underlying franchise, will determine whether the capex cycle was visionary or premature.

China Patent Expiry

All of Novo Nordisk’s core semaglutide products have their active ingredient patents expiring in China in 2026. Ozempic, Wegovy, Rybelsus, the entire franchise. China generated DKK 18.7 billion in FY2025 sales and was growing at 5% at constant exchange rates. Novo Nordisk’s Wegovy launch in China has barely begun, with only DKK 796 million in FY2025 revenue, meaning the obesity opportunity there is largely untapped at the moment the moat is about to be breached.

The practical impact will not be immediate. Biosimilar manufacturers need time to build commercial scale, achieve regulatory approvals, and establish distribution networks. Novo Nordisk’s brand recognition, safety data, and clinical relationships provide a buffer. But Chinese pharmaceutical companies are sophisticated, well-capitalised, and experienced in bringing biosimilars to market quickly. Several domestic companies were already preparing semaglutide biosimilars well before the patent expiry. The pricing pressure in China over the next two to three years will be significant, and the obesity market, which was supposed to be a major long-term growth driver in the world’s most populous country, will develop in a far more competitive and lower-margin environment than the one that drove the Western growth story.

The Injectable Efficacy Gap

Tirzepatide’s approximately 21% average weight loss versus semaglutide’s 15% is a real clinical difference that is influencing prescribing behaviour. Novo Nordisk held approximately 59.6% of global branded GLP-1 volume market share in FY2025, but the US prescription trend, Lilly at 57% of monthly prescriptions and rising versus Novo at 43% and falling, is the more relevant near-term signal. The direction matters as much as the level.

The honest risk here is timing. CagriSema, which matches tirzepatide’s efficacy at 22.7% weight loss, is filed for FDA approval with a decision expected around October 2026. If the approval is delayed, through an unexpected complete response letter, additional data requests, or manufacturing inspection issues, Novo Nordisk remains in the gap year for longer than projected. Every additional month without CagriSema is another month of injectable market share drifting toward Lilly, another month of compounders and prescribers defaulting to tirzepatide for new obesity patients, and another month of the narrative calcifying around Lilly as the dominant player. The business does not collapse in this scenario, but the re-rating catalyst is deferred and the share count of prescribers who have built tirzepatide habits grows.

Real-world GLP-1 Adherence, The Recurring Revenue Moat May be More Fragile Than it Appears

I described the recurring revenue nature of GLP-1 drugs as a feature of the moat, patients who stay on therapy for life generate predictable, growing cash flows. The critical assumption is that patients actually stay on therapy. The real-world data on this is sobering. First-year discontinuation rates for injectable GLP-1 drugs in real-world settings have been estimated at 40 to 50% in multiple analyses, significantly higher than the dropout rates observed in tightly controlled clinical trials.

The reasons are well-documented: gastrointestinal side effects concentrated in the dose-escalation phase, cost and coverage barriers, weight loss plateaus that disappoint patients expecting linear progress, and the practical difficulty of managing a weekly injection in daily life over years. If a meaningful share of the patients who started on Wegovy or Ozempic in the 2022 to 2024 wave have already discontinued, the installed base of recurring prescriptions is smaller than the volume data implies, and the forward revenue from that cohort is lower than a pure adherence model would project.

This dynamic also has a second-order implication for the capex cycle. If real-world adherence is significantly worse than clinical trial data suggests, the demand projections management used when authorising DKK 60 billion annual capital expenditure may have been built on an assumption that the treated population compounds reliably over time. If the population turns over faster, patients starting, stopping, and restarting, the demand profile becomes more volatile and harder to forecast accurately.

The Diabetes-obesity Paradox, long-term Structural Uncertainty

I discussed this in section 3 as a paradox rather than a risk, but at a multi-decade horizon it becomes one. If GLP-1 obesity drugs achieve the penetration rates the most optimistic projections envision, treating hundreds of millions of people globally over the next twenty years, the downstream effect on type 2 diabetes incidence will be measurable. The patients who avoid diabetes because of sustained GLP-1 treatment are patients who do not eventually need insulin, metformin, and diabetes-specific medications. Novo Nordisk’s diabetes franchise, still generating DKK 207 billion in FY2025, by far the larger segment, will face a structurally shrinking addressable market over a long enough time horizon.

I do not think this plays out as a crisis. The transition will be gradual, the diabetes franchise will continue generating strong cash flows for many years, and the obesity revenue replacing it operates at similarly high margins. But any honest long-range model for this business needs to account for the possibility that the company’s most important product is, over a long enough horizon, cannibalising the market for its second most important product line. The net effect is probably positive, obesity revenue grows faster than diabetes revenue declines, but the uncertainty is real and deserves acknowledgment.

The Verdict

Bearhold Universe Status: Watchlist

The Approved designation in the Bearhold Universe is purely qualitative. It has nothing to do with valuation, price, or near-term earnings visibility. It asks one question: has this business demonstrated, through a sufficient track record, that it can sustain excellence in its competitive arena the way the best businesses in history have? The answer determines the designation. The price determines when I act.

Novo Nordisk’s insulin franchise answers that question without hesitation, and I want to be clear about why. This is not a business that stumbled into a good decade. It is a business that built a durable competitive position over a century, through two world wars, through the transition from animal insulin to recombinant DNA technology, through the commoditisation of older molecules, through the arrival of new drug classes that threatened its core. In every one of those transitions, Novo Nordisk did not just survive. It adapted, invested, and emerged with a stronger position than it entered with. The operating margin holding between 41% and 46% across every single year from 2015 to 2025, through a global pandemic, a complete revenue mix transformation, and a manufacturing buildout of historic proportions, is the financial expression of a century of that institutional resilience. The insulin franchise is Approved, unambiguously and permanently.

The obesity franchise is where I have to be honest about what I know and what I do not yet know. And the distinction matters enormously to me, because the Approved designation is a statement about demonstrated quality, not about the quality I believe is coming.

What I know is this. Semaglutide’s clinical evidence base is exceptional. The SELECT trial reducing major adverse cardiac events by 20% in people with established cardiovascular disease. The FLOW trial reducing chronic kidney disease progression by 24%. The STEP trials producing average weight loss of 14.9%, extraordinary by any historical standard in obesity pharmacology. These are not marginal results. They are practice-changing outcomes that have permanently altered clinical guidelines across cardiology, nephrology, and obesity medicine simultaneously. The commercial execution behind these results has been equally impressive. DKK 82 billion in obesity care revenue in FY2025 from essentially nothing six years ago, with a global manufacturing buildout that represents the largest capital commitment in the company’s history. Management made the right strategic bet, made it early, and executed it at scale.

What I do not yet know is whether Novo Nordisk will dominate the obesity market the way it dominated the insulin market. And that distinction is exactly where the Watchlist designation lives.

Eli Lilly’s tirzepatide currently demonstrates superior injectable efficacy, approximately 21% average weight loss versus semaglutide’s 15% in their respective pivotal trials. That gap is real and it is influencing prescribing behaviour in measurable ways. By the third quarter of 2025, Lilly held more than 57% of US monthly GLP-1 prescriptions, having overtaken Novo Nordisk from a position of no market presence just three years earlier. That is a competitive trajectory that deserves honest acknowledgment. Novo Nordisk pioneered this market and is currently being challenged within it by a competitor with a better efficacy number in the most commercially important indication.

CagriSema is Novo Nordisk’s answer. Filed with the FDA in December 2025 with a decision expected around October 2026, it produced 22.7% weight loss in the REDEFINE 1 trial, essentially matching tirzepatide’s headline figure and doing so with a novel dual-mechanism approach combining semaglutide with a long-acting amylin analogue. If CagriSema is approved and demonstrates competitive real-world efficacy, it closes the injectable gap before Lilly’s next-generation retatrutide reaches market. The pipeline response is credible. But it is a promise, not yet a result. And the Approved designation requires results.

The oral market is equally unresolved. On April 1, 2026, twelve days before this report was published, the FDA approved Eli Lilly’s orforglipron, now branded Foundayo, as the second oral GLP-1 pill for obesity. The ORION indirect comparison data, presented the following day, suggests the Wegovy pill has meaningful advantages in both efficacy and tolerability. Patients on orforglipron showed approximately four times higher odds of discontinuing due to adverse events and nearly fourteen times higher odds of discontinuing specifically due to gastrointestinal side effects. These are striking numbers and they support a compelling narrative for the Wegovy pill’s commercial position. But this is an indirect comparison across separate trials, funded and presented by Novo Nordisk, with wide confidence intervals and no head-to-head trial to settle the question definitively. The oral market battle between these two drugs will play out in real prescriptions over the next twelve to eighteen months, and those real-world results are what the quality assessment requires, not an indirect comparison published the day after a competitor’s approval.

This is what the Watchlist is designed to capture. The insulin franchise is proven. The obesity franchise is promising, credibly positioned, and backed by a pipeline that could decisively establish Novo Nordisk’s leadership in the new competitive arena. But the competitive outcome has not yet been determined. The prescription share trajectory, the CagriSema approval and launch, and the oral market real-world data will together tell the story that the insulin franchise told over decades, except compressed into the next two to three years because the competitive intensity demands it.

The specific triggers that would move Novo Nordisk from Watchlist to Approved are these. CagriSema receiving FDA approval and demonstrating competitive or superior real-world efficacy versus tirzepatide in its first year of commercial prescription data. And the oral market prescription trends confirming over at least two to three quarters that the Wegovy pill’s tolerability advantage holds in actual patient behaviour, that patients are staying on it longer and discontinuing less than Foundayo in the real world, not just in an indirect trial comparison. When those two conditions are met, the obesity franchise will have earned the track record the designation requires. It will have demonstrated that Novo Nordisk can do in obesity what it did in insulin, build a leadership position and defend it against serious competition through product quality, not just first-mover advantage.

At $37.50 and 17 years of embedded cash flows, the price sits in the Attractive zone of the Bearhold valuation framework. The business I have described in this report is exceptional. The near-term headwinds, negative 2026 guidance, China patent expiry, the capex cycle compressing free cash flow, the CEO transition, are all real and all visible in the numbers. None of them concern me as a long-term investor. What keeps Novo Nordisk on the Watchlist rather than in the Approved column is not weakness. It is the honest acknowledgment that the most important competitive chapter of this company’s modern history is being written right now, in real time, with the outcome still genuinely uncertain. I will be watching that chapter closely. And when the evidence confirms what the insulin franchise already demonstrated about this company’s ability to build and defend category leadership, the designation will change.

This report reflects the author’s personal views and does not constitute investment advice. Investing carries the risk of permanent capital loss. The author held a position in NVO during the research process and exited prior to publication. No position is held at the time of publishing. Read the full disclaimer here

Sources:

Novo Nordisk Annual Report FY2025 (DKK)

Novo Nordisk Annual Report FY2024;

FDA Declaratory Order on semaglutide shortage, February 21, 2025;

Novo Nordisk NDA filing for CagriSema, December 18, 2025; REDEFINE 1 and REDEFINE 2 Phase 3 trial data;

SELECT cardiovascular outcomes trial;

FLOW kidney disease trial;

ORION indirect treatment comparison, Obesity Medicine Association 2026, April 10–12, San Diego;

OPTIC patient preference study, Novo Nordisk, October–November 2025;

FDA approval of Foundayo (orforglipron), April 1, 2026;

White House TrumpRx / MFN pricing announcement, November 2025;

Trump Administration pharmaceutical tariff Executive Order, April 2026;

Morningstar GLP-1 market analysis, December 2025;

J.P. Morgan GLP-1 market projections, 2026.

There is a line in Accenture’s FY2025 annual report that I keep returning to. It appears in the section about AI adoption among enterprise clients, and it reads with the kind of candour that large companies rarely commit to print. The gap between AI mindshare and actual adoption, the company writes, exists because “the enterprise reinvention required to truly unlock the value of advanced AI is hard and has significant costs.” They go on to note that data preparedness is nascent, organisations are siloed, cloud and ERP modernisation is still incomplete, and workforces lack the skills to operate in an AI-enabled environment.

This is Accenture explaining, in its own annual report, exactly why its clients need Accenture.

And here is the paradox at the centre of the most important question in enterprise technology right now: is AI the thing that makes Accenture indispensable, or is it the thing that eventually makes Accenture unnecessary? I do not think the answer is simple. I think it is one of the most genuinely complex questions in business strategy today, and I want to work through it honestly rather than offer the comfortable narrative that Accenture’s investor relations team would prefer.

What Accenture Actually is?

Before discussing AI’s impact, it is worth being precise about what Accenture actually sells. It is not a technology company. It is not a software company. It is the world’s largest professional services firm, a business that sells human expertise, at scale, to the world’s largest organisations. Its 779,000 employees generated $69.7 billion in revenue in FY2025. That revenue splits almost exactly in half between consulting, project-based work advising clients on strategy, technology implementation, and transformation, and managed services, longer-term contracts where Accenture runs operations, maintains systems, and manages processes on behalf of clients.

The consulting half is what most people think of when they think of Accenture: teams of analysts and consultants deployed to client sites to deliver projects. The managed services half is less visible but more financially durable, multi-year contracts with meaningful termination costs that convert to revenue slowly and predictably. The consulting business grew 5% in local currency in FY2025. The managed services business grew 9%. That divergence is not an accident, and it is central to understanding how AI will affect this company.

The Surface Narrative, and Why it is Wrong in Both Directions

There are two simple narratives about AI and Accenture, and I think both are wrong.

The first is the bull narrative: AI creates enormous demand for implementation, change management, and enterprise transformation work. Clients need help deploying AI safely and at scale. Accenture is the partner they turn to. GenAI (generative AI) bookings reached $5.9 billion in FY2025, nearly doubled from the prior year. Revenue from generative AI and agentic AI reached $2.7 billion, tripling year-over-year. The company has 77,000 AI and data professionals, up from 40,000 in FY2023. It has trained over 550,000 of its employees in generative AI fundamentals. This is a company that positioned itself early, invested $3 billion in AI capability beginning in FY2023, and is now capturing the implementation wave. The AI opportunity is additive, not destructive.

The second is the bear narrative: AI automates exactly what junior consultants do. Writing code, analysing data, producing presentations, drafting documents, summarising research, building financial models, all of these tasks are being compressed by AI tools that any client can buy for $20 per user per month. The pyramid model that underlies Accenture’s economics, many juniors supporting fewer seniors, with juniors doing the volume work and seniors doing the judgment work, collapses when AI does the junior work. Revenue per engagement compresses. Headcount requirements fall. The business model is structurally impaired.

Both narratives capture something real. Neither captures the full picture.

The Pyramid Problem, This is the Real Risk

Let me start with the bear case because I think it is more structurally important than the bull case, even though the bull case is more visible in the near-term numbers.

Accenture’s operating model is built on a leverage pyramid. A small number of senior partners and managing directors sell and oversee client relationships. A larger number of managers and senior analysts do the intellectual work, designing solutions, leading workstreams, managing client relationships day-to-day. And a very large base of junior analysts and associates does the volume work, building models, writing code, conducting research, producing deliverables. This pyramid works economically because the juniors are relatively cheap, they generate billable hours that the senior layer monetises at a premium, and the pyramid widens at the base as the firm grows.

AI directly compresses the base of this pyramid. A junior analyst who previously spent three days building a financial model can now produce the same output in three hours with AI assistance. A developer who previously wrote 200 lines of code per day can write 800 lines with an AI coding assistant. A research team that previously spent two weeks analysing industry data can complete the same analysis in two days with AI-powered synthesis tools. These are not hypothetical capabilities — they are tools that Accenture’s own clients are deploying right now, and that Accenture’s own employees are using internally.

The implications for the business model are significant. If junior labour is three to four times more productive with AI, you need three to four times fewer juniors to deliver the same volume of work. That is not a problem if revenue grows proportionally, if the addressable market expands fast enough to absorb the productivity gain. But it is a fundamental structural problem if clients start asking why they should pay for 20 junior consultants when 5 can now deliver the same output. The answer, “because we have 779,000 people and can deploy them globally”, becomes less compelling when the leverage comes from AI rather than headcount.

The financial evidence of this tension is already visible, though subtle. Accenture’s gross margin fell to 31.9% in FY2025 from 32.6% in FY2024. The company attributed this to higher payroll costs. But the more revealing data point is the headcount reduction the company initiated in FY2025, $344 million in severance charges for “headcount reductions we are making in a compressed timeline.” A company that is simultaneously tripling its AI revenue and cutting headcount in a compressed timeline is not just managing capacity. It is restructuring its delivery pyramid in real time.

The Managed Services Moat

Here is where I think the bear narrative goes too far. It focuses almost entirely on the consulting business and largely ignores the managed services business, which is both larger and structurally different in ways that make it far more resistant to AI disruption.

Managed services, the $34.6 billion half of Accenture’s business, are long-term contracts where Accenture runs operations on behalf of clients. Application maintenance, infrastructure management, business process outsourcing, security operations. These contracts typically run three to five years with significant termination costs. They are based on outcome commitments, Accenture guarantees certain service levels, response times, and cost savings, rather than on the hourly billing of consultant time.

This is critically important. A client who has outsourced their SAP environment, their finance operations, or their cybersecurity monitoring to Accenture on a five-year contract does not reduce their payments because AI makes Accenture’s delivery team more efficient. Accenture captures the productivity gain from AI as margin expansion rather than passing it through as price reductions. The economics of managed services actually improve with AI, the same service level can be delivered with fewer people at lower internal cost, while the contractual revenue remains fixed.

This is the opposite dynamic from the consulting business, where clients can and will renegotiate based on observed productivity improvements. In managed services, the productivity gain is Accenture’s to keep. And the managed services business grew 9% in FY2025, faster than consulting at 5%, suggesting that clients are moving more work into this format precisely because they want to lock in AI-enabled efficiency gains without managing the complexity themselves.

The Agentic AI Moment

There is a dimension of the AI story that I think deserves specific attention because it is moving faster than most investors appreciate. Agentic AI, AI systems that can take autonomous actions, chain multiple tasks together, and operate continuously without human intervention, is beginning to change what enterprise AI deployment looks like.

Accenture describes deploying agentic AI systems that can “reinvent core business operations, streamline workflows and boost agility.” A client referenced in the annual report is deploying a system with 90 agents and 3,000-plus employees working alongside them. This is not a productivity tool layered on top of an existing workflow. It is a fundamental redesign of how work gets done, with AI agents operating in parallel with humans rather than simply assisting them.

For Accenture, agentic AI is both an opportunity and an existential question. The opportunity is that designing, deploying, and managing multi-agent systems at enterprise scale is genuinely complex work that requires deep expertise in AI architecture, change management, and process redesign, exactly the kind of work Accenture sells. The existential question is whether the agents themselves eventually replace the consultants who deployed them. An agentic system that automates a business process does not need to be maintained by a team of consultants indefinitely, it runs. The deployment engagement generates one-time revenue. The ongoing advisory relationship it displaces was recurring revenue.

This is the deepest tension in Accenture’s AI story. It is selling the tools that, if fully successful, reduce the long-term demand for its core product. Every enterprise AI transformation it helps a client achieve makes that client slightly less dependent on Accenture. The most successful consulting relationship is one that eventually makes itself unnecessary, and AI is accelerating that timeline.

The $5.9 Billion Number

Accenture reported $5.9 billion in generative AI bookings in FY2025 and $2.7 billion in generative AI revenue. These numbers are cited prominently in the annual report and in every investor communication. They are real, they are growing fast, and they tell you something important: clients are paying Accenture to help them deploy AI.

But the annual report contains a parenthetical that most analysts gloss over. These numbers, Accenture notes, “reflect only revenue and bookings specifically related to advanced AI and do not include data, classical AI or AI used in delivery of our services.” In other words, the $2.7 billion is a narrow slice of AI-related activity, specifically defined to exclude AI that Accenture uses internally to deliver its services more efficiently.

This matters because the most transformative AI happening inside Accenture right now is not the $2.7 billion, it is the AI that its own consultants and engineers are using daily to do their jobs faster. That AI does not show up in the headline AI revenue figure. It shows up in the gross margin compression, the headcount restructuring, and the quiet redesign of delivery pyramids that is happening across every large professional services firm simultaneously.

The $5.9 billion in generative AI bookings is the revenue opportunity. The pyramid restructuring is the cost reality. The net effect of both determines whether AI is a net positive or net negative for Accenture’s long-term economics.

My Honest Assessment

I think Accenture navigates the near-term AI transition better than most investors expect and worse than the company’s own narrative implies.

Better than expected because the managed services business, which now represents 50% of revenue and is growing faster than consulting, is structurally insulated from AI-driven price compression in ways that the consulting business is not. The long-term contractual nature of managed services means Accenture captures AI productivity gains as margin rather than passing them through as price cuts. This is a meaningful and durable economic advantage that the bear case on Accenture’s business model largely ignores.

Worse than the company’s narrative implies because the consulting business is facing a genuine structural challenge that cannot be resolved by rebranding it as AI-enabled transformation work. Clients who are becoming more sophisticated about AI, who are building internal capabilities, hiring their own AI teams, and deploying their own tools, will increasingly ask whether they need a 20-person Accenture consulting team or whether three of their own people with AI tools can deliver comparable output. That question gets harder to answer in Accenture’s favour with each passing year as AI tools improve.

The most honest summary is this: Accenture is one of the most capable organisations on earth at helping large companies navigate technology transitions. It has done this successfully through the internet era, the cloud era, and the mobile era. Each transition generated significant consulting revenue as clients needed help adapting. Each transition also eventually reduced the long-term demand for certain types of advisory work as the new technology became standard.

AI is the same pattern, but faster and more fundamental. Will the business emerge from the AI transition as large, as profitable, and as structurally advantaged as the one that entered it. On that question, I am genuinely uncertain. The managed services business argues yes. The consulting pyramid economics argue no. And the agentic AI dynamic, where Accenture’s most successful work makes its clients less dependent on it, introduces a long-term structural headwind that has no easy resolution.

For investors, the honest framing is not whether Accenture is a good business, it clearly is. It is whether the current price adequately reflects the structural uncertainty of a 779,000-person consulting firm navigating a technology transition that is, by its own admission, compressing the economics of the very work that built it.

That question deserves its own valuation analysis. But the starting point for that analysis has to be honest about what AI does to the consulting pyramid, not just what it does for the AI bookings number.

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

There is a number that appears in almost every corporate earnings release, every leveraged buyout pitch, every bank credit memo, and almost every discussion of whether a company is financially healthy.

That number is EBITDA, Earnings Before Interest, Taxes, Depreciation, and Amortisation.

And in my view, it is one of the most overused and most misleading metrics in corporate finance.

This is not a fringe opinion. Charlie Munger once called EBITDA “Bullsh*t earnings.” Warren Buffett has spent decades explaining why depreciation is a very real cost that management teams conveniently prefer to ignore. But despite those warnings, EBITDA remains the dominant lens through which banks assess a company’s ability to repay debt, and the dominant shorthand through which analysts compare businesses.

The better alternative, Operating Cash Flow, sits right there in every set of financial statements, far more revealing, far harder to manipulate, and almost universally ignored in favour of the number that makes everything look bigger.

Here is why that matters, and why as a long-term investor, you should train yourself to reach past EBITDA every time.

What EBITDA Actually Is

EBITDA starts with net income and adds back four things: interest expense, tax expense, depreciation, and amortisation. The resulting number is supposed to represent a company’s core operating earnings, what the business generates before the effects of how it is financed, how it is taxed, and how its assets wear out over time.

The logic behind the addbacks seems reasonable on the surface. Interest expense varies depending on how much debt a company carries, strip it out so you can compare businesses with different capital structures. Tax rates vary by jurisdiction, strip those out too. Depreciation and amortisation are non-cash charges, add them back because no cash actually left the building when the accountant recorded them.

The problem is that the moment you reconstruct EBITDA in your mind, you realise it lives entirely in the income statement. It is built from revenue and expenses as recognised by the company’s accountants, not from cash that actually moved. And that distinction, which seems technical, turns out to be enormous in practice.

What Operating Cash Flow Actually Is

Operating Cash Flow (OCF) starts in a completely different place. It begins with net income and then adjusts for everything that happened between the income statement and the company’s actual bank account.

The most important adjustments are the working capital movements: things like changes in accounts receivable (money owed to the company by customers), inventory (goods sitting in a warehouse waiting to be sold), and accounts payable (money the company owes to its suppliers).

These three items represent the business cycle in brief, the lag between when revenue is recognised on the income statement and when cash actually arrives, and the lag between when expenses are recognised and when they are actually paid.

A company that books $100M in revenue but has not yet collected any of it has a wonderful income statement and an empty bank account. OCF captures that reality. EBITDA does not.

Why EBITDA Is Almost Always Higher

Here is a mechanical truth that most financial commentary glosses over: in most businesses, in most years, EBITDA will be higher than Operating Cash Flow. Sometimes significantly higher.

The reasons are structural. Working capital typically consumes cash as a business grows, receivables and inventory expand as sales increase, and this cash outflow never touches the income statement. Meanwhile, depreciation and amortisation, which were added back to create EBITDA, represent real economic consumption of the asset base that will eventually require real cash to replace. A piece of machinery that depreciates over ten years does not magically regenerate itself at the end of year ten. The cash to replace it has to come from somewhere.

When you add back depreciation to create EBITDA and then use that number to assess a company’s financial health, you are implicitly claiming that the machinery doesn’t need replacing. Every manufacturing company knows that is not true.

The Manipulation Problem

EBITDA is not just theoretically imprecise. It is also practically easy to inflate.

The most straightforward manipulation is recognising revenue aggressively. A company can book a sale the moment goods leave the warehouse, even if the customer hasn’t paid or won’t pay for six months. That revenue flows directly into EBITDA. It does not flow into Operating Cash Flow, where the receivables balance would swell visibly and alert any attentive analyst that something is off.

This is not a hypothetical risk. It is one of the most common patterns in corporate fraud.

Sunbeam, the American appliance manufacturer, provides a textbook case. In the late 1990s, CEO Al Dunlap, known as “Chainsaw Al”, drove reported earnings higher by selling products to retailers at heavily discounted prices with generous return rights, recognising the revenue immediately. EBITDA looked healthy. Operating Cash Flow told a very different story, the company was consuming cash at an alarming rate as receivables ballooned. Sunbeam filed for bankruptcy in 2001.

Closer to the present, many highly leveraged companies that appeared financially manageable through the EBITDA lens, revealed their true fragility when interest rates rose and their working capital cycles deteriorated. The income statement said they were profitable. The cash flow statement said they were running dry.

Why Banks Use EBITDA Anyway

If EBITDA is so flawed, why does almost every bank in the world use it as the primary measure of debt capacity?

The answer is partly historical, partly structural, and partly, I will be direct, because it serves the bank’s commercial interests.

Historically, EBITDA became the standard in leveraged finance during the 1980s leveraged buyout boom. Dealmakers needed a metric that could justify higher debt levels on acquisitions, and EBITDA, which ignores working capital movements, strips out the cost of replacing assets, and excludes the interest expense on the very debt being assessed, produced the highest possible number. It became institutionalised.

Structurally, the banking system adopted it so broadly that any single bank switching to OCF-based underwriting would be at a competitive disadvantage, they would approve smaller loans than their peers, lose deals, and see revenue decline. The incentive to use the more conservative metric is weak when competitors are not.

And then there is the commercial reality: a higher EBITDA justifies a larger loan. A larger loan generates more fee income, more interest income, and a bigger balance sheet. There is a direct financial incentive for the banking system to use the metric that produces the highest debt capacity, and EBITDA is that metric.

I spent fifteen years in institutional finance. I have sat in credit committees where the EBITDA multiple was the headline figure and the cash flow statement was barely discussed. This is not a theoretical observation, it is a standard practice.

What to Use Instead

Operating Cash Flow is not perfect either. It can be managed through timing of receivables collections, stretching of payables, and opportunistic working capital draws before year-end. A skilled CFO can compress the working capital cycle in the fourth quarter to produce a better-looking OCF number than the underlying trend warrants.

But the manipulation is harder, the signals are clearer, and the number is fundamentally more honest because it reflects cash that actually moved.

For assessing a company’s debt capacity, OCF minus maintenance capex, what some call Owner Earnings or Free Cash Flow, is the most relevant figure. It represents what the business actually generated after keeping the existing asset base functional. That is what is available to service debt, pay dividends, fund growth, or return to shareholders. EBITDA does not answer that question cleanly. FCF does.

For comparing profitability across businesses, operating margin, operating income as a percentage of revenue, is a more reliable starting point than EBITDA margin, because operating income includes depreciation and therefore acknowledges the cost of the assets generating the revenue.

The Investor’s Takeaway

When I look at a business, I use EBITDA as a starting point at most, a rough orientation before I do the real work. The questions that matter to me are:

How does Operating Cash Flow compare to EBITDA? If the gap is consistently large, I want to understand why. A large and growing gap is often the first sign that something is wrong in the working capital cycle.

Is FCF growing alongside revenue, or is the business consuming more cash as it scales? A business that grows revenue but consistently burns cash is not compounding, it is borrowing against the future.

What is the capex-to-OCF ratio, and how much of capex is maintenance versus growth? Maintenance capex is not optional. It should never be ignored when assessing a business’s true earning power.

EBITDA will tell you what a company wants you to think about its earnings. Operating Cash Flow will tell you what is actually happening.

The Outlook

There is a condition that affects nearly one billion people on earth. Most of them don’t know they have it. Their doctors haven’t diagnosed it. Their partners have complained about the snoring, the gasping, the restless sleep, but the link to a treatable medical condition has never been made. Obstructive sleep apnea, or OSA, is one of the most prevalent and undertreated chronic conditions in modern medicine, and ResMed has spent thirty years quietly building the most comprehensive platform for diagnosing, treating, and managing it.

This is not a story about a niche medical device company. It is a story about a platform business with thirty million cloud-connected patients, a proprietary data advantage that compounds with every device sold, and a software layer that makes it operationally difficult for the healthcare providers who use it to switch to anyone else. The hardware is just the door into the ecosystem.

Revenue has grown at 11.9% annually for a decade. Operating margins have expanded from 24% to 33%. Free cash flow has increased more than fivefold. And yet fewer than 20% of the people who need this product have ever received it.

The stock is not cheap. At 23 years of embedded cash flows, ResMed sits in the Hold zone of the Bearhold valuation framework, a fair price for a business of exceptional quality. I am not buying here. But I am watching, and this report explains exactly what I am waiting for.

At a Glance

Company: ResMed Inc.

Ticker: $RMD · NYSE

Sector: Healthcare

Industry: Medical Devices & Instruments

Market Cap: $32.65 billion (at $224)

Dividend Yield: ~0.95% ($2.12 per share, FY2025)

Status: Approved, Bearhold Universe

First Coverage: April 2026

Valuation Zone: Hold (last updated April 2026)

Disclaimer: This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The author does not currently hold a position in $RMD at the time of publication.

1. The Business

What the Company Does

ResMed makes the devices and software that treat sleep-disordered breathing. The flagship products are CPAP (Continuous Positive Airway Pressure) and APAP (Automatic Positive Airway Pressure) machines, compact bedside devices that deliver pressurised air through a mask while the patient sleeps, keeping the airway open and eliminating the breathing disruptions that cause OSA. The condition, if left untreated, is associated with hypertension, stroke, type 2 diabetes, and coronary artery disease, which is why the clinical community increasingly treats it as a cardiovascular risk factor, not just a sleep nuisance.

Revenue breaks down into three streams: devices at approximately 52% of the total, masks and accessories at 36%, and Residential Care Software at 12%. The structure matters. Devices are event-driven, a patient buys one at diagnosis and replaces it every few years. Masks are recurring, replaced every three to six months for as long as the patient stays on therapy. Software is subscription-based. The combination produces a revenue profile far more stable than a pure device company, with the recurring mask and software streams anchoring the base even in softer device years.

How the Business Was Built

ResMed traces its origins to June 1989, when Dr. Peter Farrell founded the company, originally called ResCare, in Sydney, Australia, to commercialise nasal CPAP technology invented by Professor Colin Sullivan at the University of Sydney in 1981. Baxter Healthcare had licensed the technology and then decided not to pursue it. Farrell recognised what Baxter had missed.

ResMed Inc. was incorporated in Delaware in March 1994 and went public on June 1, 1995, trading on NASDAQ. The company moved its primary listing to the New York Stock Exchange in September 1999.

For its first two decades, ResMed was a device company that grew by making better CPAP machines and expanding geographically. The inflection came around 2014, when the company began embedding cellular connectivity into devices as standard, a decision that looks obvious in hindsight but required genuine conviction at the time. Connected devices enabled remote monitoring at scale. Clinicians could adjust therapy settings without requiring patients to return to a clinic. And every connected patient became a source of real-world clinical data. That data now feeds the machine learning algorithms that make each new device generation smarter than the last. Today, ResMed manages over 30 million cloud-connected patients through its AirView platform, with more than 10 million active on myAir, the patient-facing therapy management app.

The flywheel is real: more patients generate more data, which improves therapy outcomes, which attracts more patients and more providers into the ecosystem.

The Philips Recall, and What Actually Happened

In June 2021, Philips issued a recall of millions of CPAP, bilevel, and ventilator devices after discovering that the polyester-based sound abatement foam inside the machines was degrading and potentially releasing particles and gases into the patient’s airway. It was a significant product safety failure that triggered multi-billion euro legal settlements and years of operational disruption for Philips.

ResMed was the only large-scale alternative with the manufacturing capacity to absorb displaced patients quickly. The impact on ResMed’s numbers was real but more targeted than widely reported. Overall revenue growth remained broadly consistent with historical trends. The visible surge was concentrated in the US, Canada, and Latin America device segment specifically, where device revenue grew approximately 24% in FY2022 and approximately 35% in FY2023, compared with around 9% in the year before the recall. By FY2024, device growth in that segment had normalised to approximately 11%, and FY2025 came in at 9.8% for total revenue, a return to the underlying demand trajectory. The recall pulled forward some volume and concentrated it geographically, but the business was not propped up by it.

Scale

ResMed employs more than 10,600 people across more than 140 countries. The US, Canada, and Latin America generate approximately 58% of Sleep and Breathing Health revenue. Combined Europe, Asia, and other markets contribute approximately 29%. Residential Care Software, sold only in the US and Germany, rounds out the remaining 12%. Manufacturing is split across Australia, Singapore, and the US, with the company running an active foreign currency hedging programme to manage the exposure this creates.

2. The Moat

Four Walls, One Ecosystem

ResMed’s competitive position is not a single advantage, it is four advantages that reinforce each other.

The first is clinical data. ResMed has more real-world sleep therapy data than any organisation on earth. Thirty million cloud-connected patients generate continuous information, therapy compliance, apnea-hypopnea index, mask leak, breathing patterns. This data feeds the algorithms that make the AirSense 11, and whatever comes after it, progressively more effective. A competitor launching a CPAP device today faces not just a product quality gap but a data gap that will take years to close.

The second is the installed base and the recurring revenue attached to it. Thirty million active patients buying masks every three to six months is a durable annuity that does not depend on the next product launch. Patients who have established a functioning therapy routine are unlikely to switch ecosystems.

The third is the software layer. Brightree, the leading home medical equipment (HME) software platform in the US, and MEDIFOX DAN in Germany are deeply integrated into the administrative and clinical workflows of thousands of care providers. These platforms are not standalone software businesses, they are the connective tissue between device sales and the care delivery system. When a provider uses Brightree to manage billing, patient records, and inventory, switching to a competitor means disrupting those workflows entirely. That is a meaningful switching cost that goes well beyond product preference.

The fourth is regulatory and clinical credibility. ResMed’s devices are approved across virtually every major regulatory jurisdiction globally, supported by decades of peer-reviewed clinical evidence. New entrants face not just a commercial challenge but a multi-year regulatory validation process. That is a barrier that does not exist in consumer device categories.

The Wearables Tailwind

An often overlooked accelerant is the integration of OSA detection into consumer wearables. Apple Watch and Samsung Galaxy Watch now feature FDA (US Food and Drug Administration)-cleared breathing disturbance detection. These devices are identifying undiagnosed OSA patients at population scale and nudging them toward clinical care. ResMed has positioned itself as the natural destination for that flow, its myAir app integrates directly with Apple Health and Samsung Health, and CEO Mick Farrell has explicitly described the consumer wearables ecosystem as building the company’s “data lake.” The most powerful referral engine ResMed could imagine is a device worn by hundreds of millions of people, many of whom don’t yet know they need a CPAP machine.

The Numbers Don’t Lie

The financial record is the most reliable evidence of a moat. ResMed’s operating margin expanded from 24.4% in FY2015 to 32.8% in FY2025. ROIC (Return on Invested Capital) averaged 18.9% over the decade, well above the estimated cost of capital throughout. A business losing competitive position does not do that while tripling its revenue.

The comparison with Philips makes the point most cleanly. Before the recall, Philips operated at approximately 8% operating margin in its health technology division, a level ResMed was already far above and moving away from. After the recall, Philips fell into losses in 2022 and 2023. By 2025, it had only recovered back to that same 8% baseline. Over the same period, ResMed’s operating margin continued to expand. Two companies nominally competing in the same market, on very different structural trajectories.

3. Financial Performance

A Decade in Numbers

Revenue grew from $1.68 billion in FY2015 to $5.15 billion in FY2025, an 11.9% compound annual growth rate (CAGR) over ten years. That growth was primarily organic. Two meaningful acquisitions, the Brightree HME software business in FY2016 and MEDIFOX DAN in FY2023, added inorganic revenue, but the underlying Sleep and Breathing Health segment has compounded consistently without acquisition support.

Operating margin expanded from 24.4% to 32.8%, with a ten-year average of 26.5%. Gross margin averaged 57.6% across the decade, reflecting the premium positioning of ResMed’s clinical products relative to commodity device alternatives. Net margin in FY2025 reached 27.2%, up from 21.0% in FY2015, aided in part by a below-trend effective tax rate of 16.5% due to one-time items, a level that should not be assumed to repeat.

Diluted EPS (Earnings Per Share) grew from $2.47 in FY2015 to $9.51 in FY2025, a 14.4% CAGR. The share count has been essentially stable over this period, rising only 3.2% from 142.7 million to 147.3 million diluted shares. EPS growth here reflects genuine business improvement rather than financial engineering.

ROIC averaged 18.9% over the decade and reached 23.3% in FY2025. In every year of the available record, ResMed earned returns materially above its estimated cost of capital, a consistency that is more impressive than any single-year figure.

Free Cash Flow, the Real Story

Free cash flow (FCF) grew from $311M in FY2015 to $1,651M in FY2025, a 5.3x increase at an 18.2% CAGR. There was one significant dip: FY2022, when FCF collapsed to $195M despite strong revenue. The cause was working capital. The Philips recall demand surge required ResMed to draw down inventories and then rapidly rebuild them, creating a large transient cash outflow. Simultaneously, an elevated FY2021 effective tax rate of 46.3%, driven by a one-time $200M charge related to pre-acquisition earnings, further compressed cash in that period. Both were temporary. FCF recovered to $559M in FY2023, $1,286M in FY2024, and $1,651M in FY2025.

The FCF margin of 32.1% in FY2025 is the highest in the company’s history. Capex (capital expenditure) as a percentage of operating cash flow has fallen from 19% in FY2015 to just 6% in FY2025, reflecting the asset-light nature of a platform built primarily on software, data, and intellectual property rather than physical infrastructure.

Balance Sheet

Cash and equivalents stood at $1.21 billion at June 30, 2025, against total debt of approximately $670M, producing a net cash position of roughly $540M. Debt-to-equity has improved dramatically from the 0.38 reading in FY2023 (following the MEDIFOX DAN acquisition) to 0.14 at year-end FY2025. The revolving credit facility of $1.5 billion remains fully undrawn, maturing in 2027.

One genuine weakness worth naming: goodwill of $3.05 billion represents approximately 37% of total assets. This reflects the accumulated premium paid for acquisitions, primarily Brightree, Propeller Health, and MEDIFOX DAN. Tangible book value per share is substantially lower than reported book value. The intrinsic value of this business rests almost entirely on intangible assets, data, software, clinical relationships, regulatory approvals. That is a strength when the business performs and an accounting vulnerability if any major acquisition disappoints.

ResMed also pays a dividend of $2.12 per share in FY2025, representing a yield of approximately 0.95% at the current price, a signal of financial maturity that has grown steadily from $1.12 per share a decade ago.

4. Growth Levers

The Diagnosis Gap, the Single Biggest Lever

Here is the most important number in this entire report: fewer than 20% of OSA sufferers in the United States have been diagnosed and treated. In most international markets, the figure is closer to 10%.

ResMed does not need to take market share from anyone. It just needs the healthcare system to get better at finding the patients who already exist. Every percentage point improvement in diagnosis rates represents millions of people entering a care pathway that runs directly through ResMed’s ecosystem. This is the kind of structural growth driver that does not require macroeconomic tailwinds, product cycles, or competitive displacements. It just requires time.

ResMed is actively investing to accelerate this. NightOwl, a portable, cloud-connected, fully disposable diagnostic device that measures OSA severity overnight without requiring a clinic visit, launched across the US in April 2025. The acquisition of VirtuOx, an independent diagnostic testing facility, in May 2025 further expands the company’s ability to bring diagnosis into the home. The goal is to compress the traditional pathway, specialist referral, sleep lab, equipment pickup, device initiation, into something much closer to a single session at home.

International Penetration, COPD, and Software

The international opportunity mirrors the domestic one, large, underpenetrated, and growing as clinical awareness spreads and reimbursement coverage expands. International Sleep and Breathing Health revenue grew 9% in FY2025, and this segment operates at a fraction of US penetration levels across most geographies.

COPD (Chronic Obstructive Pulmonary Disease) affects approximately 480 million people globally and is the world’s third leading cause of death. ResMed’s non-invasive ventilation (NIV) and high-flow therapy (HFT) products for COPD patients represent a growing segment that the revenue breakdown does not currently call out separately, but it is a meaningful adjacency that deepens the platform’s clinical reach beyond sleep.

Residential Care Software, currently sold only in the US and Germany, grew 10% in FY2025 to $641M. Geographic expansion of this segment is a medium-term option that has not yet been exercised.

5. Management

The Farrell Family and Long-Term Alignment

ResMed is, at its core, a founder-influenced business. Dr. Peter Farrell built ResCare from a single licensed technology in Sydney in 1989 and steered it to become the global leader in sleep therapy. His son Mick Farrell has served as CEO since 2013, presiding over the company’s transformation from a device manufacturer into a connected care platform.

The family maintains meaningful skin in the game. Mick Farrell holds approximately 0.32% of outstanding shares, valued at roughly $105M at current prices. Dr. Peter Farrell, as founder and board director, directly owns a further 60,773 shares. While institutional investors including Vanguard and BlackRock collectively own the majority of the company, the Farrell family’s retained ownership signals genuine long-term conviction rather than founders who cashed out at the earliest opportunity.

Mick Farrell’s compensation structure reinforces that alignment. Approximately 91-92% of his total pay is performance-based, stock awards and options tied to specific financial metrics including revenue growth and EPS. Base salary accounts for only about 8% of total compensation. This is the kind of structure I look for in management: the CEO is economically motivated by the same outcomes that matter to long-term shareholders.

His communication style has been consistently direct on difficult topics. When the GLP-1 (glucagon-like peptide-1) panic hit in mid-2023 and ResMed’s stock fell more than 30%, Farrell engaged with the clinical evidence head-on rather than deflecting. He presented ResMed’s own patient data on GLP-1 users, made the probability-weighted case for ongoing demand, and continued investing in the business rather than cutting costs to manage short-term numbers. That is the kind of management behaviour that matters over a full market cycle.

Capital Allocation

R&D (Research and Development) spending of $331M in FY2025, representing 6.4% of revenue, has been sustained consistently across the decade. This is the right posture for a business whose competitive position depends on staying ahead clinically and technically.

On acquisitions, the track record is mixed but acceptable. Brightree has been clearly value-creating, it transformed ResMed from a device company into a platform company with deep provider relationships. The MEDIFOX DAN acquisition at approximately EUR 975M in FY2023 is too early to assess definitively, though integration appears to be progressing. The Propeller Health acquisition in FY2019 at $225M has been harder to evaluate but is smaller in scale.

Shareholder returns have grown steadily: dividends increased from $1.12 to $2.12 per share over the decade, and buybacks of $300M were executed in FY2025. Together with dividends, that represents approximately 37% of FCF returned to shareholders, the remainder retained for investment. I find that balance reasonable given the available organic growth runway.

6. Valuation

What the Market Is Pricing In

At $224 per share, I estimate the market is pricing ResMed at approximately 23 years of discounted future cash flows. My valuation framework expresses price as the number of years of a company’s future cash flows, discounted at an appropriate rate, that are already embedded in today’s price. The assumptions I use are consistent with the company’s current and historical operating performance. Nothing heroic, nothing pessimistic.

23 years puts ResMed in the Hold zone.

To be direct about what that means for me: I don’t initiate new positions in the Hold zone. The Bearhold framework is built around the idea that when you are buying a stake in a business, you want the price working in your favour, not just the fundamentals. The Attractive zone (16–20 years) and the Exceptionally Attractive zone (below 15 years) are where I look to deploy capital. At those levels, the price embeds significantly less of the company’s future than the business’s quality justifies, and an investor captures both the fundamental compounding and the valuation correction as it plays out.

At 23 years, I am essentially paying a fair price for quality I can see clearly. The fundamentals of this business are genuinely exceptional, but there is limited margin of safety in the entry price. Every dollar of return has to be earned through the business’s ongoing performance, there is no valuation tailwind to help.

What I Am Waiting For

ResMed becomes interesting to me as a new position somewhere in the Attractive and the Exceptionally Attractive zones. That does not happen often for businesses of this quality. It tends to happen when the market becomes temporarily preoccupied with a specific risk, a GLP-1 study result, a reimbursement cut, an earnings miss driven by inventory timing, and the stock reprices faster than the underlying business warrants.

7. Risks

The GLP-1 Question

Since mid-2023, the dominant narrative around ResMed has been the GLP-1 risk. Glucagon-like peptide-1 agonist drugs, Ozempic, Wegovy, Zepbound and others, cause significant weight loss in a meaningful proportion of users, and obesity is a primary driver of OSA in a large patient population. If these drugs reduce OSA prevalence materially, the argument goes, ResMed’s addressable market shrinks.

The clinical evidence is real. The FDA approved tirzepatide (Zepbound) in December 2024 specifically for the treatment of moderate-to-severe OSA in adults with obesity, after clinical trials demonstrated meaningful reductions in apnea-hypopnea index among treated patients.

I take this risk seriously. But I believe it is more limited than the 2023 market reaction implied, for three reasons.

First, OSA is not purely mechanical. The condition has neurological and anatomical components, airway geometry, muscle tone, neural respiratory drive, that weight loss does not fully resolve. ResMed’s own connected patient data shows that a meaningful proportion of GLP-1 users who achieve significant weight reduction continue to require CPAP therapy.

Second, the undiagnosed population dwarfs the treated population. The 80% of OSA sufferers who have never received a diagnosis are entering the care pathway as awareness grows. This demand source is entirely independent of GLP-1 penetration.

Third, real-world GLP-1 adherence is substantially lower than clinical trial completion rates. Weight regain is common on discontinuation. Access constraints, particularly outside developed markets, further limit penetration.

This is a risk that deserves ongoing monitoring, particularly as longer-duration GLP-1 data accumulates. It is not a reason to avoid the business; it is a reason to track it carefully and incorporate it into the price I am willing to pay.

Reimbursement and Policy Risk

A meaningful portion of ResMed’s revenue flows through Medicare, Medicaid, and private insurers. The US DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics and Supplies) Competitive Bidding Program has historically placed downward pressure on Medicare reimbursement rates. CMS (Centers for Medicare & Medicaid Services) rate changes and ACA (Affordable Care Act) enrollment policy are ongoing headwinds. The recently enacted One Big Beautiful Bill Act makes changes to Medicaid funding and ACA enrollment that could reduce the insured patient population over time, though the specific effect on sleep therapy demand remains uncertain.

This is a persistent risk that ResMed has navigated through multiple policy cycles. It acts as a headwind to pricing power but has not historically disrupted the underlying demand trajectory.

Goodwill and Acquisition Risk

Goodwill of $3.05 billion, 37% of total assets, reflects the cumulative premium paid for acquisitions. The MEDIFOX DAN acquisition at approximately EUR 975M is the largest and most recent at scale. If integration underdelivers, or if the German software market dynamics shift unfavourably, a material impairment charge would hit reported equity significantly. This is the honest weakness in an otherwise strong balance sheet.

Tariffs and Supply Chain

ResMed manufactures primarily in Australia and Singapore. The tariff environment as of early 2025 has created some input cost uncertainty, though medical device tariff relief has been confirmed through US Customs as of the FY2025 filing date. The situation remains dynamic and worth monitoring.

What Would Change My Mind?

If GLP-1 clinical data continues to accumulate showing high real-world adherence and sustained OSA resolution, not just single-study results, that would require a fundamental reassessment of the long-term volume outlook. If operating margins begin contracting despite revenue growth, that signals competitive pricing pressure and potential moat erosion. If a major acquisition integrates poorly or requires a goodwill writedown, that is a capital allocation warning I would take seriously.

8. The Verdict

ResMed is one of the clearest examples of a business with genuine, compounding structural advantages. The data platform took thirty years to build. The installed base generates recurring revenue that grows with each diagnosis. The software layer makes providers sticky. The clinical evidence is deep and growing. And the addressable market, driven by the vast undiagnosed population, has decades of runway left.

The financial record across ten years confirms the quality: revenue tripled, operating margins expanded by 8.4 percentage points, ROIC averaged 18.9%, and free cash flow grew fivefold. This is what a durable competitive advantage looks like in the numbers.

The GLP-1 risk is real. The goodwill load deserves monitoring. Reimbursement policy is a persistent headwind. These are honest weaknesses and they belong in any fair assessment of the business.

ResMed is Approved in the Bearhold Universe. It sits in the Hold zone at the time of this publication. I am not buying today. But if the price moves into the Attractive zones, whether through a market correction, a temporary earnings disruption, or another episode of fear about a risk the market overstates, I will be ready to act.

Disclaimer: This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The author does not currently hold a position in $RMD at the time of publication.

Sources

• ResMed Inc. Form 10-K, Fiscal Year Ended June 30, 2025 (filed August 8, 2025)

• ResMed Inc. Form 10-K, Fiscal Year Ended June 30, 2024 (filed August 9, 2024)

• GuruFocus Financial Database — ResMed (NYSE: RMD), extracted April 4, 2026

• GuruFocus Financial Database — Philips (NYSE: PHG), extracted April 5, 2026

• Philips Annual Reports 2020–2025

• Lancet Respiratory Medicine (2019): “Estimation of the global prevalence and burden of obstructive sleep apnoea”

• FDA Drug Approval: Tirzepatide (Zepbound) for OSA, December 2024

• ResMed Press Releases: NightOwl US launch (April 2025); VirtuOx acquisition (May 2025)

• CMS DMEPOS Competitive Bidding Program documentation

• ResMed Proxy Statement (DEF 14A), filed October 2025 — executive compensation and insider ownership

There is a question I ask about every business before anything else: can I tell, with reasonable confidence, how this company will look in five years?

Not the exact numbers. Not the precise revenue figure or the margin to the decimal. Just the shape of it, the competitive position, the pricing power, the reason customers keep coming back regardless of what is happening in the world around them.

For most businesses I cover, the answer is grounded in something structural. An automotive parts distributor benefits from an ageing vehicle fleet that gets more complex and more expensive to repair every year. A salvage auction operator sits at the intersection of rising total loss frequency and a global buyer network that took decades to build. A payment network processes more volume every time a cash transaction moves to digital. These businesses have tailwinds I can reason about independently of consumer sentiment, cultural trends, or what happens to be fashionable this season.

Nike does not have that. And that is the reason it is not included in the Bearhold Universe.

What Nike Actually Sells

Nike is one of the most recognised brands on earth. The marketing is exceptional. The athlete relationships are unmatched. The distribution is global. None of that is in question.

But when you strip it back to what the customer is actually paying for, the answer is identity. The person buying a pair of Air Maxes or a Nike training kit is not primarily paying for a functional outcome. They are paying to be associated with something they find culturally relevant, a feeling, an image, an aspiration. That relationship is real. It is also fragile in a way that other business models simply are not.

Identity is subject to taste. And taste shifts without warning, without logic, and without giving management teams much time to respond.

The Problem with Taste as a Business Driver

The history of consumer brands is full of businesses that looked like compounders until the moment they didn’t. Brands that commanded premium pricing, built loyal followings, and generated strong returns for years, right up until something shifted in the culture and the loyal customer turned out to be loyal to the aesthetic, not the company.

This is not a management failure. It is a category characteristic. When your competitive advantage rests on cultural relevance, you are permanently exposed to a risk that no amount of operational excellence can fully insulate you from. Competitors do not need to engineer a superior product. They just need to feel fresher at the right moment.

Nike is experiencing exactly this right now. Revenue declined roughly ten percent in its most recent fiscal year. Operating margins have compressed significantly from historical levels. Competitors have established meaningful positions in running, a category that historically reinforced Nike’s performance credibility and pricing power.

The company is rebuilding its wholesale relationships after a strategic overcommitment to direct-to-consumer that did not deliver on its promise. China, which represents a meaningful share of the business, has been declining for several consecutive quarters.

Some of this is execution. But not all of it. Some of it is simply what happens when taste moves on and the brand has to work harder to stay relevant than it used to.

Subscribe now

What I Need to See Instead

When I build a position in a business, I want to be able to answer one question clearly: why will this company’s customers still be here in five years?

For the businesses that pass the quality filter, the answer is almost always structural. The switching costs are high, the network effects are real, or the service is so deeply embedded in the customer’s operations that replacing it is more painful than paying for it. These businesses do not need to be culturally relevant. They need to be necessary.

Nike is not necessary. It is desired. And desire, unlike necessity, is something that has to be earned back every season.

The status

Nike is Rejected in the Bearhold Universe. Not because it is a bad company, it is not. Not because the brand is broken, it is not. But because the uncertainty embedded in its revenue model is not the kind of uncertainty I am willing to hold through cycles.

The quality filter exists precisely for moments like this. A well-known name, a strong brand, a long operating history, none of that is sufficient if the fundamental question cannot be answered with confidence.

I want to own businesses where the answer to “why will customers still be here in five years” is obvious. For Nike, it is not.

Subscribe now

This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

The Outlook

Copart is one of the most quietly exceptional businesses in the United States. It operates in a market that many investors have never thought about, the online auctioning of salvage vehicles, and it has built a position in that market that is almost impossible to challenge. The business requires more land than almost any competitor can afford to acquire, it improves as it gets bigger, and its primary customers have no viable alternative. The stock price at the time of writing reflects a business priced for moderate expectations, which is unusual for a business of this quality.

The two risks that matter, concentration among insurance sellers, and the long-term question of autonomous vehicles, are real and deserve honest treatment. Neither, in my view, overrides the fundamental quality of what has been built here. This report addresses both directly.

At a Glance

Company: Copart, Inc

Ticker: $CPRT · NASDAQ

Sector: Industrials

Industry: Online Vehicle Auctions & Remarketing

Market Cap: $31.9 billion (at $33.06)

Status: Approved

First Coverage: April 2026

Valuation Zone: Attractive (last updated in April 2026)

Disclosure update: The author now holds a position in CPRT. The position was initiated after the original publication date of this report. All analysis and conclusions remain unchanged. This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

1. The Business

What it Does

Copart operates online auctions for salvage and total-loss vehicles. When a car is involved in an accident and the insurance company determines that the cost of repair exceeds the vehicle’s value, the car is declared a total loss. The insurance company pays the policyholder the car’s pre-accident value, takes title to the vehicle, and then needs to dispose of it. That is where Copart comes in.

Copart takes possession of the vehicle, transports it to one of its storage facilities, photographs and documents it thoroughly through its proprietary technology, and lists it for sale on its VB3 online auction platform. Buyers from around the world, vehicle dismantlers, rebuilders, used car dealers, exporters, bid against each other in real time. Copart collects fees from both the seller and the buyer. The vehicle sells. The process repeats.

This description makes the business sound simple. It is operationally complex at scale, and that complexity is the foundation of the moat.

How the Company Makes Money

Copart earns fees at multiple points in the process. Sellers, primarily insurance companies, pay processing fees, listing fees, transportation fees, and storage fees. Buyers pay transaction fees, title fees, and loading fees. Because a significant portion of fees are tied to the final auction selling price under Copart’s Percentage Incentive Program, the company has a direct financial incentive to maximise the value each vehicle achieves. This alignment between Copart’s revenue and its sellers’ outcomes is a structural differentiator.

In fiscal year 2025 (ended July 31, 2025), Copart generated total revenues of $4.65 billion, of which $3.97 billion was service revenue and $678 million was vehicle sales revenue, the latter from markets like the UK, where Copart purchases and resells vehicles on a principal basis.

History and Origin

Copart was founded in 1982 by Willis Johnson in Vallejo, California with a single salvage yard. The founding insight was straightforward but consequential: insurance companies needed a professional, efficient, and geographically distributed way to dispose of total-loss vehicles. The fragmented industry of local salvage dealers was not meeting that need well.

The business grew through acquisitions of regional salvage yards over the following decade and went public in 1994. For most of its early history Copart held physical auctions, buyers would travel to its yards to bid on vehicles in person. The transformative moment came when the company began migrating its auction process online in the early 2000s, completing the transition across its US operations by the mid-2000s. This was not an incremental improvement. It was a fundamental reshaping of who could participate in each auction.

By opening every sale to buyers anywhere in the world with internet access, Copart dramatically expanded the pool of bidders competing for each vehicle. More bidders means more competition. More competition means higher prices. Higher prices means insurance companies get better returns on their salvage. Better returns means insurance companies want to work with Copart. The flywheel that would define the business for the next twenty years was set in motion.

Willis Johnson stepped back from day-to-day operations and the company is now led by Jeffrey Liaw, who joined Copart in 2016 as CFO. He was promoted to President in 2019 and became Co-CEO in 2022 before taking over the sole CEO position.

Scale and Footprint

Copart operates in the United States, Canada, the United Kingdom, Germany, Brazil, Spain, Ireland, Finland, the UAE, Oman, and Bahrain. The US business generates approximately 83% of total revenues and is the operational core of the company.

Copart operates over 21,000 acres of land globally, they own more than 90% of their operational land outright, a key differentiator from competitors who typically lease their facilities. In the US alone, Copart owns or leases facilities in every state. The company owns approximately $2.39 billion worth of land on its balance sheet, a figure that significantly understates fair value given how long much of this land has been held and how dramatically land prices around major population centres have appreciated.

The international business is less mature and operates differently in some markets, particularly the UK, where Copart buys vehicles outright. But the global buyer base is central to the model: Copart now maintains a database of approximately 1 million registered members across every continent. The scale of that global buyer pool, and the competitive pressure it places on every auction, remains central to the financial returns Copart delivers to its insurance sellers.

2. The Moat

Source of Competitive Advantage

Copart’s competitive position rests on three interlocking advantages that have strengthened over time. Understanding each one individually understates how they reinforce each other.

The first is physical infrastructure. Copart requires large parcels of land near major population centres to store the high volume of vehicles it processes before they sell. This land is expensive, increasingly scarce, and subject to complex local zoning restrictions that make new entrants face a fundamentally different cost environment than the one Copart faced when it was building its network. The company has spent decades and billions of dollars assembling a footprint that a competitor would need to replicate entirely, at today's land prices, with today's zoning restrictions, competing for the same properties in the same markets. No rational capital allocator would attempt it. This is not a moat that can be disrupted by software or a new technology. It is a physical asset base that took forty years to build.

The second is the global buyer network. Copart has accumulated hundreds of thousands of registered buyers across every continent. The value of this network is directly proportional to its size: more buyers means more competition for each vehicle, which means higher selling prices for insurance companies, which means insurance companies prefer Copart. A new entrant cannot simply build a marketplace without supply. It cannot build supply without having already demonstrated it can achieve competitive selling prices. The chicken-and-egg nature of this problem is the classic marketplace moat, and Copart has been building its side of it for four decades.

The third is the contractual relationships with insurance companies. While no single insurance company accounts for more than 10% of Copart's revenues, an important point to which we will return, the company has established long-term supply agreements with the major carriers. These agreements are built on trust, track record, and the demonstrable financial returns Copart generates for its sellers. Switching costs are not contractual so much as they are practical: an insurance company that moves its business to a smaller competitor will likely see lower auction returns, a worse buyer experience, and disruption to its operations. The cost of switching exceeds the benefit in almost every realistic scenario.

Evidence of the Moat

The financial record is unusually clean on this point. Copart has maintained ROIC consistently above 20% in every year of the past decade, averaging approximately 28% over the last ten years. Operating margins have ranged between 32% and 42% throughout this period. Gross margins have held in a narrow band around 45% for a decade. These are not the numbers of a business that competes on price. They are the numbers of a business that sets the standard.

The most revealing evidence of moat is what has happened to the competition. Insurance Auto Auctions (IAA), Copart's primary US competitor, was acquired by Ritchie Bros. Auctioneers in 2023 after years of underperformance relative to Copart. The combined entity has not threatened Copart's position in any meaningful way.

Moat Trajectory

The moat is strengthening, not weakening. Each additional facility Copart opens makes the network more valuable to insurance sellers because of improved geographic coverage. Each additional buyer who registers on the platform increases the competitive pressure on every auction. Each year of accumulated auction data improves the company’s IntelliSeller tool, which uses machine learning to help sellers optimise their pricing decisions. These are all self-reinforcing dynamics that become harder to replicate as they compound.

Competitive landscape

Copart’s meaningful competition is effectively limited to IAA (now part of Ritchie Bros.) in the US. This is a two-player market for insurance-company salvage vehicles at national scale. Local and regional operators exist but cannot replicate the global buyer network or the geographic coverage that national carriers require. The fact that this market has not attracted more serious competition in four decades is itself informative. The capital requirements are enormous, the zoning challenges are real, and the buyer network takes decades to build.

3. Financial Performance

Revenue Growth

Copart has grown revenue from $1.15 billion in fiscal 2015 to $4.65 billion in fiscal 2025, a compound annual growth rate of 15% over a decade. For a business operating in physical infrastructure with significant real-world constraints, sustaining that rate over ten years is exceptional.

The growth has been driven by four forces operating simultaneously: an increase in total loss frequency rates as vehicles have become more technologically complex and therefore more expensive to repair; market share gains at the expense of smaller regional competitors; geographic expansion both within the US and internationally; and an increase in revenue per transaction driven by higher average vehicle values and an expanded global buyer network.

In fiscal 2025, total revenues grew 9.7% year over year to $4.65 billion. Service revenues, the higher-quality, fee-based component, grew 11.4% to $3.97 billion. The recent moderation from earlier rates reflects the natural effect of a larger base and some normalisation following the elevated total-loss activity of the pandemic years.

Profitability

Copart’s profitability record is one of the clearest expressions of the structural strength of its competitive position. Operating margin in fiscal 2025 was 36.5%, above the ten-year average of 36.3% and meaningfully higher than the 30.1% the business generated a decade ago in fiscal 2015. The direction of travel matters as much as the level: a business that has expanded operating margins by 6.4 percentage points over ten years while growing revenue at 15% annually is not merely maintaining its competitive position, it is strengthening it. Operating income compounded at 17.3% annually from fiscal 2015 to fiscal 2025, growing from $344 million to around $1.70 billion. This outpaced revenue growth, which is precisely what margin expansion looks like in the financials.

Net income in fiscal 2025 was $1.55 billion, up 13.9% from $1.36 billion in fiscal 2024. The net margin of 33.4% is above the ten-year average of 29.6% and almost double the 19.2% the business earned in fiscal 2015. The steady expansion in net margin reflects operating leverage, the benefit of a larger and more efficient network, and the growing contribution of interest income, the company earned $178.9 million in net interest income in fiscal 2025 on its $4.79 billion net cash position, a meaningful source of earnings that did not exist a decade ago.

On earnings per share: diluted EPS grew from $0.21 in fiscal 2015 to $1.59 in fiscal 2025, a compound annual growth rate of 22.4%, ahead of both revenue and net income growth. This performance was bolstered by an overall reduction in diluted share count, which fell from approximately 1.05 billion in fiscal 2015 to 978 million in fiscal 2025. While the share count has drifted slightly higher since 2021 due to stock-based compensation, the long-term decline reflects the cumulative impact of Copart’s historical share buybacks (especially the aggressive buybacks between 2015-2017) and disciplined capital allocation.

Free Cash Flow

Free cash flow grew from $186 million in fiscal 2015 to $1.23 billion in fiscal 2025, a compound annual growth rate of 20.8% over a decade. That represents a 6.6-fold increase in the business’s capacity to generate cash, which is a meaningful claim about the quality of the underlying economics.

The capex-to-operating-cash-flow ratio tells a particularly revealing story about where the business stands today. Over the past decade, this ratio averaged approximately 44%, meaning Copart reinvested roughly 44 cents of every operating dollar back into the physical infrastructure that generates its competitive moat. In fiscal 2025, that ratio fell to 31.6%, its second lowest level in ten years. The business is indeed entering a higher-harvest phase in the US, but it remains an investment-heavy business globally.

Return on Invested Capital

Over the past decade, ROIC has averaged 28.4% and reached as high as 32% in fiscal 2022. In fiscal 2025, ROIC was 29%, essentially in line with the long-run average. This consistency is more impressive than a single peak figure. A business that has compounded at 15% annually in revenue while sustaining high returns on incremental capital is, by the standard definitions, a genuine compounder. Every dollar reinvested in the business has generated returns well above any reasonable estimate of the cost of capital in every year of the available record.

Balance Sheet

Copart’s balance sheet at July 31, 2025 was exceptional. The company held $2.78 billion in cash and restricted cash plus $2.01 billion in held-to-maturity securities, a combined liquid position of $4.79 billion against total financial debt of effectively zero. Total liabilities of $883 million were overwhelmingly operational in nature. This is a fortress balance sheet. It provides management with complete flexibility to act, whether to acquire land, weather a severe recession, respond to catastrophic weather events, or return capital to shareholders. The net cash position also generates meaningful interest income that did not exist in prior cycles, adding a new dimension to earnings quality.

Capital Expenditure

Copart spent $569 million on capex in fiscal 2025, the majority directed toward land acquisition and facility development. Importantly, the majority of Copart’s capex is growth-oriented, acquiring land and building new facilities that generate long-term structural barriers, rather than maintenance capex spent on preserving the existing asset base. This distinction matters when evaluating the quality of the free cash flow figure.

4. Growth Levers & Addressable Market

Copart is not a business that has exhausted its runway. The US network is maturing, but that maturation is precisely what frees capital and management attention for the next phase of growth. There are four distinct levers that can drive the business forward from here, and they are not speculative: each has evidence of traction today.

A) The structural Tailwind in Total Loss Frequency

The single most important driver of Copart’s domestic volume is total loss frequency, the percentage of accident-involved vehicles that insurers choose to declare a total loss rather than repair. In fiscal 2025, CEO Jeff Liaw described the full-year total loss frequency rate of 22.2% as an all-time annual high. This is not an anomaly. It is the result of forces that have been building for decades and show no sign of reversing.

Modern vehicles are fundamentally more expensive to repair than their predecessors. Advanced driver assistance systems, cameras, sensors, integrated infotainment, and complex structural materials mean that even moderate collision damage frequently triggers repair estimates that exceed the vehicle's value. Electric vehicles add a further dimension: EVs require approximately four additional labour hours per repair compared to internal combustion vehicles and carry roughly 30% higher repair costs. As EV penetration grows and as ADAS technology becomes standard across more model lines and price points, the economics of repair versus total loss continue to shift in Copart's favour. The average age of vehicles on US roads has also reached 12.8 years, meaning a large portion of the fleet consists of older vehicles where even modest damage tips the repair-versus-salvage calculation toward salvage. Each of these trends compounds the other, and none of them is cyclical.

B) International Expansion, the Majority of the Opportunity

The US salvage auction market (calculated based on the Auction Fees paid to the auction house) is estimated at $3.8 billion in 2025 and is projected to reach $7.2 billion by 2030, growing at around 13.6% CAGR. Copart’s domestic service revenue in fiscal 2025 was approximately $3.4 billion (including buyer fees, seller fees, transportation fees, and title processing) meaning the company is already capturing the largest share of a market that is still growing. The domestic runway is real but finite.

The international opportunity is a different order of magnitude. The global online salvage auction market was estimated at $12.4 billion in 2025 and is projected to reach $27.2 billion by 2030 at a 17% CAGR, a faster growth rate than the US market and from a base where Copart's penetration is a fraction of what it has achieved domestically. In fiscal 2025, international service revenue growth reached 18.9% for the full year, significantly outpacing the 10.4% growth in U.S. service revenue. The direction of travel is clear.

The specific international market opportunities are substantial. Germany's online salvage market was worth approximately $1.1 billion in 2025 and is projected to grow at a 21% CAGR through 2030, a market where Copart has been building infrastructure since 2017 and where the transition from a principal-based model to a consignment model is already delivering margin improvement. Brazil sits at approximately $480 million with mid-teens growth. India, which Copart briefly entered and then paused to wait for the market to develop further, is estimated at $230 million and growing at approximately 23% annually, a market that Copart is well-positioned to re-enter as formal insurance penetration and salvage regulation matures. In the UK, Copart already holds approximately 60–70% of the insurance-customer market, making it the dominant operator in Europe's most developed salvage market. Asia-Pacific is the fastest-growing region globally, expanding at a 16–24% CAGR depending on the source.

Copart's international buyer pool is a direct competitive advantage in these markets. The most recent available data indicates that international buyers purchasing US vehicles were acquiring vehicles significantly higher in value than comparable vehicles purchased by domestic US buyers, a reflection of the quality and purchasing power of the global member base Copart has assembled over four decades. That same buyer network can be directed toward inventory in Germany, Brazil, or any market Copart enters, providing an immediate advantage that a local competitor could not replicate. This is network effects working across geographies, not just within them.

C) Expanding Beyond Insurance, Blue Car and Adjacent Categories

Approximately 81% of Copart’s vehicle volume originates from insurance company sellers. That concentration is a risk, but it also reveals the size of the untapped opportunity in non-insurance channels.

Blue Car, Copart’s service offering aimed at banks, rental car companies, and fleet operators, delivered strong double-digit growth in fiscal 2025, as reported in the annual report. This is not a minor product line. Banks and financial institutions need to liquidate repossessed vehicles and lease maturities efficiently; fleet operators and rental companies cycle through vehicles on a regular cadence and need the same combination of geographic reach, global buyer access, and transparent pricing that insurance companies value. As Copart's platform becomes better known outside the insurance vertical, the addressable supply base expands materially without requiring any new infrastructure investment.

Purple Wave, Copart's heavy equipment and agricultural machinery auction platform, delivered continued growth in fiscal 2025. Heavy equipment and farm machinery represent a large and fragmented global market that benefits from exactly the same dynamics that made Copart successful in salvage vehicles: a global buyer pool competing for local inventory, transparent price discovery, and specialist services for sellers who lack efficient alternatives. This is early innings, but the model is proven.

D) The EV Transition as a Structural Accelerator

Electric vehicles are widely discussed as a long-term threat to Copart through the autonomous vehicle channel. The near-term reality is almost exactly the opposite. EVs are more expensive to repair than internal combustion vehicles by a meaningful margin. Battery damage, which occurs in a significant proportion of EV collisions, is frequently uneconomical to repair at all, either because the battery module is deeply integrated into the vehicle’s structure or because replacement costs are prohibitive. This drives EV total loss rates materially above ICE vehicle rates at comparable damage severity levels. As EV penetration of the vehicle fleet grows, still in its early stages globally, it adds a structural tailwind to Copart’s volume that did not exist a decade ago and that will intensify over the coming years before autonomous vehicle adoption becomes a countervailing force.

What the TAM Picture Tells us

A business that controls roughly half of the US domestic market, that is in the early stages of penetrating a $10.6 billion global market growing at 15% annually, and that is actively expanding into adjacent vehicle categories through Blue Car and heavy equipment, is not running out of room. The presence of a massive growth runway is undeniable; the real variable is Copart’s ability to scale operations and deploy capital with its trademark efficiency. Given its historical financial performance, the company has already proven it possesses the discipline to execute.

5. Management

Leadership and Tenure

Copart is effectively a founder-influenced business. Willis Johnson, who founded the company in 1982, remains Chairman of the Board. His operating philosophy, own the land, build the infrastructure, focus on seller returns, expand the buyer network, is deeply embedded in how the company operates.

Liaw joined in 2016 as CFO. He brought a sophisticated private equity background (formerly at TPG Capital) that sharpened the company's approach to capital allocation, ROIC, and international M&A. He served as Co-CEO with Jay Adair before becoming the sole CEO on April 1, 2024.

The transition from founder Willis Johnson to his son-in-law Jay Adair (now Executive Chairman), and then to Jeff Liaw, represents one of the most successful leadership successions in the industrial sector. The team's ownership mindset is reflected in their lack of a dividend; they prefer to reinvest every dollar into land or opportunistic buybacks.

Skin in the Game

Insiders, including Willis Johnson and his affiliates, collectively own a significant portion of Copart’s outstanding shares, exceeding 11% of shares outstanding as of the most recent proxy. Executive compensation is weighted heavily toward equity, tying financial outcomes directly to long-term share price performance. Options issued to senior executives include market conditions requiring the stock to trade above a specified price threshold before exercise, a feature that further aligns incentives with shareholder value creation.

Capital Allocation Track Record

Copart’s capital allocation record reflects a management team that has consistently prioritised long-term value over short-term return metrics. The primary deployment of free cash flow has been into land acquisition and facility development, investments that have generated ROIC averaging 28% over the past decade and that have deepened the structural barriers protecting the business.

Copart has historically been a reluctant repurchaser, preferring to build a massive cash pile for internal reinvestment. Aside from a defining $739 million buyback in 2017, the company remained largely dormant on this front until early 2026, when it deployed $500 million to take advantage of recent share price volatility. Combined with a total absence of dividends since its 1994 IPO, this reflects a management team strictly focused on long-term compounding over immediate distributions.

The primary reservation is the accumulation of $4.79 billion in liquid assets earning treasury rates when the business historically generates returns above 20% on invested capital. This is capital that could be working harder.

Communication and Transparency

Copart’s management communicates with shareholders in a manner that reflects genuine confidence in the business and a willingness to engage with difficult questions. Earnings calls are substantive. The risk factor disclosures in annual filings acknowledge real challenges rather than papering over them. The 10-K filings are unusually detailed about the operational mechanics of the business.

6. Valuation

Current valuation

Our valuation framework measures how much of the sum of a company’s future cash flows, discounted back to today at an appropriate rate, is already embedded in the current stock price. Rather than expressing this as a precise figure, we express it as an approximation in years.

At the time of this report, with the stock trading at $33.06, the market is pricing Copart at approximately 16 years of discounted future cash flows. This is an approximation, not an exact calculation. The assumptions embedded in our model are consistent with the company’s current and historical operating performance, they are not heroic, and they are not pessimistic. This figure is monitored and updated on a monthly basis as the stock price and business performance evolve. This places the business in the Attractive zone of the valuation gauge.

What 16 years means

What 16 years means in practical terms is this: the current price assumes that Copart will stop generating meaningful cash flows after year 16. Every year of cash generation beyond that point comes to you as an investor for free.

For a business with the structural characteristics described in this report, physical infrastructure that compounds in value, a buyer network that deepens with each passing year, contractual relationships with insurance companies that have persisted for decades, and a non-discretionary market that has existed since automobiles did, the question of whether Copart will still be generating substantial cash flows in year 17 and beyond seems like a reasonable bet.

Hold, Add, and Exit Logic

The valuation framework is not a buy-and-sell signal generator. It is a tool for thinking about price relative to value, and for making disciplined capital allocation decisions across the Bearhold Universe.

The current Attractive zone suggests the price does not demand excessive optimism about the future. For a business of this quality, that is a reasonable entry point.

The general logic across all five zones is as follows. In the Exceptionally Attractive and Attractive zones, the price is working in your favour, you are receiving more embedded future cash flows per dollar deployed than the market typically offers for a business of this quality. In the Hold zone, the business is fairly recognised, neither compelling to initiate a new position nor a reason to exit one already held. In the Expensive and Exceptionally Expensive zones, the price is embedding a level of optimism that the historical record does not automatically support.

My approach is straightforward: when a position moves into the Expensive zone, I sell and reallocate the capital to other quality businesses in the Bearhold Universe where the price sits in the Attractive and Exceptionally Attractive zones. The logic is simple, if you own a collection of exceptional businesses, your capital should always be working in the most attractively priced names available to you. Holding an Expensive position when an Attractive alternative exists is an opportunity cost that compounds against you over time. Discipline on the exit is as important as discipline on the entry.

Growth Engines

Every stock price is driven by one of two engines, or both simultaneously. Understanding which is working in your favour, and which might work against you, is as important as understanding the business itself.

The first engine is fundamental growth. Over time, a stock price tracks the growth of free cash flow per share. If a business compounds its FCF per share at 15% annually, that is roughly what the fundamental engine contributes to investor returns over a full holding period. It is steady, it is predictable, and it is the engine that quality businesses run on indefinitely.

The second engine is valuation re-rating. When a stock is mispriced, when the market is embedding fewer years of future cash flows than the business's quality and durability justify, the price tends to correct upward simply to reach fair value. This engine can produce returns that dwarf what fundamentals alone would deliver. It can also run in reverse: when a stock sits in the Expensive zone, the market is embedding too many years, and any mean reversion subtracts from returns even as the business continues to perform. A good business at the wrong price is still a poor investment.

For Copart at the time of writing, both engines appear to be working in the investor's favour. Over the past decade, Copart has compounded FCF per share at approximately 21% annually, one of the strongest rates among large businesses in any sector. That is the fundamental engine, running in full. The valuation engine has room to contribute as well: at 16 years of embedded cash flows in the Attractive zone, the market is not fully pricing the duration and quality of what Copart has built. An investor entering at this price is not relying on optimism, they are being paid by both the business performing and the price catching up.

The risk scenario is equally clear. If the stock moves into the Expensive zone, driven by price appreciation that outpaces fundamental growth, the valuation engine begins working against the position. In that scenario, the approach is to sell and reallocate capital to a quality business in the Bearhold Universe.

7. Risks

Risk 1 - Insurance Company Concentration

Copart obtains approximately 81% of its vehicle volume from insurance company sellers. While no single insurer accounts for more than 10% of consolidated revenues, the collective dependence on a relatively small number of large carriers is a genuine structural risk. If the major US insurers were to consolidate their salvage operations, pursue vertical integration, or develop a credible alternative platform, Copart’s supply would be at risk.

The probability of this materialising is low. Insurance companies are not in the business of operating salvage yards. The operational complexity, the land requirements, and the need to build a global buyer network from scratch are formidable disincentives. Moreover, the financial returns Copart delivers to its insurance partners, through higher auction prices enabled by its global buyer network, are difficult to replicate. An insurer attempting to internalise this function would almost certainly achieve worse financial outcomes than it does today working with Copart.

The risk is real but its probability of materialising is low, and the mechanism by which it would occur requires insurance companies to act against their own financial interests.

Risk 2 - Autonomous Vehicles and Declining Accident Rates

This is the risk that deserves the most honest treatment in any Copart analysis, and the one with the longest time horizon.

The thesis is straightforward: if autonomous vehicles eventually reduce accident rates materially, or eliminate them entirely, the supply of total-loss vehicles that feeds Copart’s business would decline in parallel. A 50% reduction in accident rates would, all else being equal, reduce Copart’s volume significantly.

There are several important qualifications a serious investor must hold simultaneously.

First, the timeline for meaningful autonomous vehicle adoption is deeply uncertain. The promises of full self-driving technology have been pushed out repeatedly over the past decade. Even optimistic estimates place widespread adoption of truly autonomous vehicles well into the 2030s or beyond in the United States.

Second, vehicle complexity has historically been a tailwind for total loss frequency, not a headwind. Modern vehicles, with advanced driver assistance systems, cameras, sensors, and complex structural materials, are more expensive to repair than older vehicles. This has driven total loss frequency higher over the past thirty years even as vehicle safety technology has improved. The transition period from human-driven to autonomous vehicles is likely to involve even more complex and expensive-to-repair vehicles, maintaining or increasing total loss frequency in the near and medium term.

Third, even in a world where US domestic accident rates eventually decline, Copart’s international business and its global buyer network provide a degree of diversification that pure domestic exposure would not.

The autonomous vehicle risk is real, horizon-dependent, and does not present itself as an imminent threat to the business. An investor with a ten-year horizon should have it on the watch list. An investor with a twenty-year horizon needs to weigh it more carefully as part of any thesis.

What Would Change my Mind?

Meaningful and sustained market share losses to IAA or a new entrant, over two or more consecutive years, would be an early warning signal that the moat is weakening. If total loss frequency begins a sustained multi-year decline attributable to measurable reductions in accident rates from driver assistance technology, not just a single year of mild weather, that would require a fundamental reassessment of the long-term volume outlook. If a major insurance carrier publicly announces plans to internalise salvage operations, that would warrant immediate re-evaluation.

8. The Verdict

Copart is the kind of business that takes decades to build and is almost impossible to replicate once built. It occupies a structural position in a non-discretionary market, behind barriers that compound in strength each year, run by a management team whose interests are aligned with long-term shareholders and whose operational record demonstrates consistent execution across three decades.

The two risks discussed, insurance concentration and autonomous vehicles, are not trivial. They are real, they deserve ongoing monitoring, and they prevent this from being a thesis where no adverse scenario is imaginable. But neither risk, assessed honestly against the current time horizon, overrides the fundamental quality of what has been built.

At a valuation of 16 years of embedded cash flows, the market is asking for reasonable performance from a business with an exceptional track record. That is a combination worth owning.

Copart is the kind of business that quietly makes you wealthy if you give it time and leave it alone.

Disclosure update: The author now holds a position in CPRT. The position was initiated after the original publication date of this report. All analysis and conclusions remain unchanged. This report reflects the author’s personal views and is not an investment advice. Investing carries the risk of permanent capital loss. Read the full disclaimer here

There is a specific kind of discouragement that hits investors with small accounts, and it has nothing to do with their actual performance.

It happens when they see someone else post a $50,000 gain. Or read about a fund that returned $200 million last year. Or watch a portfolio tracker tick upward by $800 on a good day and feel, despite knowing better, that $800 is not enough to matter.

This is the dollar sign trap. And it quietly destroys more good investors than bad decisions ever will.

The Comparison That is Not a Comparison

When you see a $50,000 gain, you are looking at an output. You have no idea what the input was. If that gain came from a $2 million account, it represents a 2.5% return, a number that trails inflation in most years and would be unremarkable by any professional standard. If your $800 gain came from a $5,000 account, it represents a 16% return. You outperformed every major index, most hedge funds, and the overwhelming majority of retail investors, and you felt bad about it.

This is not a minor perceptual error. It is a fundamental miscalibration of what investing success actually means.

Dollars are an output of two things: percentage returns and capital deployed. In the early stages of building wealth, you have limited control over the second variable. You have complete control over the first. The only rational scorecard, at any account size, is percentage return, full stop.

What Dollar Thinking Actually Costs You

The danger of anchoring on dollar amounts is not just psychological discomfort. It produces a specific and predictable chain of bad decisions.

When progress feels too slow because the balance is small, the instinct is to accelerate. To take more risk. To concentrate more heavily. To look for the one trade that closes the gap between where you are and where you feel you should be. This is the moment investors reach for leverage, pile into speculative positions, or abandon a disciplined process that was, by any honest measure, working.

The account that blows up is almost never the one that made bad decisions from the start. It is the account with a solid process that got abandoned because the investor compared their dollar returns to someone else’s and concluded, incorrectly, that they were falling behind.

Comparison is not motivating in investing. It is corrosive. The person you are comparing yourself to has different capital, different time horizons, different risk tolerance, and different life circumstances. Their dollar number tells you nothing useful about your performance.

Subscribe now

The Professional Standard

Consider what the investment management industry considers exceptional performance.

A fund that consistently returns 15% per year, net of fees, is considered elite. Institutions allocate billions to managers who deliver 12%. Warren Buffett’s long-run average at Berkshire Hathaway, widely considered the greatest investment track record in history, is approximately 20% per year compounded over decades.

These numbers are percentages. Nobody in the professional investment world measures manager quality in dollar terms, because dollar terms tell you nothing without knowing the size of the capital base. The entire infrastructure of institutional investing, benchmarks, Sharpe ratios, alpha, information ratios, is built around percentage returns precisely because they are the only comparable unit of measurement.

The retail investor who abandons a 15% annual process because the dollar amounts feel small is walking away from elite level performance because they forgot to look at the right number.

The Mathematics of Patience

The reason percentage thinking matters so much in the early years is that compounding is not linear. The returns do not feel significant when the capital base is small. They become significant when the capital base is large, and the capital base only becomes large if the percentage returns are preserved and compounded consistently over time.

A $10,000 account returning 15% per year becomes $163,000 in twenty years. The same account returning 15% per year but losing half its value once, because the investor abandoned the process and took a catastrophic risk, recovers to roughly $80,000. The single moment of abandoning discipline costs more than the entire first decade of compounding.

This is the mathematics the dollar sign hides from you. The impulse to chase a faster dollar return feels like ambition. In practice it is the most expensive thing an investor can do to their long term wealth.

The Only Comparison Worth Making

There is one comparison that is genuinely useful, and it has nothing to do with other investors.

Compare your percentage return to the market. If the index returned 10% and you returned 13%, you created alpha. You did something that most professionals, most algorithms, and most institutional capital failed to do. That is the only external benchmark that tells you anything real about the quality of your process.

Everything else, the dollar amounts other people made, the account sizes you see on social media, the feeling that your progress is too slow, is noise that will cost you if you let it reshape your decisions.

A small account with a sound process and a correct scorecard is not a problem to be solved. It is the beginning of something that compounds.

Subscribe now

Let’s Start with the comparison most people make, and watch it collapse under scrutiny.

Boston Dynamics Spot: 33 kilograms, 14 kilogram payload capacity, top speed of 1.6 meters per second, IP54 weather resistance. Price: $74,500. Unitree B2: 60 kilograms, 40 kilogram payload capacity when walking, top speed of 6 meters per second, nearly four times faster, IP67 weather resistance, which means it handles full water immersion, not just splashing. Price: approximately $25,000.

These are not a toy and a professional machine. They are both industrial quadruped robots designed for the same category of work: facility inspection, perimeter security, hazardous environment monitoring, emergency response. The B2 is heavier, faster, carries nearly three times the payload, has superior weather resistance, and costs one third as much.

This is the starting point that makes what follows so interesting. Because in a normal market, that comparison would end the conversation.

What a Normal Market Would Do

When a competitor offers a comparable product at one third the price, one of two things happens. Either the premium product justifies its cost through some combination of superior reliability, better software, stronger enterprise support, or a proven track record, and commands a loyal customer base willing to pay for that, or it loses market share until pricing corrects.

Boston Dynamics Spot does have genuine advantages. It has a longer deployment history, more third party integrations, better enterprise support infrastructure, and software autonomy that is more mature. These are real things worth paying for in mission critical applications. The 3 to 1 price ratio is not entirely irrational.

But here is what the normal market logic misses entirely: a significant portion of the customer base for these robots cannot buy the cheaper product. Not because they don’t want to. Not because the B2 is inferior for their purposes. But because the law prohibits it.

The Wall, Updated

The 2025 National Defense Authorization Act, Section 1078, mandated a study on the Department of Defense’s use of unmanned ground vehicles manufactured in China and established a mechanism by which a procurement ban could automatically spring into effect without further Congressional action. The FY2026 NDAA expanded the legislative architecture further, increasing defense spending to $855.7 billion for the Department of Defense and broadening the scope of restrictions on Chinese manufactured autonomous systems.

The legislation also extended to components. Effective June 2026, DoD is prohibited from procuring items from entities on the 1260H list, a list of companies with alleged ties to the Chinese military. By June 2027, the prohibition extends further: no items in the supply chain may contain components from those entities. The net is getting wider, and it is doing so automatically, with each annual defense bill adding another layer.

This is no longer a targeted measure aimed at a handful of named companies. It is becoming a structural feature of how the US government procures technology, a standing presumption against Chinese-origin hardware in sensitive applications, with the burden of proof reversed.

Meanwhile, in December 2025, Congress encouraged the DoD to designate Unitree, the manufacturer of the B2, as a Chinese military company. In its own filings with the Shanghai Stock Exchange, Unitree executives acknowledged receiving funding from PLA connected programs.

The wall is not a diplomatic position that might soften with a change of administration. It is becoming code. It is being written into procurement law, supply chain regulations, and component-level traceability requirements. Each NDAA adds another brick.

Subscribe now

The Mirror

China’s side of this equation is less visible to Western observers but operates on the same logic in reverse.

China’s defense procurement naturally flows to domestic manufacturers. State investment in robotics has accelerated dramatically, the government views humanoid and industrial robots as a strategic industry, not merely a commercial one. Chinese firms developing hardware for PLA programs receive preferential access to government contracts that American competitors simply cannot reach regardless of product quality.

The result is two parallel customer bases, each reserved for its domestic manufacturer. The US government’s $855 billion defense budget flows to companies that can clear American procurement requirements. China’s state budget flows to companies embedded in its own industrial ecosystem. Neither pot of money is accessible to the other side’s competitors.

This is what the price ratio actually reflects. It is not purely a quality gap. It is a market structure gap. American manufacturers are not competing against the best product in the world for government contracts, they are competing among themselves, for a buyer that cannot go elsewhere.

The Technological Consequences

This is where the long-term implications become genuinely serious, and where I think most analysis stops too early.

The first consequence is the loss of competitive pressure as a forcing function for improvement.

In open markets, you must be better than the best competitor in the world to win. That pressure produces a specific kind of discipline: constant benchmarking, aggressive iteration, an acute sensitivity to where you are falling behind. When legislation removes the most aggressive competitor from your addressable market, that pressure relaxes. The American robotics industry now competes primarily against itself for its largest contracts. self competition is less brutal than global competition. Over time, that matters.

The second consequence is diverging technical standards, and this one is underappreciated.

When two large ecosystems develop in isolation, they do not merely produce different products, they eventually produce incompatible ones. Communication protocols. Software interfaces. Sensor specifications. Navigation architectures. The longer the two ecosystems develop separately, the harder integration becomes, even in a hypothetical future where the political environment shifts. We have already seen this play out in telecommunications with Huawei. What took a decade to build in that industry is now structurally very difficult to unwind. Robotics is following the same trajectory.

The third consequence is a distortion in how we measure quality.

When a manufacturer’s primary customer cannot buy from anyone else regardless of price, quality, or performance, the normal feedback loop between product and market breaks down. Customers who cannot walk away are not the same as customers who choose to stay. The former will tell you what works within the constraints they have. The latter tell you what is genuinely best. A robotics industry that serves a captive government buyer loses access to the harshest and most honest signal the market provides.

The fourth consequence, and perhaps the most consequential over a decade, is what happens when the Chinese commercial market matures.

Right now, Chinese manufacturers can sell freely into the global commercial market while American manufacturers cannot access the Chinese market and Chinese manufacturers cannot access the American government market. If you are a Chinese robotics company with PLA funding, a cost structure shaped by domestic manufacturing economics, and access to every non aligned commercial market in the world, you are competing aggressively in the 80% of the market that is unrestricted. American manufacturers, by contrast, are competing fiercely in the government market and also in that same unrestricted commercial market, but without the structural advantage of a captive home buyer funding their fixed costs.

In other words, the American government market funds American manufacturers’ balance sheets. It also, subtly, insulates them from the most brutal form of commercial competition. That insulation may feel like strength. Over twenty years, it may prove to be fragility.

What this means for investors

I want to be precise here, because there is an easy mistake to make.

The legislative protection is real. It is durable over any reasonable investment horizon. A business that sells industrial inspection robots to the US government, and whose Chinese competitors are legally prohibited from doing the same, has a structural advantage worth paying for. That is not in dispute.

What is in dispute is whether that structural advantage is the same thing as a durable competitive moat. They are related but not identical.

A moat, properly defined, is an advantage that is self-reinforcing, one that gets harder to overcome as time passes. The legislative wall has some of that character, because each NDAA adds restrictions rather than removes them, and because supply chain compliance infrastructure becomes more embedded over time. But it also has a vulnerability that a pure product moat does not: it depends on a political environment that, while stable, is not guaranteed.

More importantly, it does not force the innovation that a pure product moat requires. A company protected by legislation does not have to be better than its Chinese competitor to win contracts. It only has to be compliant, reliable, and good enough. That is a different standard. And businesses that optimize for a different standard tend, over time, to produce a different quality of product.

The robotics companies I find most interesting in this environment are not necessarily the ones with the most government contracts. They are the ones that are winning in the unrestricted commercial market, where Chinese competitors are present, where price matters, and where the product has to earn its position on merit alone. Those companies are being sharpened by a harder benchmark.

A company that thrives only behind the wall is not the same as a company that thrives despite having a wall available.

A Note on Honesty

The robotics sector presents a recurring challenge for the kind of investing I try to practice. The structural dynamics I have described above are real and investable. But most robotics companies, even excellent ones, do not yet pass the quality filter I apply before any serious analysis: high certainty of being larger and more profitable in ten years.

The capital intensity is high. The competitive dynamics are still resolving. The technology is advancing faster than any individual company’s moat can calcify. And the geopolitical foundations of the structural advantage, while durable, are a different kind of durability than the kind produced by decades of customer switching costs or brand loyalty.

I am watching this sector carefully. I am not yet ready to put anything on the Approved List. When I am, you will know.

Subscribe now

I have been a student of the Adobe business model since their pivotal shift to the SaaS (Software as a Service) model in 2013. On paper, Adobe is the quintessential quality compounder. It is the kind of business that usually sits at the very top of my universe of names.

The fundamentals are, quite simply, a dream for any disciplined investor:

• Net Profit Margins: Consistently hovering around 30%.

• Cash Flow Dominance: A Free Cash Flow (FCF) margin above 40%, meaning the company generates more actual cash than its accounting profit suggests. This is rare and indicative of a capital light masterpiece.

• The Standard Moat: 90% of the world’s creative professionals use Photoshop. It isn’t just a tool; it is a language.

However, as we look at the landscape in 2026, a new variable has entered the equation: Generative AI, while the market is currently in a state of panic selling, the real risk isn't the noise, it’s the lack of structural visibility. Here is why I am hitting the pause button on Adobe, despite the attractive price tag.

1. The Casual User and the Erosion of the Low End Moat

Adobe’s moat has always been protected by a high wall of complexity. If you wanted professional results, you had to invest hundreds of hours into learning the Adobe suite. That learning curve created immense switching costs. You didn’t just buy the software; you invested your career in it.

AI is lowering that wall. For the casual or non professional user, the small business owner, the social media manager, the student, AI native tools like Canva (integrated with Magic Media) or Midjourney are now good enough.

We don’t yet know what percentage of Adobe’s 30 million+ subscribers are these casuals. If 20% of their base realizes they no longer need a $60/month Creative Cloud subscription because a $10 AI tool does 90% of what they need, the valuation of the entire company must be permanently rerated lower.

Subscribe now

2. The Threat of Seat Contraction and Workflow Deflation

In the institutional world, Adobe makes money by the seat. If an advertising agency has 100 designers, they pay for 100 licenses. This has been a steady, predictable stream of income for a decade.

But AI introduces workflow deflation. If AI integrated Firefly tools make a designer 50% more efficient, that agency faces a mathematical choice. They don’t necessarily produce 50% more work; they might just realize they only need 60 designers to produce the same output.

This leads to seat contraction. Even if Adobe attempts to raise the price per seat to capture some of that AI value, they are fighting a structural headwind they’ve never faced: A shrinking customer base within their own power users.

3. Is Firefly a Bridge or a Pier?

Adobe’s management argues that their proprietary AI, Firefly, is the solution. They believe that by embedding AI directly into Photoshop, they make their moat even deeper.

But here is the Risk Analysis view: Is Firefly a bridge to a more profitable future, or a pier that lead to nowhere? If AI becomes a commodity, where every software has a generate button, then Adobe loses its unique selling proposition. If the magic is in the AI model and not the software interface, then the value shifts from Adobe to the model providers (like OpenAI or Midjourney).

In this scenario, Adobe becomes a shell for someone else’s technology. Their 40% FCF margins would likely collapse as they pay massive compute fees to stay relevant.

4. Pricing Power vs. The Good Enough Substitution

A true compounding machine relies on the ability to raise prices without losing customers. Historically, Adobe did this with the confidence of a monopoly.

But substitution is the enemy of pricing power. In a world where specialized AI native startups are popping up every week, Adobe’s all in one bundle starts to look expensive. If a marketing team can get 80% of Adobe’s value from a suite of smaller, cheaper AI tools, Adobe loses the leverage to hike prices by 5–10% annually. Without those price hikes, the revenue growth story slows down significantly.

Investor vs. Gambler: The Certainty Gap

The vast majority of fund managers dumping $ADBE today are doing so out of a lack of technical understanding. They see a headline and sell. They are reacting to price, not value.

But there is a flip side. Buying the stock just because it is down 66% from its high without understanding the 10 year structural impact of AI isn’t value investing, it’s gambling.

My philosophy for Bearhold Research is built on the margin of safety. This margin isn’t just found in the stock price; it is found in the predictability of the business.

Adobe is one of the best businesses ever built. But being a great business isn’t enough to trigger a buy. I need to be able to model the next decade with high confidence. Right now, the AI Fog has reduced that visibility to near zero.

The Verdict: Why I am Waiting

I would rather miss a cheap stock that eventually recovers than own a business whose core competitive advantage is being structurally reshaped in ways I cannot quantify.

Adobe remains a magnificent machine, but until we see how seat contraction and casual substitution play out in the future, it stays on the watchlist, not in the Bearhold Universe.

Subscribe now

Let’s start with a simple question.

If someone offered to sell you a small business, a café, a laundromat, a car wash, how would you decide what it’s worth?

You’d probably ask how much money it makes. How reliably it makes it. Whether it’s likely to make more or less in the future. And then you’d figure out how much you’d be willing to pay today for that future stream of cash flow.

That’s it. That’s valuation. Everything else is just a more complicated version of that same question.

The problem is that somewhere between that simple café example and the modern financial industry, valuation became a discipline designed to produce precise answers to questions that don’t have precise answers. And in doing so, it gave investors false confidence in numbers that are largely fictional.

Let me show you what I mean.

The Standard Approach, and Why it Often Fails

The most widely taught method of valuing a business is the Discounted Cash Flow model, the DCF. You forecast the business’s future cash flows, apply a discount rate, and arrive at a “intrinsic value” that tells you whether the stock is cheap or expensive.

In theory it’s elegant. In practice it has a fatal flaw.

The terminal value.

In a standard DCF, the terminal value, the value assigned to all cash flows beyond your forecast period, typically accounts for 70 to 90 percent of the total calculated value. Seventy to ninety percent. Which means that most of the number you’re working so hard to calculate is just a disguised assumption about what happens in year five or six and beyond.

Change one assumption, the long-term growth rate, by a single percentage point, and your “intrinsic value” changes by 30, 40, sometimes 50 percent. The precision is an illusion. You’re not calculating the value of a business. You’re laundering your assumptions through a spreadsheet.

This doesn't mean DCF is useless. It means you have to use it honestly, as a framework for thinking, not a machine for producing answers.

A Better Way to Think About it

Here’s the mental model I use instead, and the one that sits at the heart of everything I write about on Bearhold Research

When you buy a stock, you’re buying a claim on a business’s future cash flows. The question isn’t “what is this business worth?” in some abstract sense. The question is: how many years of today’s free cash flow are already embedded in the current price?

Let me make that concrete.

Imagine a business generating $100 million in free cash flow this year. The stock is trading at a market capitalisation of $2 billion.

That’s 20 times free cash flow. Which means at today’s earnings power, the market is asking you to pay for 20 years of cash flows upfront.

Now ask yourself: is this business likely to still be generating at least this much free cash flow in 20 years? Is it likely to generate more? And what could go wrong?

If the business has genuine competitive advantages, a long reinvestment runway, and operates in a growing market, 20 years of cash flows might be a reasonable price to pay. If it’s a cyclical business in a declining industry with a weak balance sheet, 20 years of cash flows is terrifying.

The number of years embedded in the price tells you how much has to go right for the investment to work out. The higher the number, the less room for error.

Why This Framework Matters for Beginners

If you’re new to investing, here’s what to take from this.

Don’t let anyone convince you that valuation is too complex to understand. The fundamentals are simple: you’re buying future cash flows, and the price you pay determines how good a deal you’re getting. Everything else, the models, the ratios, the financial jargon, is just different ways of answering that same question.

Start by getting comfortable with one number: free cash flow. Not earnings, free cash flow. The actual cash the business generates after maintaining and growing its operations. That’s the number that matters. Everything else can be dressed up.

Subscribe now

Why this Framework Matters for Experienced Investors

If you’ve been investing for a while, here’s the harder truth.

Most of the time when you think you’re doing rigorous analysis, you’re actually doing elaborate rationalisation. You’ve decided you like a business, and you’re building a model that confirms it. The terminal value assumption you chose, the one that makes the DCF work, is the assumption that happens to justify the price you’re already willing to pay.

The years-of-cash-flows framework forces honesty because it starts with the current price and works backwards. Instead of asking “what is this worth?”, which invites you to construct a narrative, it asks “what does the current price assume?” That’s a much harder question to answer dishonestly.

A Word on The Simplicity of This Approach

Before we go further, an important clarification.

Dividing market capitalisation by free cash flow is a sanity check, not a complete valuation. It gives you a quick, honest starting point for understanding what the current price is assuming, but it deliberately ignores two factors that significantly affect the real answer.

The first is the growth rate of free cash flow. A business growing its free cash flow at 15% annually is worth considerably more than one generating the same cash flow today with no growth. If free cash flow is growing, the “years embedded in the price” calculation overstates how long it actually takes to justify the price, because each future year generates more cash than today.

A Practical Example

Let’s use a real business to make this tangible, Visa.

Visa generates extraordinary free cash flow. In its most recent fiscal year it produced roughly $19 billion in free cash flow on a market capitalisation of around $560 billion at the time of writing.

That’s approximately 29 times free cash flow. Nearly three decades of today’s earnings power embedded in the current price.

Is that expensive? It depends entirely on what you believe about Visa’s next 30 years.

If you believe Visa will continue displacing cash globally, growing its network, expanding into new payment categories, and compounding at high returns on capital, then 29 years of cash flows might be a reasonable price for that outcome. The business has structural tailwinds, a genuine network effect, and near-zero capital requirements.

If you think the payments landscape will be disrupted, margins will compress, or growth will slow, then 29 years of cash flows is a lot to pay for an uncertain outcome.

The framework doesn't tell you what to think. It tells you what you need to believe for the investment to make sense. That's its value.

What to Do With This?

Next time you’re looking at a stock, before you build a model or read an analyst report, do one thing:

Divide the market capitalisation by the free cash flow.

That number tells you how many years of today’s free cash flow the market is asking you to pay for. Then ask yourself honestly: does the quality of this business, its competitive position, and its growth runway justify that number?

If yes, you might have found something worth owning. If no. move on.

If you’re not sure, that’s where the real work begins.

Subscribe now

Nobody tells you this when you start investing.

They teach you how to read a balance sheet. How to calculate a PE ratio. How to build a discounted cash flow model. What they don’t teach you is what happens inside your head when the stock you just bought falls 30%, and you have to decide what to do next.

I learned that part the hard way. Several times.

The Big Name Trap

Early in my investing journey I bought a stock because it was cheap. Not cheap in the way a rigorous analyst means, not cheap relative to intrinsic value, not cheap relative to the quality of the business. Just cheap because the price had fallen and the name was big.

A well-known company with a recognisable brand. I figured the name alone was a kind of safety net. Big names don’t disappear, right?

What I missed was that the fundamentals were deteriorating. The price had fallen for a reason. I held on, not because my analysis supported it, but because I didn’t want to admit I’d made a mistake. The stock kept falling. I eventually sold at a loss, not because I had a clear reason to sell, but because I couldn’t take it anymore.

The lesson came later, quietly: price going down is not a reason to hold. Only the fundamentals are.

Waiting to Break Even

This one is more embarrassing to admit.

I bought a stock. It fell. I waited, not because I believed in the business, but because I needed the price to come back to where I bought it so I could sell without feeling like I’d lost.

Eventually it did. The price recovered. I sold immediately, relieved.

Then I watched the stock double over the next two years. It was the beginning of a bull market and I had just sold my position at breakeven because my ego needed to feel like it hadn’t made a mistake.

The stock didn’t know what I paid for it. The market doesn’t care about your entry price. But I was making decisions based on a number that only existed in my own head.

Subscribe now

News as noise

When I first started investing, every headline felt like information.

A disappointing earnings report. A negative analyst note. A macro scare. Each one triggered a response, sometimes panic, sometimes doubt, sometimes the urge to do something just to feel in control.

It took years to understand that most news is noise. That the market’s reaction to a headline is rarely proportional to the actual impact on a business’s long term value. That a great business reporting one bad quarter is almost never a reason to sell, and a falling stock price on heavy volume on a day when nothing fundamental has changed is almost never a reason to panic.

Learning to distinguish signal from noise is not an analytical skill. It’s a psychological one. And it takes time, usually measured in mistakes.

The loneliness of conviction

This one surprised me the most.

When you make a decision based on your own analysis and hold it through volatility, success feels strangely lonely. You start looking for affirmation. Did anyone else buy this? Are other investors talking about it? Is anyone else holding through this drawdown?

The crowd becomes a comfort blanket. If other people are in the same position, the decision feels safer, even if their reasons for owning it have nothing to do with yours.

But here’s what I eventually understood: the right decision has nothing to do with the crowd being with you.

In fact, the most interesting opportunities, the ones that compound the most over time, are almost always the ones where you’re making a decision the crowd hasn’t fully made yet. Waiting for consensus before acting is just a sophisticated way of buying high.

Conviction by definition means you've done the work independently. The crowd agreeing with you later is nice. It's just not relevant to whether you were right.

What Changed

None of this clicked overnight. It accumulated slowly, through losses, through missed opportunities, through regret, through watching positions I sold at breakeven turn into multi-baggers.

What eventually changed was simple: I stopped asking “what is the market telling me?” and started asking “what does the business tell me?”

The business doesn’t know what the stock price is. It doesn’t care about the macro environment. It just keeps doing what it does, compounding value if it’s genuinely exceptional, or slowly deteriorating if it isn’t. Your job as an investor is to understand the business well enough that the price movements stop feeling like information.

That’s the whole game. Everything else is just noise you have to learn to ignore.

Subscribe now

In 1957, Charles O’Reilly opened a single auto parts store in Springfield, Missouri. He had no venture capital, no grand vision of market domination, and no particular reason to believe he was building anything exceptional. He just wanted to sell car parts.

Sixty nine years later, that store is one of the greatest compounding businesses in America, and almost nobody outside of serious investing circles knows it exists.

O’Reilly Automotive operates over 6,300 stores across the US, Mexico, and Canada. But the store count misses the point. What O’Reilly has actually built is a logistics and service machine so efficient that it has achieved something almost impossible in retail: 33 consecutive years of comparable store sales growth. Through recessions, financial crises, a pandemic, and the supposed existential threat of Amazon and electric vehicles, the business just kept growing.

The auto parts business looks simple from the outside. Buy parts cheaply, sell them at a markup, repeat. But the real business is distribution, getting the right part to the right place at the right time. A mechanic waiting on a brake caliper isn't going to wait two days for an Amazon delivery. They need it in an hour. O'Reilly's dense distribution network, hub stores, superhubs, overnight lanes, means they can fulfill an extraordinary percentage of orders same day or next day. That's the moat. Not the brand, not the price, not the loyalty card. The speed.

Subscribe now

The numbers that matter:

• ROIC consistently above 20% since 2014.

• Gross margins above 50%

• Over $25 billion returned to shareholders through buybacks since 2011

• 33 consecutive years of comparable store sales growth

The average American vehicle is now 12.5 years old, the oldest fleet in recorded history. Older cars break down more. They need more maintenance. They require more parts. O’Reilly’s best customer isn’t someone buying a new car accessory, it’s a mechanic keeping a 2009 Honda Civic running for another three years. That customer is becoming more common, not less.

O’Reilly is the kind of business that makes you question what “exciting” means in investing. No viral product launches. No disruptive technology. No celebrity CEO. Just disciplined execution, a culture built around service, and a distribution network that gets better every year.

That’s what compounding actually looks like in practice.

I write about businesses like this every week, quality compounders that reward patience and punish hype. If this kind of thinking resonates, please subscribe below.

Subscribe now